WO2005014563A1 - Piperazine with or-substituted phenyl group and their use as glyt1 inhibitors - Google Patents

Piperazine with or-substituted phenyl group and their use as glyt1 inhibitors Download PDF

Info

Publication number
WO2005014563A1
WO2005014563A1 PCT/EP2004/008633 EP2004008633W WO2005014563A1 WO 2005014563 A1 WO2005014563 A1 WO 2005014563A1 EP 2004008633 W EP2004008633 W EP 2004008633W WO 2005014563 A1 WO2005014563 A1 WO 2005014563A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
piperazin
methanesulfonyl
fluoro
methanone
Prior art date
Application number
PCT/EP2004/008633
Other languages
French (fr)
Inventor
Synese Jolidon
Robert Narquizian
Matthias Heinrich Nettekoven
Roger David Norcross
Emmanuel Pinard
Henri Stalder
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34130061&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2005014563(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CN2004800297559A priority Critical patent/CN1867554B/en
Priority to EP04763703A priority patent/EP1656361B1/en
Priority to PL04763703T priority patent/PL1656361T3/en
Priority to DK04763703T priority patent/DK1656361T3/en
Priority to NZ544820A priority patent/NZ544820A/en
Priority to MEP-2008-277A priority patent/ME00116B/en
Priority to CA2534675A priority patent/CA2534675C/en
Priority to RS20060076A priority patent/RS53252B/en
Priority to SI200430616T priority patent/SI1656361T1/en
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Priority to DE602004011076T priority patent/DE602004011076T2/en
Priority to MXPA06001665A priority patent/MXPA06001665A/en
Priority to EA200600336A priority patent/EA009986B1/en
Priority to JP2006522944A priority patent/JP4252598B2/en
Priority to BRPI0413497A priority patent/BRPI0413497B8/en
Priority to AU2004263306A priority patent/AU2004263306B2/en
Priority to YUP-2006/0076A priority patent/RS20060076A/en
Publication of WO2005014563A1 publication Critical patent/WO2005014563A1/en
Priority to IL173274A priority patent/IL173274A/en
Priority to NO20060541A priority patent/NO332263B1/en
Priority to TNP2006000042A priority patent/TNSN06042A1/en
Priority to EGPCTNA2006000136A priority patent/EG26404A/en
Priority to HK07104591.8A priority patent/HK1098147A1/en
Priority to HR20080137T priority patent/HRP20080137T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers

Definitions

  • the present invention relates to compounds of the general formula I
  • R 1 is hydrogen or ( -C 6 )-alkyl
  • R 2 is hydrogen, (C ⁇ -C 6 )-alkyl, (C 2 -C 6 ) -alkenyl, (Cj.-C 6 )-alkyl substituted by halogen, (Ci-CMalkyl substituted by hydroxy, (CH 2 ) n -(C 3 -C ) -cycloalkyl optionally substituted by (C ⁇ -C 6 )-alkoxy or by halogen, or is CH(CH 3 )-(C 3 -C )-cycloalkyl, (CH 2 ) n+ ⁇ -C(O)-R 9 , (CH 2 ) n+1 -CN, bicyclo[2.2J]heptyl, (CH 2 ) n+1 -O-(C ⁇ -C 6 )-alkyl, (CH 2 ) n -heterocycloalkyl, (CH 2 ) n -aryl or (CH 2 ) n -5 or 6-membered heteroary
  • R 5 is NO 2 , CN, C(O)R 9 or SO 2 R 10 ;
  • R and R 8 independently from each other are hydrogen or ( -C ⁇ -alkyl
  • R 9 is hydrogen, (C C 6 ) -alkyl, (C 1 -C 6 )-alkoxy or NR 7 R 8 ;
  • R 10 is ( - -alkyl optionally subtituted by halogen, (CH 2 ) n -(C 3 -C 6 )-cycloalkyl, (CH 2 ) n -(C 3 -C 6 )-alkoxy, (CH 2 ) n -heterocycloalkyl or NR 7 R 8 ;
  • n 0, 1, or 2; and to pharmaceutically acceptable acid addition salts thereof, with the proviso that l-[5-(aminosulfonyl)-2-methoxybenzoyl]-4-(3-chlorophenyl)-piperazine, l-[5-(aminosulfonyl)-2-methoxybenzoyl]-4-(4-fluorophenyl)-piperazine, l-[5-(aminosulfonyl)-2-methoxybenzoyl] -4- [3-(trifluoromethyl)phenyl] -piperazine, 4-(3-amino-4-nitrophenyl)-l-[4-(dimethylamino)-2-methoxy-5-nitrobenzoyl]-2- methyl-piperazine, l-[4-(dimethylamino)-2-methoxy-5-nitrobenzoyl]-2-methyl-4-(4-nitrophenyl)- piperazine, 4-[4
  • the other excluded compounds are commercially available products.
  • the present invention relates to compounds of general formula I, to pharmaceutical composition containing them and their use in the treatment of neurological and neuropsychiatric disorders. It has surprisingly been found that the compounds of general formula I are good inhibitors of the glycine transporter 1 (GlyT-1), and that they have a good selectivity to glycine transporter 2 (GlyT-2) inhibitors.
  • GlyT-1 glycine transporter 1
  • GlyT-2 GlyT-2
  • Schizophrenia is a progressive and devastating neurological disease characterized by episodic positive symptoms such as delusions, hallucinations, thought disorders and psychosis and persistent negative symptoms such as flattened affect, impaired attention and social withdrawal, and cognitive impairments (Lewis DA and Lieberman JA, Neuron, , 28:325-33, 2000).
  • PCP phencyclidine
  • ketamine non- competitive NMDA receptor antagonists
  • transgenic mice expressing reduced levels of the NMD ARI subunit displays behavioral abnormalities similar to those observed in pharmacologically induced models of schizophrenia, supporting a model in which reduced NMDA receptor activity results in schizophrenia-like behavior (Mohn AR et al., Cell, 98: 427-236, 1999).
  • Glutamate neurotransmission, in particular NMDA receptor activity plays a critical role in synaptic plasticity, learning and memory, such as the NMDA receptors appears to serve as a graded switch for gating the threshold of synaptic plasticity and memory formation (Wiley, NY; Bliss TV and Collingridge GL, Nature, 361: 31-39, 1993).
  • mice overexpressing the NMDA NR2B subunit exhibit enhanced synaptic plasticity and superior ability in learning and memory (Tang JP et al., Natur, 401- 63-69, 1999).
  • enhancing glutamate transmission in particular via NMDA receptor activation, would be predicted to produce both anti-psychotic and cognitive enhancing effects.
  • the amino acid glycine is known to have at least two important functions in the CNS. It acts as an inhibitory amino acid, binding to strychnine sensitive glycine receptors, and it also influences excitatory activity, acting as an essential co-agonist with glutamate for N-methyl-D-aspartate (NMDA) receptor function. While glutamate is released in an activity-dependent manner from synaptic terminals, glycine is apparently present at a more constant level and seems to modulate/ control the receptor for its response to glutamate. One of the most effective ways to control synaptic concentrations of neurotransmitter is to influence their re-uptake at the synapses.
  • Neurotransmitter transporters by removing neurotransmitters from the extracellular space, can control their extracellular lifetime and thereby modulate the magnitude of the synaptic transmission (Gainetdinov RR et al, Trends in Pharm. Sci., 23(8): 367-373, 2002).
  • Glycine transporters which form part of the sodium and chloride family of neurotransmitter transporters, play an important role in the termination of post-synaptic glycinergic actions and maintenance of low extracellular glycine concentration by re- uptake of glycine into presynaptic nerve terminals and surrounding fine glial processes.
  • GlyT-1 and GlyT-2 Two distinct glycine transporter genes have been cloned (GlyT-1 and GlyT-2) from mammalian brain, which give rise to two transporters with ⁇ 50 % amino acid sequence homology.
  • GlyT-1 presents four isoforms arising from alternative splicing and alternative promoter usage (la, lb, lc and Id). Only two of these isoforms have been found in rodent brain (GlyT-la and GlyT-lb).
  • GlyT-2 also presents some degree of heterogeneity.
  • Two GlyT-2 isoforms (2a and 2b) have been identified in rodent brains.
  • GlyT-1 is known to be located in CNS and in peripheral tissues, whereas GlyT-2 is specific to the CNS.
  • GlyT-1 has a predominantly glial distribution and is found not only in areas corresponding to strychnine sensitive glycine receptors but also outside these areas, where it has been postulated to be involved in modulation of NMDA receptor function (Lopez-Corcuera B et al., Mol. Mem. Biol, 18: 13-20, 2001).
  • one strategy to enhance NMDA receptor activity is to elevate the glycine concentration in the local microenvironment of synaptic NMDA receptors by inhibition of GlyT- 1 transporter (Bergereon R. et al., Proc. Natl. Acad. Sci. USA, 95: 15730-15734, 1998; Chen L. et al., /.
  • Glycine transporters inhibitors are suitable for the treatment of neurological and neuropsychiatric disorders.
  • the majority of diseases states implicated are psychoses, schizophrenia (Armer RE and Miller DJ, Exp. Opin. Ther. Patents, 11 (4): 563-572, 2001), psychotic mood disorders such as severe major depressive disorder, mood disorders associated with psychotic disorders such as acute mania or depression, associated with bipolar disorders and mood disorders, associated with schizophrenia, (Pralong ET et al., Prog. Neurobiol, 67: 173-202, 2002), autistic disorders (Carlsson ML, /. Neural Trans,.
  • cognitive disorders such as dementias, including age related dementia and senile dementia of the Alzheimer type, memory disorders in a mammal, including a human, attention deficit disorders and pain (Armer RE and Miller DJ, Exp. Opin. Ther. Patents, 11 (4): 563-572, 2001).
  • NMDA receptors via GlyT-1 inhibition may lead to agents that treat psychosis, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.
  • Objects of the present invention are the compounds of formula I per se, the use of compounds of formula I and their pharmaceutically acceptable salts for the manufacture of medicaments for the treatment of diseases related to activation of NMDA receptors via Glyt-1 inhibition, their manufacture, medicaments based on a compound in accordance with the invention and their production as well as the use of compounds of formula I in the control or prevention of illnesses such as psychoses, disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.
  • alkyl denotes a saturated straight- or branched-chain group containing from 1 to 6 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, n-butyl, i-butyl, 2-butyl, t-butyl and the like.
  • Preferred alkyl groups are groups with 1 - 4 carbon atoms.
  • halogen denotes chlorine, iodine, fluorine and bromine.
  • aryl denotes a monovalent cyclic aromatic hydrocarbon radical consisting of one or more fused rings in which at least one ring is aromatic in nature, for example phenyl, benzyl, naphthyl, biphenyl or indanyl.
  • 6-membered heteroaryl containing one, two or three nitrogen atoms denotes a monovalent aromatic carbocyclic radical, for example pyrid l, pyrazinyl, pyrimidinyl, pyridazinyl or 1,3,5-triazinyl.
  • heterocycloalkyl denotes a non aromatic hydrocarbon radical, for example oxetanyl, tetrahydroruranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl or thiomorpholinyl.
  • 5-membered aromatic heterocycle containing 1 - 4 heteroatoms, selected from N and O
  • 5 or 6-membered heteroaryl containing one, two or three heteroatoms, selected from the group consisting of oxygen, sulphur or nitrogen denotes a monovalent aromatic carbocyclic radical, for example pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, thiazolyl, thienyl, furyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl or isoxazolyl.
  • alkyl, substituted by halogen denotes for example the following groups: CF 3 , CHF 2 , CH 2 F, CH 2 CF 3 , CH 2 CHF 2 , CH 2 CH 2 F, CH 2 CH 2 CF 3 , CH 2 CH 2 CH 2 CF 3 , CH 2 CH 2 C1, CH 2 CF 2 CF 3 , CH 2 CF 2 CHF 2 , CF 2 CHFCF 3 , C(CH 3 ) 2 CF 3 , CH(CH 3 )CF 3 or CH(CH 2 F)CH 2 F.
  • alkyl, substituted by hydroxy denotes for example the following groups: CH(OH)CH 3 , CH 2 CH(OH)CH 3 , CH 2 CH(CH 3 )CH 2 OH, (CH 2 ) 2 OH, (CH 2 ) 3 OH or CH 2 C[(CH 3 )] 2 -CH 2 OH.
  • pharmaceutically acceptable acid addition salts embraces salts with inorganic and organic acids, such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methane-sulfonic acid, p-toluenesulfonic acid and the like.
  • inorganic and organic acids such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methane-sulfonic acid, p-toluenesulfonic acid and the like.
  • One embodiment of the invention are compounds of the general formula
  • Ar is substituted aryl or unsubstituted or substituted 6-membered heteroaryl, containing one, two or three nitrogen atoms, and wherein the aryl and the heteroaryl groups are substituted by one or more substituents selected from the group consisting of hydroxy, halogen, NO 2 , CN, (CrC 6 )-aIkyl, (C 1 -C 6 )-alkyl substituted by halogen, (C r C 6 )-alkoxy, (C C 6 )-alkoxy substituted by halogen, NR 7 R 8 , C(O)R 9 or SO 2 R 10 ;
  • R 1 is hydrogen or ( -C- ⁇ J-alkyl
  • R 2 is (CrC 6 ) -alkyl, (CrC 6 )-alkyl substituted by halogen, (C 3 -C 6 )-cycloalkyl, heterocycloalkyl, (CrC 6 )-alkyl-(C 3 -C 6 )-cycloalkyl, (C ⁇ -C 6 )-alkyl-heterocycloalkyl, (C C 6 )-alkyl-C(O)-R 9 , (C C 6 )-alkyl-CN, (C 2 -C 6 )-alkyl-O-R 13 , (C 2 -C 6 )-alkyl- NR 7 R 8 , aryl or 6-membered heteroaryl containing one, two or three nitrogen atoms, (C ⁇ -C 6 )-alkyl-aryl or ( -C 6 )-alkyl-5 or-6-membered heteroaryl containing one, two or three heteroatoms, selected from
  • R 3 , R 4 and R 6 independently from each other are hydrogen, hydroxy, halogen, CN, (Ci-C 6 )-alkyl, ( -C 6 )-alkoxy or NR 7 R 8 ;
  • R 5 is NO 2 , CN, C(O)R 9 , SO 2 R 10 or NR 1 *R 12 ;
  • R 7 and R 8 independently from each other are hydrogen or (CrC 6 )-alkyl
  • R 9 is hydroxy, (C C 6 )-alkyl, (C 3 -C 6 )-cycloalkyl, (C ⁇ -C 6 )-alkoxy or NR 7 R 8 ;
  • R 10 is (C ⁇ - )-alkyl, (C 3 -C 6 )-cycloalkyl or NR 7 R 8 ;
  • R 11 and R 12 independently from each other are hydrogen, C(O)-(CrC 6 )-alkyl, SO 2 -(C 1 -C 6 )-alkyl, or form together with the N-atom a 5-membered heteroaryl group, optionally substituted by halogen, (C ⁇ -C 6 )-alkyl, ( -C ⁇ -alkyl substituted by halogen or (C . -C ⁇ Mycloalkyl; R 13 is hydroxy, (C ⁇ - )-alkyl or (C 3 -C 6 ) -cycloalkyl;
  • R is hydrogen or halogen; R is hydrogen or halogen;
  • R " is CN, C(O)-(C ⁇ -C 6 )-alkyl, (C 1 -C 6 )-alkyl substituted by halogen or S(O) 2 -(CrC 6 )- alkyl; R is hydrogen;
  • R 5 is S(O) 2 -(C r C 6 )-alkyl, S(O) 2 NH 2 or NO 2 ;
  • R 2 is (Q-Q -alkyl, (C 3 -C 6 )-cycloalkyl, (C r C 6 )-alkyl-(C 3 -C 6 )-cycloalkyl, (C 1 -C 6 )-alkyl substituted by halogen, -(CH 2 ) 2 O-(CrC 6 )-alkyl, benzyl or aryl, optionally substituted by halogen;
  • a further embodiment of the invention are those compounds of formula la, wherein
  • R is hydrogen or fluoro
  • R is hydrogen or fluoro
  • R " is CN, C(O)CH 3 , CF 3 or S(O) 2 -CH 3 ;
  • R is hydrogen;
  • R 5 is S(O) 2 -CH 3 , S(O) 2 NH 2 or NO 2 ;
  • R 2 is (C ⁇ -C 6 )-alkyl, -CH 2 -cyclopropyl, cyclopentyl, -CH 2 -CF 3 , or -(CH 2 ) 2 -O-CH 3) benzyl or phenyl substituted by fluoro; for example the following compounds:
  • a furher embodiment of the present invention are compounds, wherein R 5 is S(O) 2 -CH 3 and R 2 is
  • Preferred compounds of formula I of the present invention are those, wherein Ar is substituted phenyl, R 2 is (C ⁇ -C 6 )-alkyl and R 5 is S(O) 2 CH 3 or S(O) 2 CH 2 CH 3 .
  • a further preferred group of compounds of formula I are those, wherein Ar is substituted phenyl, R 2 is (CH 2 ) n -(C 3 -C 7 )-cycloalkyl and R 5 is S(O) 2 CH 3 , for example the following compounds l- ⁇ 4-[4-(2-cyclopropylmethoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-3-fluoro- phenylj-ethanone,
  • Ar is substituted phenyl
  • R 2 is (C ⁇ -C 6 )-alkyl substituted by halogen
  • R 5 is S(O) 2 CH 3 .
  • Preferred compounds of formula I of the present invention are further those, wherein Ar is substituted phenyl, R 2 is (C 1 -C 6 )-alkyl, ( -C 6 )-alkyl substituted by halogen, CH 2 ) n -(C 3 -C 7 ) -cycloalkyl, bicycle[2.2J]heptyl, (CH 2 ) n -O-(C 1 -C 6 )-alkyl or CH 2 ) n -heterocycloalkyl and R 5 is NO 2 , for example the following compounds:
  • a further preferred group of compounds of formula I are those, wherein Ar is a substituted 6-membered heteroaryl group, containing one, two or three nitrogen atoms, R 2 is (C 1 -C 6 )-alkyl or CH 2 ) n -(C 3 -C 7 )-cycloalkyl, and R 5 is SO 2 CH 3 , for example:
  • a compound of formula ROH optionally in the presence of a catalyst, such as Cu(I)I and a base like potassium carbonate, cesium carbonate or sodium, to a compound of formula
  • X is halogen, mesylate or triflate and the other substituents are as defined above, or
  • R 9 is (C C 6 ) -alkyl, (C 3 -C 6 )-cycloalkyl, ( - ) -alkoxy or NR 7 R 8 ; and the other substituents are as defined above, or
  • R is H or alkyl and the other substituents are as defined above, or
  • R is H or alkyl and the other substituents are as defined above, and if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts.
  • the compounds of formula I may be prepared in accordance with process variant a) to h) and with the following schemes 1 to 8.
  • the starting material is commercially available or maybe prepared in accordance with known methods.
  • Compounds of general formula I can be prepared by reacting piperazine derivatives of formula II with a corresponding acid of formula III in the presence of an activating agent like TBTU (2-( lH-benzotriazole-l-yl)-lJ,3,3-tetramethyluroniumtetrafluoroborate).
  • the acid of formula III can be prepared by reaction of an acid of formula IV with an alcohol of formula R 2 OH, optionally in the presence of a copper salt like Cu(I)Br.
  • Piperazine derivatives of formula II can be prepared by heating of the corresponding piperazine with ArX or by reacting of a N-protected piperazine with ArX in the presence of palladium catalyst followed by cleavage of the protective group.
  • the protective group is typically tert-butoxycarbonyl (Boc) .
  • compounds of general formula I can be prepared by reaction of an acyl- piperazine of formula V and an alcohol of formula R 2 OH, optionally in the presence of a copper salt like Cu(I)I.
  • Acylpiperazine derivatives of formula V can be prepared by reaction of an acid of formula IV with piperazine derivatives of formula II in the presence of an activating agent like TBTU (2-(lH-benzotriazole-l-yl)-lJ,3,3- tetramethyluroniumtetrafluoroborate).
  • Compounds of general formula I can be prepared by reacting phenol of formula VI with an alcohol of formula R 2 OH under Mitsunobu condition, in the presence of a phosphine like triphenylphosphine or diphenyl-2-pyridylphosphine, and a dialkylazadicarboxylate like diethylazadicarboxylate or di-tert-butyl azodicarboxylate.
  • a phosphine like triphenylphosphine or diphenyl-2-pyridylphosphine
  • a dialkylazadicarboxylate like diethylazadicarboxylate or di-tert-butyl azodicarboxylate.
  • the compound of formula VI can be prepared by deprotection (for example using hydrogen) of a phenol protected as a benzyl ether (I with R 2 : benzyl).
  • a compound of formula VI can be prepared by reacting piperazine derivatives of formula II with an acid of formula VII in the presence of an activating agent like TBTU (2-(lH-benzotriazole-l-yl)-l,l,3,3- tetramethyluroniumtetrafluoroborate).
  • R 9 is (C ⁇ -C 6 )-alkoxy or NR 7 R 8 ;
  • Compounds of general formula le wherein R is H or alkyl and R 9 is (C,-C 6 )-alkyl or (C 3 -C 6 )-cycloalkyl can be prepared by reacting a compound of formula lc bearing a carbonyl group, with a reducing agent like sodium borohydride (when R is H) or an alkylating agent like alkyllithium (when R is alkyl).
  • Racemic mixtures of chiral compounds of formula I can be separated using chiral HPLC.
  • the acid addition salts of the basic compounds of formula I may be converted to the corresponding free bases by treatment with at least a stoichiometric equivalent of a suitable base such as sodium or potassium hydroxide, potassium carbonate, sodium bicarbonate, ammonia, and the like.
  • a suitable base such as sodium or potassium hydroxide, potassium carbonate, sodium bicarbonate, ammonia, and the like.
  • RT room temperature
  • n-Boc-piperazine tert-Butyl 1 -piperazin ecarboxylate
  • oxone® (potassium peroxymonosulfate) 2KHSOs , KHSO , K 2 SO , EtOAc: ethyl acetate
  • THF tetrahydrofuran
  • the aqueous layer was extracted 3 times with CH 2 C1 2 .
  • the combined extracts were dried over Na 2 SO , filtered and the solvent was removed in vacuo.
  • the crude gum was purified on silicagel (eluent: heptane/ethylacetate 0%-20% (10 min) to provide the title compound 1.8.
  • Example 1J2 Preparation of 5-Cyano-2-(2,2,2-trifluoro-ethoxy)-benzoic acid
  • a mixture of 11.3 mmol sodium in 66 mmol 2,2,2-trifluoroethanol was heated to 100°C until all sodium was dissolved (20 min.).
  • a solution of 5.5 mmol 5-cyano-2-iodo- benzoic acid [CAS: 219841-92-6; WO9901455] in 2 ml N-methyl-2-pyrrolidone and 0.5 mmol copper (I) bromide were added and the reaction mixture heated to 120° C for 2 h.
  • the reaction mixture was poured onto water, acidified to pH 2 with cone. HCl and extracted 3x with ethyl acetate.
  • Example 99 was prepared in analogy to Example 66 using l-(chloromethyl)-2,2,3,3- tetrafluorocyclobutane [356-80-9]. MS (m/e): 536.3 (M+H ⁇ 100%).
  • Example 107 was prepared in analogy to example 106 using 4-chloro-6-trifluoromethyl- pyrimidine [37552-81-1]. MS (m/e): 473.1 (M+H + , 100%). Example 2.6
  • 2-(4-Fluoro-phenoxy)-5-nitro-benzoic acid can be prepared by a similar method to that described in the literature (e.g. WO9938845) by reaction of 2-Chloro-5-nitro-benzoic acid ethyl ester [16588-17-3] with 4-Fluoro-phenol [371-35-7] yielding 2-(4-Fluoro- phenoxy)-5-nitro-benzoic acid ethyl ester.
  • 2-(4-Fluoro-phenoxy)-5-nitro-benzoic acid ethyl ester can then be hydrolysed with sodium hydroxide for example to yield the title compound.
  • Example 2.8 was prepared in analogy to Example 2.7 using 2,4,5-trifluorobenzonitrile. MS (m/e): 224.3 (M+H + , 100%). Example 2.9
  • 2,4,5-Trifluoro-benzenesulfonyl chloride [220227-21-4], 2.5 g was added portionwise onto a solution of sodium sulfite (10.3 g) in 50 ml of water.
  • the reaction mixture was kept under basic conditions by the addition of the proper amount of 20% NaOH and was stirred at room temperature for 1 hour.
  • Methanol was added to the reaction mixture and the reaction mixture was stirred at room temperature for another hour. After such time the reaction mixture was cooled down with an ice bath and was then acidified by the addition of 20% H 2 SO solution until reaching pH 2.
  • the aqueous solution was then extracted several times with diethyl ether and ethyl acetate.
  • the aqueous solution was further extracted with etyl acetate using a Kutscher-Steudel apparatus (continuous extraction).
  • the combined organic phases were dried (sodium sulfate) an concentrated in vacuo to yield the title compound as a white solid (2J g).
  • the tide compound was obtained by separation of rac-5-Methanesulfonyl-2-(2,2,2- trifluoro-l-methyl-ethoxy)-benzoic acid methyl ester by chiral HPLC (Chiralcel OD, 15 % ethanol/ Heptane, flow 35 ml, 220 nm, retention time: 86 min.).
  • the tide compound was obtained by separation of rac-5-Methanesulfonyl-2- (2,2,2- trifluoro-1 -methyl-ethoxy) -benzoic acid methyl ester by chiral HPLC (Chiralcel OD, 15 % ethanol/ Heptane, flow 35 ml, 220 nm, retention time: 74 min.).
  • Example 5J0 Preparation of l-(3-Fluoro-4-methanesulfonyl-phenyl)-piperazine The compound was prepared in analogy to compound 2.20 from 2,4- difluorobenzenesulfonylchloride (commercial). MS (m/e): 259J (MH + , 100%)
  • the compound can be prepared from 4-Nitro-2-trifluoromethyl-pyridine 1-oxide [ 147149-97- 1 ] in analogy to the procedure used for the preparation of 4-Bromo-2- methyl-6-trifluoromethyl-pyridine [615579-78-1] (WO03087056). MS (m/e): 227 (M+H + , 100%)
  • Example 5J8 Preparation of l-(6-Methyl-pyridin-3-yl)-piperazine
  • Example 463 Preparation of ⁇ 4- [2-Fluoro-4- ( 1-hydroxy- 1 -methyl-ethyl)-phenyl] -piperazin- 1- yl ⁇ -(2-isopropoxy-5-methanesulfonyl-phenyl)-methanone
  • a solution of 0J73 mmol l- ⁇ 3-Fluoro-4-[4-(2-isopropoxy-5-methanesulfonyl- benzoyl)-piperazin-l-yl]-phenyl ⁇ -ethanone in tetrahydrofuran (2 ml) was added dropwise 0J90 mmol 1.6M Methylhthium solution in ether at -75°C.
  • the tide compound was prepared in analogy to Example 2.25 using 3-Dimethylamino-2- methanesulfonyl-allylidene-dimethyl-ammonium; chloride as starting material. MS (m/e): 243.1 (M+H + , 100%).
  • the tide compound was prepared in analogy to example 5 from l-(3-Fluoro-5- trifluoromethyl-pyridin-2-yl)-piperazine (compound 5.5) and 2-Benzyloxy-5- methanesulfonyl-benzoic acid (compound 7.5). MS (m/e): 538.4 (MH + , 100%)
  • the tide compound was prepared in analogy to example 5 from l-(2-Fluoro-4- methanesulfonyl-pheny
  • the compounds of formula I and their pharmaceutically usable addition salts possess valuable pharmacological properties. Specifically, it has been found that the compounds of the present invention are good inhibitors of the glycine transporter I (GlyT-1).
  • DMEM complete medium Nutrient mixture F-12 (Gibco Life- technologies), fetal bovine serum (FBS) 5 %, (Gibco life technologies), Penicillin/Streptomycin 1 % (Gibco life technologies), Hygromycin 0.6 mg/ml (Gibco life technologies), Glutamine 1 mM Gibco life technologies)
  • Flp-inTM-CHO (Invitrogen Cat n° R758-07)cells stably transfected with mGlyTlb cDNA.
  • mammalian cells (Flp-inTM-CHO), transfected with mGlyT-lb cDNA , were plated at the density of 40,000 cells/well in complete F-12 medium, without hygromycin in 96-well culture plates.
  • the medium was aspirated and the cells were washed twice with uptake buffer (UB).
  • the cells were then incubated for 20 min at 22°C with either (i) no potential competitor, (ii) 10 mM non-radioactive glycine , (iii) a concentration of a potential inhibitor.
  • a range of concentrations of the potential inhibitor was used to generate data for calculating the concentration of inhibitor resulting in 50 % of the effect (e.g.
  • the prepared compounds show an IC 5 Q ( ⁇ M) at GlyT-1 in the range of 0.006 - 5.0.
  • the preferred compounds show an ICs 0 ( ⁇ M) at GlyT-1 in the range of 0.006 - 0.05, as shown in the table below.
  • the compounds of formula I and the pharmaceutically acceptable salts of the compounds of formula I can be used as medicaments, e.g. in the form of pharmaceutical preparations.
  • the pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions.
  • the administration can, however, also be effected rectally, e.g. in the form of suppositories, parenterally, e.g. in the form of injection solutions.
  • the compounds of formula I can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical preparations.
  • Lactose,corn starch or derivatives thereof, talc, stearic acids or its salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragees and hard gelatine capsules.
  • Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like. Depending on the nature of the active substance no carriers are however usually required in the case of soft gelatine capsules.
  • Suitable carriers for the production of solutions and syrups are, for example, water, polyols, glycerol, vegetable oil and the like.
  • Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.
  • the pharmaceutical preparations can, moreover, contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
  • Medicaments containing a compound of formula I or a pharmaceutically acceptable salt thereof and a therapeutically inert carrier are also an object of the present invention, as is a process for their production, which comprises bringing one or more compounds of formula I and/or pharmaceutically acceptable acid addition salts and, if desired, one or more other therapeutically valuable substances into a galenical administration form together with one or more therapeutically inert carriers.
  • the most preferred indications in accordance with the present invention are those, which include disorders of the central nervous system, for example the treatment or prevention of schizophrenia, cognitive impairment and Alzheimer's disease.
  • the dosage can vary within wide limits and will, of course, have to be adjusted to the individual requirements in each particular case.
  • the dosage for adults can vary from about 0.01 mg to about 1000 mg per day of a compound of general formula I or of the corresponding amount of a pharmaceutically acceptable salt thereof.
  • the daily dosage may be administered as single dose or in divided doses and, in addition, the upper limit can also be exceeded when this is found to be indicated.
  • Microcrystalline Cellulose 30 30 30 150 Magnesium Stearate 1 1 1 1 1 Total 167 167 167 831 Manufacturing Procedure
  • Item Ingredients mg/capsulle 5mg 25 mg 100 mg 500

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)

Abstract

The invention relates to compounds of formula (I) wherein the substituents are described in claim 1. The compounds may be used in the treatment of illnesses based on the glycine uptake inhibitor, such as psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.

Description

ERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND THEIR USE AS GLYTl INHIBITORS
The present invention relates to compounds of the general formula I
Figure imgf000002_0001
wherein
Ar is unsubstituted or substituted aryl or 6-membered heteroaryl, containing one, two or three nitrogen atoms, and wherein the aryl and the heteroaryl groups may be substituted by one or more substituents selected from the group consisting of hydroxy, halogen, NO2, CN, (Cι-C6)-alkyl, (Cι- )-alkyl substituted by halogen, (Cι-C6)-alkyl substituted by hydroxy, (CH2)n-(C1-C6)-alkoxy, ( -C^-alkoxy substituted by halogen, NR7R8, C(O)R9, SO2R10, -C(CH3)=NOR7, or by a 5- membered aromatic heterocycle, containing 1 - 4 heteroatoms, selected from N and O, which is optionally substituted by (Cι-C6)-alkyl;
R1 is hydrogen or ( -C6)-alkyl;
R2 is hydrogen, (Cι-C6)-alkyl, (C2-C6) -alkenyl, (Cj.-C6)-alkyl substituted by halogen, (Ci-CMalkyl substituted by hydroxy, (CH2)n-(C3-C ) -cycloalkyl optionally substituted by (Cι-C6)-alkoxy or by halogen, or is CH(CH3)-(C3-C )-cycloalkyl, (CH2)n+ι-C(O)-R9, (CH2)n+1-CN, bicyclo[2.2J]heptyl, (CH2)n+1-O-(Cι-C6)-alkyl, (CH2)n-heterocycloalkyl, (CH2)n-aryl or (CH2)n-5 or 6-membered heteroaryl containing one, two or three heteroatoms, selected from the group consisting of oxygen, sulphur or nitrogen wherein aryl, heterocycloalkyl and heteroaryl are unsubstituted or substituted by one or more substituents selected from the group consisting of hydroxy, halogen, (Ci-CMalkyl or (Cι-C6)-alkoxy; R , R and R independently from each other are hydrogen, hydroxy, halogen, ( -Q -alkyl, (C C6) -alkoxy or O-(C.-C_)-cycloalkyl;
R5 is NO2, CN, C(O)R9 or SO2R10;
R and R8 independently from each other are hydrogen or ( -C^-alkyl;
R9 is hydrogen, (C C6) -alkyl, (C1-C6)-alkoxy or NR7R8;
R10 is ( - -alkyl optionally subtituted by halogen, (CH2)n-(C3-C6)-cycloalkyl, (CH2)n-(C3-C6)-alkoxy, (CH2)n-heterocycloalkyl or NR7R8;
n is 0, 1, or 2; and to pharmaceutically acceptable acid addition salts thereof, with the proviso that l-[5-(aminosulfonyl)-2-methoxybenzoyl]-4-(3-chlorophenyl)-piperazine, l-[5-(aminosulfonyl)-2-methoxybenzoyl]-4-(4-fluorophenyl)-piperazine, l-[5-(aminosulfonyl)-2-methoxybenzoyl] -4- [3-(trifluoromethyl)phenyl] -piperazine, 4-(3-amino-4-nitrophenyl)-l-[4-(dimethylamino)-2-methoxy-5-nitrobenzoyl]-2- methyl-piperazine, l-[4-(dimethylamino)-2-methoxy-5-nitrobenzoyl]-2-methyl-4-(4-nitrophenyl)- piperazine, 4-[4-(dimethylamino)-2-methoxy-5-nitrobenzoyl]-2-methyl-l-(4-nitrophenyl)- piperazine, l-(2-chloro-4-nitrophenyl)-4-[4-(dimethylamino)-2-methoxy-5-nitrobenzoyl]- piperazine, l-[4-(dimethylamino)-2-methoxy-5-nitrobenzoyl]-4-(2,4-dinitrophenyl)-2-methyl- piperazine, l-(4-chloro-2-nitrophenyl)-4-[4-(dimethylamino)-2-methoxy-5-nitrobenzoyl]- piperazine and 4-[4-(dimethylamino)-2-methoxy-5-nitrobenzoyl]-l-(2,4-dinitrophenyl)-2-methyl- piperazine are excluded.
The compounds l-[5-(aminosulfonyl)-2-methoxybenzoyl]-4-(3-chlorophenyl)-piperazine, l-[5-(aminosulfonyl)-2-methoxybenzoyl]-4-(4-fluorophenyl)-piperazine and l-[5-(aminosulfonyl)-2-methoxybenzoyl]-4-[3-(trifluoromethyl)phenyl] -piperazine are specifically described in EP 0171636, possessing inhibiting activity towards carbonic anhydrase which plays a determining role in many physiological and pathological processes.
The other excluded compounds are commercially available products. The present invention relates to compounds of general formula I, to pharmaceutical composition containing them and their use in the treatment of neurological and neuropsychiatric disorders. It has surprisingly been found that the compounds of general formula I are good inhibitors of the glycine transporter 1 (GlyT-1), and that they have a good selectivity to glycine transporter 2 (GlyT-2) inhibitors. Schizophrenia is a progressive and devastating neurological disease characterized by episodic positive symptoms such as delusions, hallucinations, thought disorders and psychosis and persistent negative symptoms such as flattened affect, impaired attention and social withdrawal, and cognitive impairments (Lewis DA and Lieberman JA, Neuron, , 28:325-33, 2000). For decades research has focused on the "dopaminergic hyperactivity" hypothesis which has led to therapeutic interventions involving blockade of the dopaminergic system (Vandenberg RJ and Aubrey KR., Exp. Opin. Ther. Targets, 5(4): 507-518, 2001; Nakazato A and Okuyama S, et al., Exp. Opin. Ther. Patents, 10(1): 75-98, 2000). This pharmacological approach poorly address negative and cognitive symptoms which are the best redictors of functional outcome (Sharma T., Br.]. Psychiatry, 174(suppl. 28): 44-51, 1999). A complementary model of schizophrenia was proposed in the mid- 1960' based upon the psychotomimetic action caused by the blockade of the glutamate system by compounds like phencyclidine (PCP) and related agents (ketamine) which are non- competitive NMDA receptor antagonists. Interestingly in healthy volunteers, PCP- induced psychotomimetic action incorporates positive and negative symptoms as well as cognitive dysfunction, thus closely resembling schizophrenia in patients (Javitt DC et al., Biol. Psychiatry, 45: 668-679, 1999). Furthermore transgenic mice expressing reduced levels of the NMD ARI subunit displays behavioral abnormalities similar to those observed in pharmacologically induced models of schizophrenia, supporting a model in which reduced NMDA receptor activity results in schizophrenia-like behavior (Mohn AR et al., Cell, 98: 427-236, 1999). Glutamate neurotransmission, in particular NMDA receptor activity, plays a critical role in synaptic plasticity, learning and memory, such as the NMDA receptors appears to serve as a graded switch for gating the threshold of synaptic plasticity and memory formation (Wiley, NY; Bliss TV and Collingridge GL, Nature, 361: 31-39, 1993). Transgenic mice overexpressing the NMDA NR2B subunit exhibit enhanced synaptic plasticity and superior ability in learning and memory (Tang JP et al., Natur, 401- 63-69, 1999). Thus, if a glutamate deficit is implicate in the pathophysiology of schizophrenia, enhancing glutamate transmission, in particular via NMDA receptor activation, would be predicted to produce both anti-psychotic and cognitive enhancing effects.
The amino acid glycine is known to have at least two important functions in the CNS. It acts as an inhibitory amino acid, binding to strychnine sensitive glycine receptors, and it also influences excitatory activity, acting as an essential co-agonist with glutamate for N-methyl-D-aspartate (NMDA) receptor function. While glutamate is released in an activity-dependent manner from synaptic terminals, glycine is apparently present at a more constant level and seems to modulate/ control the receptor for its response to glutamate. One of the most effective ways to control synaptic concentrations of neurotransmitter is to influence their re-uptake at the synapses. Neurotransmitter transporters by removing neurotransmitters from the extracellular space, can control their extracellular lifetime and thereby modulate the magnitude of the synaptic transmission (Gainetdinov RR et al, Trends in Pharm. Sci., 23(8): 367-373, 2002). Glycine transporters, which form part of the sodium and chloride family of neurotransmitter transporters, play an important role in the termination of post-synaptic glycinergic actions and maintenance of low extracellular glycine concentration by re- uptake of glycine into presynaptic nerve terminals and surrounding fine glial processes. Two distinct glycine transporter genes have been cloned (GlyT-1 and GlyT-2) from mammalian brain, which give rise to two transporters with ~50 % amino acid sequence homology. GlyT-1 presents four isoforms arising from alternative splicing and alternative promoter usage (la, lb, lc and Id). Only two of these isoforms have been found in rodent brain (GlyT-la and GlyT-lb). GlyT-2 also presents some degree of heterogeneity. Two GlyT-2 isoforms (2a and 2b) have been identified in rodent brains. GlyT-1 is known to be located in CNS and in peripheral tissues, whereas GlyT-2 is specific to the CNS. GlyT-1 has a predominantly glial distribution and is found not only in areas corresponding to strychnine sensitive glycine receptors but also outside these areas, where it has been postulated to be involved in modulation of NMDA receptor function (Lopez-Corcuera B et al., Mol. Mem. Biol, 18: 13-20, 2001). Thus, one strategy to enhance NMDA receptor activity is to elevate the glycine concentration in the local microenvironment of synaptic NMDA receptors by inhibition of GlyT- 1 transporter (Bergereon R. et al., Proc. Natl. Acad. Sci. USA, 95: 15730-15734, 1998; Chen L. et al., /. Neurophysiol, 89(2): 691-703, 2003). Glycine transporters inhibitors are suitable for the treatment of neurological and neuropsychiatric disorders. The majority of diseases states implicated are psychoses, schizophrenia (Armer RE and Miller DJ, Exp. Opin. Ther. Patents, 11 (4): 563-572, 2001), psychotic mood disorders such as severe major depressive disorder, mood disorders associated with psychotic disorders such as acute mania or depression, associated with bipolar disorders and mood disorders, associated with schizophrenia, (Pralong ET et al., Prog. Neurobiol, 67: 173-202, 2002), autistic disorders (Carlsson ML, /. Neural Trans,. 105: 525-535, 1998), cognitive disorders such as dementias, including age related dementia and senile dementia of the Alzheimer type, memory disorders in a mammal, including a human, attention deficit disorders and pain (Armer RE and Miller DJ, Exp. Opin. Ther. Patents, 11 (4): 563-572, 2001).
Thus, increasing activation of NMDA receptors via GlyT-1 inhibition may lead to agents that treat psychosis, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease. Objects of the present invention are the compounds of formula I per se, the use of compounds of formula I and their pharmaceutically acceptable salts for the manufacture of medicaments for the treatment of diseases related to activation of NMDA receptors via Glyt-1 inhibition, their manufacture, medicaments based on a compound in accordance with the invention and their production as well as the use of compounds of formula I in the control or prevention of illnesses such as psychoses, disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.
The preferred indications using the compounds of the present invention are schizophrenia, cognitive impairment and Alzheimer's disease. Furthermore, the invention includes all racemic mixtures, all their corresponding enantiomers and/or optical isomers. As used herein, the term "alkyl" denotes a saturated straight- or branched-chain group containing from 1 to 6 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, n-butyl, i-butyl, 2-butyl, t-butyl and the like. Preferred alkyl groups are groups with 1 - 4 carbon atoms.
The term "halogen" denotes chlorine, iodine, fluorine and bromine.
The term "aryl" denotes a monovalent cyclic aromatic hydrocarbon radical consisting of one or more fused rings in which at least one ring is aromatic in nature, for example phenyl, benzyl, naphthyl, biphenyl or indanyl. The term "6-membered heteroaryl containing one, two or three nitrogen atoms" denotes a monovalent aromatic carbocyclic radical, for example pyrid l, pyrazinyl, pyrimidinyl, pyridazinyl or 1,3,5-triazinyl.
The term "heterocycloalkyl" denotes a non aromatic hydrocarbon radical, for example oxetanyl, tetrahydroruranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl or thiomorpholinyl.
The term "5-membered aromatic heterocycle, containing 1 - 4 heteroatoms, selected from N and O" denotes for example 1,2,4-oxadiazolyl, oxazolyl, 1,3,4-oxadiazolyl or tetrazolyl. The term "5 or 6-membered heteroaryl containing one, two or three heteroatoms, selected from the group consisting of oxygen, sulphur or nitrogen" denotes a monovalent aromatic carbocyclic radical, for example pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, thiazolyl, thienyl, furyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl or isoxazolyl.
The term "alkyl, substituted by halogen" denotes for example the following groups: CF3, CHF2, CH2F, CH2CF3, CH2CHF2, CH2CH2F, CH2CH2CF3, CH2CH2CH2CF3, CH2CH2C1, CH2CF2CF3, CH2CF2CHF2, CF2CHFCF3, C(CH3)2CF3, CH(CH3)CF3 or CH(CH2F)CH2F.
The term "alkyl, substituted by hydroxy" denotes for example the following groups: CH(OH)CH3, CH2CH(OH)CH3, CH2CH(CH3)CH2OH, (CH2)2OH, (CH2)3OH or CH2C[(CH3)]2-CH2OH.
The term "pharmaceutically acceptable acid addition salts" embraces salts with inorganic and organic acids, such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methane-sulfonic acid, p-toluenesulfonic acid and the like. One embodiment of the invention are compounds of the general formula
Figure imgf000007_0001
wherein
Ar is substituted aryl or unsubstituted or substituted 6-membered heteroaryl, containing one, two or three nitrogen atoms, and wherein the aryl and the heteroaryl groups are substituted by one or more substituents selected from the group consisting of hydroxy, halogen, NO2, CN, (CrC6)-aIkyl, (C1-C6)-alkyl substituted by halogen, (CrC6)-alkoxy, (C C6)-alkoxy substituted by halogen, NR7R8, C(O)R9 or SO2R10;
R1 is hydrogen or ( -C-βJ-alkyl;
R2 is (CrC6) -alkyl, (CrC6)-alkyl substituted by halogen, (C3-C6)-cycloalkyl, heterocycloalkyl, (CrC6)-alkyl-(C3-C6)-cycloalkyl, (Cι-C6)-alkyl-heterocycloalkyl, (C C6)-alkyl-C(O)-R9, (C C6)-alkyl-CN, (C2-C6)-alkyl-O-R13, (C2-C6)-alkyl- NR7R8, aryl or 6-membered heteroaryl containing one, two or three nitrogen atoms, (Cι-C6)-alkyl-aryl or ( -C6)-alkyl-5 or-6-membered heteroaryl containing one, two or three heteroatoms, selected from the group consisting of oxygen, sulphur or nitrogen wherein aryl, heterocycloalkyl and heteroaryl are unsubstituted or substituted by one or more substituents selected from the group consisting of hydroxy, halogen, (C C6)-alkyl or ( -C^-alkoxy;
R3, R4 and R6 independently from each other are hydrogen, hydroxy, halogen, CN, (Ci-C6)-alkyl, ( -C6)-alkoxy or NR7R8;
R5 is NO2, CN, C(O)R9, SO2R10 or NR1 *R12;
R7 and R8 independently from each other are hydrogen or (CrC6)-alkyl;
R9 is hydroxy, (C C6)-alkyl, (C3-C6)-cycloalkyl, (Cι-C6)-alkoxy or NR7R8;
R10 is (Cι- )-alkyl, (C3-C6)-cycloalkyl or NR7R8;
R11 and R12 independently from each other are hydrogen, C(O)-(CrC6)-alkyl, SO2-(C1-C6)-alkyl, or form together with the N-atom a 5-membered heteroaryl group, optionally substituted by halogen, (Cι-C6)-alkyl, ( -C^-alkyl substituted by halogen or (C.-CόMycloalkyl; R13 is hydroxy, (Cι- )-alkyl or (C3-C6) -cycloalkyl;
and pharmaceutically acceptable acid addition salts thereof, with the proviso that l-[5-(aminosulfonyl)-2-methoxybenzoyl]-4-(3-chlorophenyl)-piperazine, l-[5-(aminosulfonyl)-2-methoxybenzoyl]-4-(4-fluorophenyl)-piperazine, l-[5-(aminosulfonyl)-2-methoxybenzoyl]-4-[3-(trifluoromethyl)phenyl] -piperazine, 4-(3-amino-4-nitrophenyl)-l-[4-(dimethylamino)-2-methoxy-5-nitrobenzoyl]-2- methyl-piperazine, l-[4-(dimethylamino)-2-methoxy-5-nitrobenzoyl]-2-methyl-4-(4-nitrophenyl)- piperazine, 4-[4-(dimethylamino)-2-methoxy-5-nitrobenzoyl]-2-methyl-l-(4-nitrophenyl)- piperazine, l-(2-chloro-4-nitrophenyl)-4-[4-(dimethylamino)-2-methoxy-5-nitrobenzoyl]- piperazine, l-[4-(dimethylamino)-2-methoxy-5-nitrobenzoyl]-4-(2,4-dinitrophenyl)-2-methyl- piperazine, l-(4-chloro-2-nitrophenyl)-4-[4-(dimethylamino)-2-methoxy-5-nitrobenzoyl]- piperazine and 4-[4-(dimethylamino)-2-methoxy-5-nitrobenzoyl]-l-(2,4-dinitrophenyl)-2-methyl- piperazine are excluded.
Another embodiment of the present invention are compounds of formula la
Figure imgf000009_0001
wherein
R is hydrogen or halogen; R is hydrogen or halogen;
R" is CN, C(O)-(Cι-C6)-alkyl, (C1-C6)-alkyl substituted by halogen or S(O)2-(CrC6)- alkyl; R is hydrogen;
R5 is S(O)2-(CrC6)-alkyl, S(O)2NH2 or NO2; and
R2 is (Q-Q -alkyl, (C3-C6)-cycloalkyl, (CrC6)-alkyl-(C3-C6)-cycloalkyl, (C1-C6)-alkyl substituted by halogen, -(CH2)2O-(CrC6)-alkyl, benzyl or aryl, optionally substituted by halogen;
and pharmaceutically acceptable acid addition salts thereof, with the exception of
l-[5-(aminosulfonyl)-2-methoxybenzoyl]-4-(3-chlorophenyl)-piperazine and l-[5-(aminosulfonyl)-2-methoxybenzoyl]-4-[3-(trifluoromethyl)phenyl] -piperazine. A further embodiment of the invention are those compounds of formula la, wherein
R is hydrogen or fluoro;
R is hydrogen or fluoro;
R" is CN, C(O)CH3, CF3 or S(O)2-CH3;
R is hydrogen; R5 is S(O)2-CH3, S(O)2NH2 or NO2; and
R2 is (Cι-C6)-alkyl, -CH2-cyclopropyl, cyclopentyl, -CH2-CF3, or -(CH2)2-O-CH3) benzyl or phenyl substituted by fluoro; for example the following compounds:
2-Fluoro-4-[4-(2-isopropoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-benzonitrile, [4-(3-fluoro-4-trifluoromethyl-phenyl)-piperazin-l-yl]-(2-isopropoxy-5- methanesulfonyl-phenyl)-methanone, l-{3-fluoro-4-[4-(2-isobutoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-phenyl}- ethanone,
4-[4-(2-isobutoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-benzonitrile, 3-fluoro-4-[4-(2-isobutoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-benzonitrile,
2-fluoro-4-[4-(2-isobutoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-benzonitrile,
(2-isobutoxy-5-methanesulfonyl-phenyl)-[4-(4-trifluoromethyl-phenyl)-piperazin-l-yl]- methanone,
[4-(2-fluoro-4-trifluoromethyl-phenyl)-piperazin-l-yl]-(2-isobutoxy-5- methanesulfonyl-phenyl)-methanone or
[4-(3-fluoro-4-trifluoromethyl-phenyl)-piperazin-l-yl]-(2-isobutoxy-5- methanesulfonyl-phenyl)-methanone. A furher embodiment of the present invention are compounds, wherein R5 is S(O)2-CH3 and R2 is
CH2-cyclopropyl, for example the following compound:
4-[4-(2-cycloρropylmethoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-3-fluoro- benzonitrile.
Compounds of formula la are further those, wherein R5 is S(O)2-CH3 and R2 is CH2CF3, for example the following compounds:
[4-(2-fluoro-4-trifluoromethyl-phenyl)-piperazin-l-yl]-[5-methanesulfonyl-2-(2,2,2-tri- fluoro-ethoxy)-phenyl]-methanone or [4-(3-fluoro-4-trifluoromethyl-phenyl)-piperazin-l-yl]-[5-methanesulfonyl-2-(2,2,2-tri- fluoro-ethoxy)-phenyl] -methanone.
Compounds of formula la are further those, wherein R5 is S(O)2-CH3 and R2 is cyclopentyl, for example the following compounds:
4-[4-(2-cyclopentyloxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-3-fluoro- benzonitrile or
4- [4-(2-cyclopentyloxy-5-methanesulfonyl-benzoyl)-piperazin- 1-yl] -2-fluoro- benzonitrile.
Preferred compounds of formula I of the present invention are those, wherein Ar is substituted phenyl, R2 is (Cι-C6)-alkyl and R5 is S(O)2CH3 or S(O)2CH2CH3.
The following specific compounds relate to this group:
l-{3-fluoro-4-[4-(2-isopropoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-phenyl}- ethanone,
3-fluoro-4-[4-(2-isopropoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl] -benzonitrile,
2-Fluoro-4- [4-(2-isopropoxy-5-methanesulfonyl-benzoyl)-piperazin- 1-yl] -benzonitrile, [4-(2-fluoro-4-trifluoromethyl-phenyl)-piperazin-l-yl]-(2-isopropoxy-5- methanesulfonyl-phenyl)-methanone, l-{3-fluoro-4-[4-(2-isobutoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-phenyl}- ethanone,
4- [4-(2-isobutoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl] -benzonitrile, 3-fluoro-4-[4-(2-isobutoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl] -benzonitrile,
2-fluoro-4-[4-(2-isobutoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl] -benzonitrile,
(2-isobutoxy-5-methanesulfonyl-phenyl)-[4-(4-trifluoromethyl-phenyl)-piperazin-l-yl]- methanone, [4-(2-fluoro-4-trifluoromethyl-phenyl)-piperazin-l-yl]-(2-isobutoxy-5- methanesulfonyl-phenyl)-methanone,
[4-(3-fluoro-4-trifluoromethyl-phenyl)-piperazin-l-yl]-(2-isobutoxy-5- methanesulfonyl-phenyl)-methanone, [4-(2-fluoro-4-methanesulfonyl-phenyl)-piperazin-l-yl]-(2-isobutoxy-5- methanesulfonyl-phenyl)-methanone,
[4-(2-fluoro-4-methanesulfonyl-phenyl)-piperazin-l-yl]-(2-isopropoxy-5- methanesulfonyl-phenyl)-methanone,
2,3-difluoro-4-[4-(2-isopropoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]- benzonitrile,
2,3-difluoro-4-[4-(2-isobutoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]- benzonitrile,
2,5-difluoro-4-[4-(2-isobutoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]- benzonitrile, 2,6-difluoro-4-[4-(2-isobutoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]- benzonitrile,
3,5-difluoro-4-[4-(2-isobutoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]- benzonitrile,
4-[4-(2-tert-butoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-2,3-difluoro- benzonitrile,
5-chloro-2-[4-(2-isopropoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl] -benzonitrile,
4-[4-(2-tert-butoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-2,5-difluoro- benzonitrile,
4-[4-(2-tert-butoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-3-fluoro-benzonitrile, (2-tert-butoxy-5-methanesulfonyl-phenyl)-[4-(2-fluoro-4-trifluoromethyl-phenyl)- piperazin- 1 -yl] -methanone,
(2-tert-butoxy-5-methanesulfonyl-phenyl)-[4-(2,5-difluoro-4-methanesulfonyl-phenyl)- piperazin- 1 -yl] -methanone, l-(4-{4-[2-(2,2-dimethyl-propoxy)-5-methanesulfonyl-benzoyl]-piperazin-l-yl}-3- fluoro-phenyl)-ethanone,
4-{4-[2-(2,2-dimethyl-propoxy)-5-methanesulfonyl-benzoyl]-piperazin-l-yl}- benzonitrile,
4-{4-[2-(2,2-dimefhyl-propoxy)-5-methanesulfonyl-benzoyl]-piperazin-l-yl}-3-fluoro- benzonitrile, 4-{4-[2-(2,2-dimethyl-propoxy)-5-methanesulfonyl-benzoyl]-piperazin-l-yl}-2-fluoro- benzonitrile,
[2-(2,2-dimethyl-propoxy)-5-methanesulfonyl-phenyl]-[4-(4-trifluoromethyl-phenyl)- piperazin- 1 -yl] -methanone,
[2-(2,2-dimethyl-propoxy)-5-methanesulfonyl-phenyl]-[4-(2-fluoro-4-trifluoromethyl- phenyl)-piperazin- 1-yl] -methanone,
[2-(2,2-dimethyl-propoxy)-5-methanesulfonyl-phenyl]-[4-(3-fluoro-4-trifluoromethyl- phenyl)-piperazin- 1-yl] -methanone,
[2-(2,2-dimethyl-propoxy)-5-methanesulfonyl-phenyl]-[4-(2-fluoro-4-ethanesulfonyl- phenyl)-piperazin-l-yl]-methanone, rac- 1-{4- [4-(2-sec-butoxy-5-methanesulfonyl-benzoyl)-piperazin- 1-yl] -3-fluoro- phenyl } -ethanone, rac-4-[4-(2-sec-butoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-3-fluoro- benzonitrile, rac-4-[4-(2-sec-butoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-2-fluoro- benzonitrile, rac-(2-sec-butoxy-5-mefhanesulfonyl-phenyl)-[4-(2-fluoro-4-trifluoromethyl-phenyl)- piperazin- 1-yl] -methanone, rac-(2-sec-butoxy-5-methanesulfonyl-phenyl)-[4-(3-fluoro-4-trifluoromethyl-phenyl)- piperazin- 1 -yl] -methanone,
(2-isopropoxy-5-methanesulfonyl-phenyl)-[4-(4-trifluoromethanesulfonyl-phenyl)- piperazin- 1 -yl] -methanone, (2-isobutoxy-5-methanesulfonyl-phenyl)-[4-(4-trifluoromethanesulfonyl-phenyl)- piperazin- 1 -yl] -methanone,
2- [4-(2-isopropoxy-5-methanesulfonyl-benzoyl)-piperazin- 1-yl] -5-trifluoromethyl- benzonitrile, l-{2-fluoro-4-[4-(2-isopropoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-phenyl}- ethanone,
[4-(3-fluoro-4-methanesulfonyl-phenyl)-piperazin-l-yl]-(2-isobutoxy-5- methanesulfonyl-phenyl)-methanone, l-{2-fluoro-4-[4-(2-isobutoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-phenyl}- ethanone, 2- [4-(2-isobutoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl] -5-trifluoromethyl- benzonitrile,
(5-ethanesulfonyl-2-isopropoxy-phenyl)-[4-(2-fluoro-4-trifluoromethyl-phenyl)- piperazin- 1-yl] -methanone,
[4-(4-difluoromethyl-2-fluoro-phenyl)-piperazin-l-yl]-(2-isopropoxy-5- methanesulfonyl-phenyl)-methanone,
[4-(3-chloro-5-trifluoromethyl-pyridin-2-yl)-piperazin-l-yl]-(2-isopropoxy-5- methanesulfonyl-phenyl)-methanone, 3-fluoro-4-[4-(2-isopropoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-benzaldehyde,
[4-(4-ethanesulfonyl-2-fluoro-phenyl)-piperazin-l-yl]-(2-isobutoxy-5-methanesulfonyl- phenyl)-methanone, rac-(2-sec-butoxy-5-methanesulfonyl-phenyl)-[4-(4-ethanesulfonyl-2-fluoro-phenyl)- piperazin- 1-yl] -methanone,
[4-(4-cyclobutanesulfonyl-2-fluoro-phenyl)-piperazin-l-yl]-(2-isopropoxy-5- methanesulfonyl-phenyl)-methanone,
[4-(4-cyclopentanesulfonyl-2-fluoro-phenyl)-piperazin-l-yl]-(2-isopropoxy-5- methanesulfonyl-phenyl)-methanone, [4-(4-cyclopropanesulfonyl-2-fluoro-phenyl)-piperazin-l-yl]-(2-isobutoxy-5- methanesulfonyl-phenyl)-methanone and
[4-(4-cyclopropanesulfonyl-2,5-difluoro-phenyl)-piperazin-l-yl]-(2-isopropoxy-5- methanesulfonyl-phenyl)-mefhanone.
A further preferred group of compounds of formula I are those, wherein Ar is substituted phenyl, R2 is (CH2)n-(C3-C7)-cycloalkyl and R5 is S(O)2CH3, for example the following compounds l-{4-[4-(2-cyclopropylmethoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-3-fluoro- phenylj-ethanone,
4-[4-(2-cyclopropylmethoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl] -benzonitrile, 4-[4-(2-cyclopropylmethoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-3-fluoro- benzonitrile,
4-[4-(2-cyclopropylmethoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-2-fluoro- benzonitrile,
(2-cyclopropylmethoxy-5-methanesulfonyl-phenyl)-[4-(4-trifluoromethyl-phenyl)- piperazin- 1-yl] -methanone,
(2-cyclopropylmethoxy-5-methanesulfonyl-phenyl)-[4-(2-fluoro-4-trifluoromethyl- phenyl) -piperazin- 1-yl] -methanone,
(2-cyclopropylmethoxy-5-methanesulfonyl-phenyl)-[4-(3-fluoro-4-trifluoromethyl- phenyl) -piperazin- 1-yl] -methanone, l-{4-[4-(2-cyclopentyloxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-3-fluoro- phenyl } - ethanone,
4- [4-(2-cyclopentyloxy-5-methanesulfonyl-benzoyl)-piperazin- 1-yl] -benzonitrile,
4-[4-(2-cyclopentyloxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-3-fluoro- benzonitrile, 4-[4-(2-cyclopentyloxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-2-fluoro- benzonitrile, (2-cyclopentyloxy-5-methanesulfonyl-phenyl)-[4-(2-fluoro-4-trifluoromethyl-phenyl)- piperazin- 1 -yl] -methanone,
(2-cyclopentyloxy-5-methanesulfonyl-phenyl)-[4-(3-fluoro-4-trifluoromethyl-phenyl)- piperazin- 1 -yl] -methanone, (2-cyclopentyloxy-5-methanesulfonyl-phenyl)-[4-(4-trifluoromethyl-phenyl)-piperazin-
1-yl] -methanone,
Rac-[2-(l-cyclopropyl-ethoxy)-5-methanesulfonyl-phenyl]-[4-(4-trifluoromethyl- phenyl) -piperazin- 1-yl] -methanone,
4-[4-(2-cyclopentyloxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-2,3-difluoro- benzonitrile,
4- [4-(2-cyclopentyloxy-5-methanesulfonyl-benzoyl)-piperazin- 1-yl] -2,5-difluoro- benzonitrile,
4-[4-(2-cyclobutylmethoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-benzonitrile,
4-[4-(2-cyclobutylmethoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-2-fluoro- benzonitrile,
4-[4-(2-cyclobutylmethoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-3-fluoro- benzonitrile,
(2-cyclobutylmethoxy-5-methanesulfonyl-ρhenyl)-[4-(4-trifluoromethyl-phenyl)- piperazin- 1 -yl] -methanone, l-{4-[4-(2-cyclobutylmethoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-3-fluoro- phenylj-ethanone,
2-[4-(2-cyclobutylmethoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-5- trifluoromethyl-benzonitrile,
4-[4-(2-cyclobutylmethoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-2,3-difluoro- benzonitrile,
4-[4-(2-cyclobutylmethoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-2,5-difluoro- benzonitrile,
4-[4-(2-cyclobutylmethoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-3,5-difluoro- benzonitrile, 4-[4-(2-cyclobutylmethoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-2,6-difluoro- benzonitrile,
4-[4-(2-cyclopropylmethoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-3,5-difluoro- benzonitrile,
4- [4-(2-cyclopentyloxy-5-methanesulfonyl-benzoyl)-piperazin- 1-yl] -3,5-difluoro- benzonitrile,
4- [4-(2-cyclopropylmethoxy-5-methanesulfonyl-benzoyl)-piperazin- 1-yl] -2,6-difluoro- benzonitrile, 4- [4-(2-cyclopentyloxy-5-methanesulfonyl-benzoyl)-piperazin- 1-yl] -2,6-difluoro- benzonitrile,
5-chloro-2- [4-(2-cyclopropylmethoxy-5-methanesulfonyl-benzoyl)-piperazin- 1 -yl] - benzonitrile, 4-[4-(2-cyclohexyloxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl] -benzonitrile,
4- [4-(2-cyclohexyloxy-5-mefhanesulfonyl-benzoyl)-piperazin- 1-yl] -3-fluoro- benzonitrile,
4-[4-(2-cyclohexyloxy-5methanesulfonyl-benzoyl)-piperazin-l-yl]-2-fluoro- benzonitrile, (2-cyclohexyloxy-5-methanesulfonyl-phenyl)-[4-(4-trifluoromethyl-phenyl)-piperazin-
1-yl] -methanone,
(2-cyclohexyloxy-5-methanesulfonyl-phenyl)-[4-(3-fluoro-4-trifluoromethyl-phenyl)- piperazin- 1-yl] -methanone,
(2-cyclohexyloxy-5-methanesulfonyl-phenyl)-[4-(2-fluoro-4-methanesulfonyl-phenyl)- piperazin- 1-yl] -methanone, l-{4-[4-(2-cyclobutoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-3-fluoro-phenyl}- ethanone,
4-[4-(2-cyclobutoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-3-fluoro-benzonitrile,
(2-cyclobutoxy-5-methanesulfonyl-phenyl)-[4-(3-fluoro-4-trifluoromethyl-phenyl)- piperazin- 1-yl] -methanone,
(2-cyclopentyloxy-5-methanesulfonyl-phenyl)-[4-(4-trifluoromethanesulfonyl-phenyl)- piperazin- 1-yl] -methanone, l-{4-[4-(2-cyclopropylmethoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-2-fluoro- phenyl} -ethanone, 2-[4-(2-cyclopentyloxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-5-trifluoromethyl- benzonitrile,
(2-cyclopropylmethoxy-5-methanesulfonyl-phenyl)-[4-(4-ethanesulfonyl-2-fluoro- phenyl)-piperazin-l-yl]-methanone,
(2-cyclopentyloxy-5-methanesulfonyl-phenyl)-[4-(4-ethanesulfonyl-2-fluoro-phenyl)- piperazin- 1-yl] -methanone,
(2-cyclohexyloxy-5-methanesulfonyl-phenyl)-[4-(4-ethanesulfonyl-2-fluoro-phenyl)- piperazin- 1 -yl] -methanone,
(2-cyclopentyloxy-5-methanesulfonyl-phenyl)-[4-(4-cyclopropanesulfonyl-2-fluoro- phenyl)-piperazin- 1-yl] -methanone, (2-cyclohexyloxy-5-methanesulfonyl-phenyl)-[4-(4-cyclopropanesulfonyl-2-fluoro- phenyl) -piperazin- 1-yl] -methanone, (2-cyclobutoxy-5-methanesulfonyl-phenyl)-[4-(4-cyclopropanesulfonyl-2-fluoro- phenyl) -piperazin- 1-yl] -methanone
Preferred are further compounds, wherein Ar is substituted phenyl, R2 is (Cι-C6)-alkyl substituted by halogen and R5 is S(O)2CH3. The following compounds relate to this group:
l-(3-fluoro-4-{4-[5-methanesulfonyl-2-(2,2,2-trifluoro-ethoxy)-benzoyl]-piperazin-l- yl} -phenyl) -ethanone,
3-fluoro-4-{4-[5-methanesulfonyl-2-(2,2,2-trifluoro-ethoxy)-benzoyl]-piperazin-l-yl}- benzonitrile, [4-(2-fluoro-4-trifluoromethyl-phenyl)-piperazin-l-yl] - [5-methanesulfonyl-2-(2,2,2-tri- fluoro-ethoxy)-phenyl] -methanone,
[4-(3-fluoro-4-trifluoromethyl-phenyl)-piperazin-l-yl]-[5-methanesulfonyl-2-(2,2,2-tri- fluoro-ethoxy) -phenyl] -methanone,
[4-(2-fluoro-4-methanesulfonyl-phenyl)-piperazin-l-yl]-[5-methanesulfonyl-2-(2,2,2- trifluoro-ethoxy) -phenyl] -methanone,
3-fluoro-4-{4-[5-methanesulfonyl-2-(3,3,3-trifluoro-propoxy)-benzoyl]-piperazin-l-yl}- benzonitrile,
[4-(3-fluoro-4-trifluoromethyl-phenyl)-piperazin-l-yl]-[5-methanesulfonyl-2-(3,3,3- trifluoro-propoxy) -phenyl] -methanone, [4-(2-fluoro-4-trifluoromethyl-phenyl)-piperazin-l-yl]-[5-methanesulfonyl-2-(3,3,3- trifluoro-propoxy)-phenyl] -methanone, l-(3-fluoro-4-{4-[5-methanesulfonyl-2-(3,3,3-trifluoro-propoxy)-benzoyl]-piperazin-l- yl } -phenyl) - ethanone,
2,5-difluoro-4-[4-(5-methanesulfonyl-2-trifluoromethoxy-benzoyl)-piρerazin-l-yl]- benzonitrile,
2,3-difluoro-4-{4-[2-(2-fluoro-l-fluoromethyl-ethoxy)-5-methanesulfonyl-benzoyl]- piperazin- 1-yl} -benzonitrile,
2-fluoro-4-{4-[5-methanesulfonyl-2-(2,2,3,3,3-pentafluoro-propoxy)-benzoyl]- piperazin-l-yl}-benzonitrile, [5-methanesulfonyl-2-(2,2,3,3,3-pentafluoro-propoxy)-phenyl] - [4-(4-trifluoromethyl- phenyl) -piperazin- 1-yl] -methanone,
2,3-difluoro-4-{4-[5-methanesulfonyl-2-(2,2,3,3,3-pentafluoro-propoxy)-benzoyl]- piperazin- 1 -yl} -benzonitrile,
3,5-difluoro-4-{4-[5-methanesulfonyl-2-(2,2,3,3,3-pentafluoro-propoxy)-benzoyl]- piperazin- 1-yl} -benzonitrile, 2-{4-[2-(2-fluoro-l-fluoromethyl-ethoxy)-5-methanesulfonyl-benzoyl]-piperazin-l-yl}-
5-trifluoromethyl-benzonitrile, rac-2,3-difluoro-4-{4-[5-methanesulfonyl-2-(2,2,2-trifluoro-l-methyl-ethoxy)-benzoyl]- piperazin- 1 -yl } -benzonitrile, 2-Fluoro-4-{4-[5-methanesulfonyl-2-(2,2,3,3-tetrafluoro-propoxy)-benzoyl]-piperazin-
1 -yl} -benzonitrile,
3-fluoro-4-{4-[5-methanesulfonyl-2-(2,2,3,3-tetrafluoro-propoxy)-benzoyl]-piperazin-
1 -yl} -benzonitrile,
[5-methanesulfonyl-2-(2,2,3,3-tetrafluoro-propoxy)-phenyl]-[4-(4-trifluoromethyl- phenyl) -piperazin- 1-yl] -methanone,
[4-(2-fluoro-4-trifluoromethyl-phenyl)-piperazin-l-yl]-[5-methanesulfonyl-2-(2,2,3,3- tetrafluoro-propoxy)-phenyl] -methanone,
2,3-difluoro-4-{4-[5-methanesulfonyl-2-(2,2,3,3-tetrafluoro-propoxy)-benzoyl]- piperazin- 1 -yl}-benzonitrile, 3,5-Difluoro-4-{4-[5-methanesulfonyl-2-(2,2,3,3-tetrafluoro-propoxy)-benzoyl]- piperazin- 1 -yl}-benzonitrile,
[4-(3,4-dichloro-phenyl)-piperazin-l-yl]-[5-methanesulfonyl-2-(2,2,2-trifluoro-ethoxy)- phenyl] -methanone, rac-5-chloro-2-{4-[5-methanesulfonyl-2-(2,2,2-trifluoro-l-methyl-ethoxy)-benzoyl]- piperazin- 1-yl} -benzonitrile, rac-3,5-difluoro-4-{4-[5-methanesulfonyl-2-(2,2,2-trifluoro-l-methyl-ethoxy)-benzoyl]- piperazin- 1 -yl} -benzonitrile, rac-2,5-difluoro-4-{4-[5-methanesulfonyl-2-(2,2,2-trifluoro-l-methyl-ethoxy)-benzoyl]- piperazin- 1 -yl} -benzonitrile, rac-2,6-difluoro-4-{4-[5-methanesulfonyl-2-(2,2,2-trifluoro-l-methyl-ethoxy)-benzoyl]- piperazin- 1 -yl} -benzonitrile, rac-4-{4-[5-methanesulfonyl-2-(2,2,2-trifluoro-l-methyl-ethoxy)-benzoyl]-piperazin-l- yl} -benzonitrile, rac-3-fluoro-4-{4-[5-methanesulfonyl-2-(2,2,2-trifluoro-l-methyl-ethoxy)-benzoyl]- piperazin- 1-yl} -benzonitrile, rac-2-fluoro-4-{4-[5-methanesulfonyl-2-(2,2,2-trifluoro-l-methyl-ethoxy)-benzoyl]- piperazin- 1 -yl} -benzonitrile, rac-5-methanesulfonyl-2-(2,2,2-trifluoro- 1-methyl-ethoxy) -phenyl] - [4-(4- trifluoromethyl-phenyl) -piperazin- 1-yl] -methanone, rac- [4-(2-fluoro-4-trifluoromethyl-phenyl)-piperazin- 1-yl] - [5-methanesulfonyl-2-
(2,2,2-trifluoro-l-methyl-ethoxy)-phenyl] -methanone, rac- [4-(3-fluoro-4-trifluoromethyl-phenyl)-piperazin- 1 -yl] - [5-methanesulfonyl-2- (2,2,2-trifluoro-l-methyl-ethoxy)-phenyl] -methanone,
[4-(2-fluoro-4-trifluoromethyl-phenyl)-piperazin-l-yl]-[5-methanesulfonyl-2-((S or R)- 2,2,2-trifluoro- 1 -methyl-ethoxy)-phenyl] -methanone,
[5-methanesulfonyl-2-((S or R)-2,2,2-trifluoro-l-methyl-ethoxy)-phenyl]-[4-(4- trifluoromethyl-phenyl) -piperazin- 1-yl] -methanone and
[5-methanesulfonyl-2-((R or S)-2,2,2-trifluoro-l-methyl-ethoxy)-phenyl]-[4-(4- trifluoromethyl-phenyl) -piperazin- 1-yl] -methanone.
Preferred compounds of formula I of the present invention are further those, wherein Ar is substituted phenyl, R2 is (C1-C6)-alkyl, ( -C6)-alkyl substituted by halogen, CH2)n-(C3-C7) -cycloalkyl, bicycle[2.2J]heptyl, (CH2)n-O-(C1-C6)-alkyl or CH2)n-heterocycloalkyl and R5 is NO2, for example the following compounds:
l-(3-fluoro-4-{4-[2-(2-methoxy-ethoxy)-5-nitro-benzoyl]-piρerazin-l-yl}-phenyl)- ethanone,
(2-isopropoxy-5-nitro-phenyl)-[4-(4-trifluoromethyl-phenyl)-piperazin-l-yl]- methanone,
(2-cyclopropylmethoxy-5-nitro-phenyl)-[4-(4-trifluoromethyl-phenyl)-piperazin-l-yl]- methanone,
(2-cyclobutylmethoxy-5-nitro-phenyl)-[4-(4-trifluoromethyl-phenyl)-piperazin-l-yl]- methanone, (2-butoxy-5-nitro-phenyl)-[4-(4-trifluoromethyl-phenyl)-piperazin-l-yl]-methanone,
[2-(2,2-dimethyl-propoxy)-5-nitro-phenyl]-[4-(4-trifluoromethyl-phenyl)-piperazin-l- yl] -methanone,
(2-isobutoxy-5-nitro-phenyl)- [4-(4-trifluoromethyl-phenyl)-piperazin- 1-yl] - methanone, (2-cyclopentyloxy-5-nitro-phenyl)-[4-(4-trifluoromethyl-phenyl)-piperazin-l-yl]- methanone,
(5-nitro-2-propoxy-phenyl)-[4-(4-trifluoromethyl-phenyl)-piperazin-l-yl]-methanone,
(2-cyclobutoxy-5-nitro-phenyl)-[4-(4-trifluoromethyl-phenyl)-piperazin-l-yl]- methanone, Rac-(2-sec-butoxy-5-nitro-phenyl)-[4-(4-trifluoromethyl-phenyl)-piperazin-l-yl]- methanone,
[5-nitro-2-(2,2,3,3-tetrafluoro-propoxy)-phenyl]-[4-(4-trifluoromethyl-phenyl)- piperazin- 1 -yl] -methanone,
[5-nitro-2-(2,2,2-trifluoro-ethoxy)-phenyl]-[4-(4-trifluoromethyl-phenyl)-piperazin-l- yl] -methanone, [2-(bicyclo[2.2J]hept-2-yloxy)-5-nitro-phenyl]-[4-(4-trifluoromethyl-phenyl)- piperazin- 1 -yl] -methanone,
[2-(2-chloro-ethoxy)-5-nitro-phenyl] - [4-(4-trifluoromethyl-phenyl)-piperazin- 1-yl] - methanone and [5-nitro-2-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-[4-(4-trifluoromethyl-phenyl)- piperazin- 1 -yl] -methanone.
Preferred are further compounds, wherein Ar is substituted phenyl, R2 is (Cι-C6)-alkyl, (Cι-C6)-alkyl substituted by halogen or (CH2)n-(C3-C )-cycloalkyl and R5 is S(O)2NHCH3.
3-[4-(4-Cyano-3-fluoro-phenyl)-piperazine-l-carbonyl]-N-methyl-4-trifluoromethoxy- benzenesulfonamide,
3-[4-(4-cyano-3-fluoro-phenyl)-piperazine-l-carbonyl]-4-isobutoxy-N-methyl- benzenesulfonamide,
3-[4-(4-cyano-3-fluoro-phenyl)-piperazine-l-carbonyl]-4-cyclopentyloxy-N-methyl- benzenesulfonamide,
3- [4-(4-cyano-3-fluoro-phenyl)-piperazine- 1-carbonyl] -4-cyclobutoxy-N-methyl- benzenesulfonamide,
3-[4-(4-cyano-3-fluoro-phenyl)-piperazine-l-carbonyl]-4-cyclobutylmethoxy-N- methyl-benzenesulfonamide, 3-[4-(4-cyano-phenyl)-piperazine-l-carbonyl]-4-isobutoxy-N-methyl- benzenesulfonamide,
3- [4-(4-cyano-phenyl)-piperazine- 1-carbonyl] -4-cyclopentyloxy-N-methyl- benzenesulfonamide,
3-[4-(4-cyano-phenyl)-piperazine-l-carbonyl]-4-cyclobutylmethoxy-N-methyl- benzenesulfonamide,
3- [4-(4-cyano-2-fluoro-phenyl)-piperazine- 1-carbonyl] -4-isobutoxy-N-methyl- benzenesulfonamide,
3-[4-(4-cyano-2-fluoro-phenyl)-piperazine-l-carbonyl]-4-(2,2-dimethyl-propoxy)-N- methyl-benzenesulfonamide, 3- [4-(4-cyano-2-fluoro-phenyl)-piperazine- 1-carbonyl] -4-isopropoxy-N-methyl- benzenesulfonamide,
3-[4-(4-cyano-2-fluoro-phenyl)-piperazine-l-carbonyl]-4-cyclopentyloxy-N-methyl- benzenesulfonamide,
3-[4-(4-cyano-2-fluoro-phenyl)-piperazine-l-carbonyl]-4-cyclobutoxy-N-methyl- benzenesulfonamide, 3-[4-(4-cyano-2-fluoro-phenyl)-piperazine-l-carbonyl]-4-cyclopropylmethoxy-N- methyl-benzenesulfonamide,
3-[4-(4-cyano-2-fluoro-phenyl)-piperazine-l-carbonyl]-4-cyclobutylmethoxy-N- methyl-benzenesulfonamide, 3-[4-(4-acetyl-2-fluoro-phenyl)-piperazine-l-carbonyl]-4-isobutoxy-N-methyl- benzenesulfonamide,
3-[4-(4-acetyl-2-fluoro-phenyl)-piperazine-l-carbonyl]-4-(2,2-dimethyl-propoxy)-N- methyl-benzenesulfonamide,
3-[4-(4-acetyl-2-fluoro-phenyl)-piperazine-l-carbonyl]-4-cyclopentyloxy-N-methyl- benzenesulfonamide,
3-[4-(4-acetyl-2-fluoro-phenyl)-piperazine-l-carbonyl]-4-cyclobutoxy-N-methyl- benzenesulfonamide,
3-[4-(4-acetyl-2-fluoro-phenyl)-piperazine-l-carbonyl]-4-cyclopropylmethoxy-N- methyl-benzenesulfonamide, 4-isobutoxy-N-methyl-3-[4-(4-trifluoromethyl-phenyl)-piperazine-l-carbonyl]- benzenesulfonamide,
4-(2,2-dimethyl-propoxy)-N-methyl-3-[4-(4-trifluoromethyl-phenyl)-piperazine-l- carbonyl] -benzenesulfonamide,
4-isopropoxy-N-methyl-3-[4-(4-trifluoromethyl-phenyl)-piperazine-l-carbonyl]- benzenesulfonamide,
4-cyclopentyloxy-N-methyl-3-[4-(4-trifluoromethyl-phenyl)-piperazine-l-carbonyl]- benzenesulfonamide,
4-cyclobutoxy-N-methyl-3- [4- (4-trifluoromethyl-phenyl) -piperazine- 1-carbonyl] - benzenesulfonamide, 4-cyclopropylmethoxy-N-methyl-3-[4-(4-trifluoromethyl-phenyl)-piperazine-l- carbonyl] -benzenesulfonamide,
4-cyclobutylmethoxy-N-methyl-3-[4-(4-trifluoromethyl-phenyl)-piperazine-l- carbonyl] -benzenesulfonamide,
N-methyl-3-[4-(4-trifluoromethyl-phenyl)-piperazine-l-carbonyl]-4-(3,3,3-trifluoro- propoxy) -benzenesulfonamide,
3-[4-(4-cyano-2-fluoro-phenyl)-piperazine-l-carbonyl]-N-methyl-4-(2,2,2-trifluoro- ethoxy) -benzenesulfonamide,
N-methyl-4-(2,2,2-trifluoro-ethoxy)-3-[4-(4-trifluoromethyl-phenyl)-piperazine-l- carbonyl] -benzenesulfonamide, rac-N-methyl-4-(2,2,2-trifluoro-l-methyl-ethoxy)-3-[4-(4-trifluoromethyl-phenyl)- piperazine- 1-carbonyl] -benzenesulfonamide, rac-3-[4-(4-cyano-2,5-difluoro-phenyl)-piperazine-l-carbonyl]-N-methyl-4-(2,2,2- trifluoro- 1 -methyl-ethoxy) -benzenesulfonamide and rac-3-[4-(4-cyano-2,3-difluoro-phenyl)-piperazine-l-carbonyl]-N-mefhyl-4-(2,2,2- trifluoro-l-methyl-ethoxy)-benzenesulfonamide.
A further preferred group of compounds of formula I are those, wherein Ar is a substituted 6-membered heteroaryl group, containing one, two or three nitrogen atoms, R2 is (C1-C6)-alkyl or CH2)n-(C3-C7)-cycloalkyl, and R5 is SO2CH3, for example:
[4-(3-chloro-5-trifluoromethyl-pyridin-2-yl)-piperazin-l-yl]-(2-cyclopropylmethoxy-5- methanesulfonyl-phenyl)-mefhanone,
6- [4-(2-cyclopentyloxy-5-methanesulfonyl-benzoyl)-piperazin- 1-yl] -nicotinonitrile, (2-cyclopentyloxy-5-methanesulfonyl-phenyl)-[4-(5-trifluoromethyl-pyridin-2-yl)- piperazin- 1 -yl] -methanone,
[4-(3-chloro-5-trifluoromethyl-pyridin-2-yl)-piperazin-l-yl]-(2-cyclopentyloxy-5- methanesulfonyl-phenyl)-methanone,
(2-cyclopentyloxy-5-methanesulfonyl-phenyl)-[4-(6-trifluoromethyl-pyridin-3-yl)- piperazin- 1-yl] -methanone,
[4-(3-fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-l-yl]-(2-isopropoxy-5- methanesulfonyl-phenyl)-methanone and
(2-cyclopentyloxy-5-methanesulfonyl-phenyl)-[4-(3-fluoro-5-trifluoromethyl-pyridin-2- yl)-piperazin- 1 -yl] -methanone. Further preferred are compounds of formula I, wherein Ar is a substituted 6- membered heteroaryl group, containing one, two or three nitrogen atoms, R is ( -C6)-alkyl substituted by halogen and R5 is SO2CH3, for example the following compounds: rac-[4-(3-chloro-5-trifluoromethyl-pyridin-2-yl)-piperazin-l-yl]-[5-methanesulfonyl-2- (2,2,2-trifluoro-l-methyl-ethoxy)-phenyl] -methanone, rac-[5-methanesulfonyl-2-(2,2,2-trifluoro-l-methyl-ethoxy)-phenyl]-[4-(5- trifluoromethyl-pyridin-2-yl)-piperazin-l-yl] -methanone, rac-[4-(5-bromo-pyridin-2-yl)-piperazin-l-yl]-[5-methanesulfonyl-2-(2,2,2-trifluoro-l- methyl-ethoxy)-phenyl] -methanone, rac-[4-(3-fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-l-yl]-[5-methanesulfonyl-2- (2,2,2-trifluoro-l-methyl-ethoxy)-phenyl] -methanone, rac-[5-methanesulfonyl-2-(2,2,2-trifluoro-l-methyl-ethoxy)-phenyl]-[4-(6- trifluoromethyl-pyridin-2-yl)-piperazin-l-yl] -methanone, [5-methanesulfonyl-2-((S or R)-2,2,2-trifluoro-l-methyl-ethoxy)-phenyl]-[4-(5- trifluoromethyl-pyridin-2-yl) -piperazin- 1-yl] -methanone, [5-methanesulfonyl-2-((R or S)-2,2,2-trifluoro-l-methyl-ethoxy)-phenyl]-[4-(5- trifluoromethyl-pyridin-2-yl) -piperazin- 1-yl] -methanone,
[4-(3-fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-l-yl]-[5-methanesulfonyl-2-((S)- 2,2,2-trifluoro-l-methyl-ethoxy)-phenyl] -methanone and [4-(3-fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-l-yl]-[5-methanesulfonyl-2- (2,2,2-trifluoro-lJ-dimethyl-ethoxy)-phenyl] -methanone.
The present compounds of formula I and their pharmaceutically acceptable salts can be prepared by methods known in the art, for example, by processes described below, which process comprises
a) reacting a compound of formula
Figure imgf000023_0001
in the presence of an activating agent such as TBTU ( 2- (lH-benzotriazole- 1-yl) -1,1,3,3- tetramethyluroniumte trafluoroborate) to a compound of formula
Figure imgf000023_0002
wherein the substituents are as defined above, or b) reacting a compound of formula
Figure imgf000023_0003
with a compound of formula ROH optionally in the presence of a catalyst, such as Cu(I)I and a base like potassium carbonate, cesium carbonate or sodium, to a compound of formula
Figure imgf000024_0001
wherein X is halogen and the other substituents are as defined above, or
c) reacting a compound of formula
Figure imgf000024_0002
with a compound of formula R2X in the presence of a base and optionally in the presence of microwaves to a compound of formula
Figure imgf000024_0003
wherein X is halogen, mesylate or triflate and the other substituents are as defined above, or
d) reacting a compound of formula
Figure imgf000024_0004
with a compound of formula ROH under Mitsunobu conditions in the present of a phosphine to a compound of formula
Figure imgf000025_0001
wherein the substituents are as defined above, or
e) reacting a compound of formula
Figure imgf000025_0002
with a compound of formula ArX to a compound of formula
Figure imgf000025_0003
wherein X is halogen and the other substituents are as defined above, or
f) reacting a compound of formula
Figure imgf000025_0004
with a corresponding amine or alcohol in the presence of an activating agent to a compound of formula
Figure imgf000025_0005
wherein R9 is (C C6) -alkyl, (C3-C6)-cycloalkyl, ( - ) -alkoxy or NR7R8; and the other substituents are as defined above, or
g) reacting a compound of formula
Figure imgf000026_0001
with a compound of formula RONH2 to a compound of formula
Figure imgf000026_0002
wherein R is H or alkyl and the other substituents are as defined above, or
h) reacting a compound of formula
Figure imgf000026_0003
with a reducing agent like sodium borohydride (when R is H) or an alkylating agent like alkyllithium (when R is alkyl) to a compound of formula
Figure imgf000026_0004
wherein R is H or alkyl and the other substituents are as defined above, and if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts. The compounds of formula I may be prepared in accordance with process variant a) to h) and with the following schemes 1 to 8. The starting material is commercially available or maybe prepared in accordance with known methods.
Scheme 1
Figure imgf000027_0001
III R2DH copper catalyst
Figure imgf000027_0002
Compounds of general formula I can be prepared by reacting piperazine derivatives of formula II with a corresponding acid of formula III in the presence of an activating agent like TBTU (2-( lH-benzotriazole-l-yl)-lJ,3,3-tetramethyluroniumtetrafluoroborate). The acid of formula III can be prepared by reaction of an acid of formula IV with an alcohol of formula R2OH, optionally in the presence of a copper salt like Cu(I)Br. Piperazine derivatives of formula II can be prepared by heating of the corresponding piperazine with ArX or by reacting of a N-protected piperazine with ArX in the presence of palladium catalyst followed by cleavage of the protective group. The protective group is typically tert-butoxycarbonyl (Boc) .
Scheme 2
Figure imgf000028_0001
X: Halogen
Figure imgf000028_0002
Aternatively, compounds of general formula I can be prepared by reaction of an acyl- piperazine of formula V and an alcohol of formula R2OH, optionally in the presence of a copper salt like Cu(I)I. Acylpiperazine derivatives of formula V can be prepared by reaction of an acid of formula IV with piperazine derivatives of formula II in the presence of an activating agent like TBTU (2-(lH-benzotriazole-l-yl)-lJ,3,3- tetramethyluroniumtetrafluoroborate).
Scheme 3
Figure imgf000028_0003
Compounds of general formula I can be prepared by reacting a compound of formula VI with an electrophile of formula R2X in the presence of base like potassium carbonate and optionally in the presence of microwaves, wherein X is an halogen, mesylate or triflate. Scheme 4
Figure imgf000029_0001
Compounds of general formula I can be prepared by reacting phenol of formula VI with an alcohol of formula R2OH under Mitsunobu condition, in the presence of a phosphine like triphenylphosphine or diphenyl-2-pyridylphosphine, and a dialkylazadicarboxylate like diethylazadicarboxylate or di-tert-butyl azodicarboxylate.
The compound of formula VI can be prepared by deprotection (for example using hydrogen) of a phenol protected as a benzyl ether (I with R2: benzyl). Alternatively a compound of formula VI can be prepared by reacting piperazine derivatives of formula II with an acid of formula VII in the presence of an activating agent like TBTU (2-(lH-benzotriazole-l-yl)-l,l,3,3- tetramethyluroniumtetrafluoroborate). Scheme 5
Figure imgf000030_0001
Compounds of general formula I can be prepared by reacting a piperazine of formula VIII with ArX. Scheme 6
Figure imgf000030_0002
wherein R9 is (Cι-C6)-alkoxy or NR7R8;
Compounds of general formula lb wherein R is as defined above can be prepared by reacting an acid of formula la with a corresponding amine or alcohol in the presence of an activating agent like carbonyldimidazole.
Scheme 7
Figure imgf000030_0003
Compounds of general formula Id can be prepared in accordance with scheme 7 by reacting a compound of formula lc bearing a carbonyl group, with a compound of formula RONH2, wherein R is H or alkyl and R9 is (CrC6) -alkyl, (C3-C6)-cycloalkyl, (C C6)-alkoxy or NR7R8. Scheme 8
Figure imgf000031_0001
Compounds of general formula le wherein R is H or alkyl and R9 is (C,-C6)-alkyl or (C3-C6)-cycloalkyl can be prepared by reacting a compound of formula lc bearing a carbonyl group, with a reducing agent like sodium borohydride (when R is H) or an alkylating agent like alkyllithium (when R is alkyl).
Racemic mixtures of chiral compounds of formula I can be separated using chiral HPLC. The acid addition salts of the basic compounds of formula I may be converted to the corresponding free bases by treatment with at least a stoichiometric equivalent of a suitable base such as sodium or potassium hydroxide, potassium carbonate, sodium bicarbonate, ammonia, and the like. The following 660 examples illustrate the present invention without limiting it. All temperatures are given in degree Celsius.
The following abbreviations were used in the examples: RT: room temperature; n-Boc-piperazine: tert-Butyl 1 -piperazin ecarboxylate, oxone®: (potassium peroxymonosulfate) 2KHSOs,KHSO ,K2SO , EtOAc: ethyl acetate; THF: tetrahydrofuran;
TBTU: 2- ( 1 H-benzotriazole- 1 -yl) - 1 J ,3,3-tetramethyluroniumtetrafluoroborate; DIPEA: diisopropylethylamine, DMF: N,N-dimetyhylformamide Example 1J Preparation of l-(2-Fluoro-4-trifluoromethyl-phenyl)-piperazine
(a) 4-(2-Fluoro-4-trifluoromethyl-phenyl)-piperazine-l-carboxylic acid tert-butyl ester A mixture of 20 mmol l-bromo-2-fluoro-4-trifluoromethyl-benzene, 24.7 mmol n-Boc- piperazine, OJ mmol Tris(dibenzylideneacetone)dipalladium chloroform complex, 28.8 mmol sodium-t-butoxide and 0.4 mmol 2-(dicyclohexylphosphino)biphenyl in 50 ml toluene was heated for 16 h at 80 °C. After cooling to RT the mixture was treated with 15 g Isolute HM-N and all volatiles were removed under vacuum. The residue was purified on silica eluting with a gradient of heptane / EtO Ac to yield after evaporation the title compound.
(b) l-(2-Fluoro-4-trifluoromethyl-phenyl)-piperazine
A mixture of 9 mmol 4-(2-fluoro-4-trifluoromethyl-phenyl)-piperazine-l-carboxylic acid tert-butyl ester in 20 ml dioxane was treated with 8.93 ml 4N HCl in dioxane for 2 h at 80°C. The mixture was concentrated and treated with 20 ml water, 20 ml 2M Na2CO3 and extracted with 50 ml EtO Ac. The organic phase was washed with 30 ml saturated NaCl. All aqueous phases were combined and extracted with 50 ml EtO Ac. The combined organic phases were dried with MgSO4 and evaporated to yield the title compound 1J.
1-H-NMR (300 MHz, CDC13) δ= 7.50 (d, j = 13.3 Hz, IH, H-3), 7.45 (d, j = 8.8 Hz, IH, H-5), 7.16 (dd, j, = 8.8 Hz, j2 = 8.8 Hz, IH, H-6), 3.5-3.2 (s, br, IH, NH), 3.04 ( , 4H, piperazine), 2.87 (m, 4H, piperazine).
MS (m/e): 249.2 (MH+, 100%) Example 1.2 Preparation of 2-isopropoxy-5-methanesulfonyl-benzoic acid
(a) 2-Chloro-5-methanesulfonyl-benzoic acid
To 99 mmol 2-chloro-5-(methylthio) benzoic acid in 400 ml methanol at 0 °C 296 mmol oxone® was added and the mixture was allowed to stir at RT for 3.5 h. The precipitate was filtered off and the filtrate was concentrated under reduced pressure. The residue was extracted 3 x with 400 ml ethyl acetate and the combined organic phases washed 2 x with 300 ml IN HCl and with 300 ml saturated aqueous NaCl solution and dried with MgSO4. Evaporation under reduced pressure yielded the title compound.
(b) 2-Isopropoxy-5-methanesuIfonyl-benzoic acid
A mixture of 2J3 mmol 2-chloro-5-methanesulfonyl-benzoic acid, 0.64 mmol Cu(I)Br in 5 ml NEt3 and 25 ml isopropanol was heated to 120 °C for 16 h in a sealed tube. The volatiles were removed under vacuum and the residue was taken up in 70 ml IN HCl. Extraction with ethyl acetate drying of the combined organic fractions and evaporation yielded a residue which was purified by reversed phase preparative HPLC eluting with an acetonitrile / water gradient. Evaporation of the product fractions yielded the title compound 1.2.
MS (m/e): 257.0 (MH", 100%)
In analogy to Example 1.2(b) compounds 1.3 to 1.7 of the following table were prepared from 2-chloro-5-methanesulfonyl-benzoic acid and the appropriate alcohol:
Figure imgf000033_0001
Example 1.8 Preparation of l-{3-fluoro-4- [4-(2-fluoro-5-nitro-benzoyl)-piperazin-l-yl]- phenyl}-ethanone
A solution of 0.261 mmol 2-fluoro-5-nitro-benzoyl chloride [CAS: 7304-32-7; Feng and Burgess, Chem.Europ.J. EN, 5:3261-3272 (1999)] in 1 ml dioxane was treated with 0.522 mmol triethylamine and then with a solution of 0.261 mmol l-(3-fluoro-4-piperazin-l- yl-phenyl) -ethanone (CAS: 189763-57-3; WO 97/14,690) in 1 ml dioxane. The mixture was stirred at RT for 30 min. The solvent was removed in vacuo. The crude oil was taken up in water. The aqueous layer was extracted 3 times with CH2C12. The combined extracts were dried over Na2SO , filtered and the solvent was removed in vacuo. The crude gum was purified on silicagel (eluent: heptane/ethylacetate 0%-20% (10 min) to provide the title compound 1.8.
MS (m/e): 390.2 (MH+, 100%) Example 1.9 Preparation of (2-iodo-5-methanesulfonyl-phenyl)-[4-(4-trifluoromethyl- phenyl) -piperazin- 1 -yl] -methanone
(a) 2-Amino-5-methanesulfonyl-benzoic acid
A mixture of 4.26 mmol 2-chloro-5-methanesulfonyl-benzoic acid, 0.39 mmol Copper powder and 10 ml ammonium hydroxide 25% was heated at 125-130°C with stirring for 18 hours. Mixture was cooled to room temperature and filtered. The solid was washed with methanol. The filtrate was concentrated in vacuo. The residue was acidified with HCl IN to pH=2. The obtained solid was washed with water and dried (HV, 50°C, 1 hour) to yield the title compound. MS (m/e): 214J (M-H, 100%) (b) 2-Iodo-5-methanesulfonyl-benzoic acid
To a suspension of 3.0 mmol 2-amino-5-methanesulfonyl-benzoic acid in a mixture of 1.7 ml sulfuric acid and 1.7 ml water was added dropwise a solution of 3.92 mmol sodium nitrite in 1.7 ml water at such rate that the temperature did not exceed 3°C. The mixture was stirred at 0°C for 1 hour. A solution of 3.0 mmol Kl in 1.7 ml water was added dropwise at 0°C. The brown suspension was allowed to warm to rt and stirred for 30 minutes. Excess iodine was destroyed by addition of a few drops of a sodium hydrogenosulfite solution. The solid was filtered, washed with water and dried (HV, 50°C, 1 hour) to yield the title compound. MS (m/e): 325.0 (M-H, 100%)
(c) (2-iodo-5-methanesulfonyl-phenyl)-[4-(4-trifluoromefhyl-phenyl)-piperazin-l- yl] methanone
To a solution of 9.2 mmol 2-iodo-5-methanesulfonyl-benzoic acid in 20 ml dimethylformamide 11.5 mmol TBTU, 46.0 mmol N-ethyldiisopropylamine and 11.0 mmol l-(4-trifluoromethylphenyl)piperazine (ABCR F07741NB, [30459-17-7] )were successively added. The reaction was then stirred at RT for two hours, concentrated in vacuo and purified by column chromatography (SiO2, 50 g, CH2Cl2/MeOH/NH3 = 100/0/0 to 95/4.5/0.5), to give the title compound 1.9. MS (m/e): 539J (M+H+) Example 5 Preparation of [4- (2-fluoro-4-trifluoromethyl-phenyl)-piperaz-n- 1 -yl] - (2- isopropoxy-5-methanesulfonyl-phenyl)-methanone
A mixture of 0.05 mmol 2-isopropoxy-5-methanesulfonyl-benzoic acid (Compound 1.2), 0.06 mmol l-(2-fluoro-4-trifluoromethyl-phenyl)-piperazine, 0.055 mmol TBTU and 0.25 mmol DIPEA in 1 ml DMF was stirred at RT for 16 h. 0.5 ml MeOH / HCOOH 1/1 was added and the mixture was subjected to reversed phase preparative HPLC separation eluting with an acetonitrile / water gradient yielding the title compound.
MS (m/e): 489.2 (MH+, 100%) In analogy to Example 5 compounds 1 to 4, 6 to 46 and 52-54 of the following table were prepared from the acid derivatives and piperazine derivatives:
Figure imgf000035_0001
Figure imgf000036_0001
[4-(2-fluoro-4-methanesulfonyl- l-(2-fluoro-4- 513.3 phenyl)-piperazin-l-yl]-(2-iso- methanesulfonyl-phenyl)- butoxy-5-methanesulfonyl-phen- piperazine and Compound yl)-methanone 1.3
ϊ - {4- [4- ( 2-cyclopropylme thoxy- 1 - (3 -fluoro-4-piperazin- 1 - 475.2 5-methanesulfonyl-benzoyl)- yl-phenyl) -ethanone and piperazin-l-yl]-3-fluoro-phenyl}- Compound 1.4 ethanone
4- [4-(2-cyclopropylmethoxy-5- 4-piperazin-l-yl- 440.3 methanesulfonyl-benzoyl) -piperbenzonitrile and azin- 1 -yl] -benzonitrile Compound 1.4
4- [4-(2-cyclopropylmethoxy-5- 3-fluoro-4-piperazin- 1 -yl- 458.3 methanesulfonyl-benzoyl) -piperbenzonitrile and azin- 1 -yl] -3-fluoro-benzonitrile Compound 1.4
4- [4-(2-cyclopropylmethoxy-5- 2-fluoro-4-piperazin- 1-yl- 458.3 methanesulfonyl-benzoyl) -piperbenzonitrile and azin- 1 -yl] -2-fluoro-benzonitrile Compound 1.4
(2-cyclopropylmethoxy-5-meth- l-(4-trifluoromethyl- 483.2 anesulfonyl-phenyl)- [4-(4-tri- phenyl) -piperazine and fluoromethyl -phenyl) -piperazin- Compound 1.4 1-yl] -methanone
(2-cyclopropylmethoxy-5-meth- l-(2-fluoro-4- 501.2 anesulfonyl-phenyl)- [4-(2- trifluoromethyl-phenyl)- fluoro-4-trifluoromethyl- piperazine and Compound phenyl) -piperazin- 1 -yl] -methan- 1.4 one
Figure imgf000038_0001
Figure imgf000039_0001
Figure imgf000040_0001
Figure imgf000041_0001
Example 47 Preparation of l-{3-fluoro-4-[4-(2-methoxy-5-nitro-benzoyl)-piperazin-l-yl]- phenylj-ethanone
To a solution of 0.257 mmol l-{3-fluoro-4-[4-(2-fluoro-5-nitro-benzoyl)-piperazin-l- yl]-phenyl}-ethanone (Compound 1.8) in 1.5 ml dioxane 102 mg sodium methoxyde was added portionwise. The mixture was stirred at 100 °C for 4h. The reaction mixture was diluted with 10 ml water, neutralized with IN HCl and then extracted with ethylacetate (3 x 10 ml). Combined organic phases were concentrated in vacuo. The residue was chromatographed on silica gel: eluent: heptane/ethylacetate 0%-30% (10 min) to provide compound 47.
MS (m/e): 402.2 (M+H+, 100%).
Example 48 Preparation of (2-benzyloxy-5-methanesulfonyl-phenyl)- [4-(4-trifluoromethyl- phenyl)-piperazin- 1-yl] -methanone
A mixture of 0J9 mmol (2-iodo-5-methanesulfonyl-phenyl)- [4-(4-trifluoromethyl- phenyl) -piperazin- 1-yl] -methanone (Compound 1.9), 0.037 mmol Cul, 0.37 mmol Cs2CO3, 0.074 mmol 1,10-phenanthroline and 0.4 ml benzylic alcohol was heated at 110 °C for 16 hours. The mixture was cooled to RT, diluted with ethylacetate and filtered. The organic layer was washed twice with water, dried over Na2SO4, filtered and the solvent was removed in vacuo. The crude oil was purified on silica gel, eluent: heptane/ethylacetate 0 % -50 % (25 min) to provide compound 48.
MS (m/e): 519.2 (M+H\ 100%)
In analogy to Example 48 compounds 49 to 51 of the following table were prepared from (2-iodo-5-methanesulfonyl-phenyl)-[4-(4-trifluoromethyl-phenyl)-piperazin-l-yl]- methanone (Compound 1.9) and alcohols:
Figure imgf000043_0001
Example 1J0 Preparation of 5-Methanesulfonyl-2-(2-methoxy-ethoxy)-benzoic acid
(a) 2-Amino-5-methanesulfonyl-benzoic acid
A mixture of 4.26 mmol 2-chloro-5-mefhanesulfonyl-benzoic acid (compound 1.2a), 0.39 mmol Copper powder and 10 ml ammonium hydroxide 25% was heated at 125- 130°C with stirring for 18 hours. Mixture was cooled to room temperature and filtered. The solid was washed with methanol. The filtrate was concentrated in vacuo. The residue was acidified with HCl IN to pH=2. The obtained solid was washed with water and dried (HV, 50°C, 1 hour) to yield the title compound. MS (m/e): 214J (M-H, 100%) (b) 2-Iodo-5-methanesulfonyl-benzoic acid
To a suspension of 3.0 mmol 2-amino-5-methanesulfonyl-benzoic acid in a mixture of 1.7 ml sulfuric acid and 1.7 ml water was added dropwise a solution of 3.92 mmol sodium nitrite in 1.7 ml water at such rate that the temperature did not exceed 3°C. The mixture was stirred at 0°C for 1 hour. A solution of 3.0 mmol Kl in 1.7 ml water was added dropwise at 0°C. The brown suspension was allowed to warm to rt and stirred for 30 minutes. Excess iodine was destroyed by addition of a few drops of a sodium hydrogenosulfite solution. The solid was filtered, washed with water and dried (HV, 50°C, 1 hour) to yield the title compound. MS (m/e): 325.0 (M-H, 100%) (c) 5-Methanesulfonyl-2-(2-methoxy-ethoxy)-benzoic acid
To a solution of 1.6 mmol 2-iodo-5-methanesulfonyl-benzoic acid in 30 ml 2- methoxyethanol and 6 ml triethylamine were added 79 mg copper (I)bomide and the reaction mixture heated to 120°C for 4 h. The solvent was distilled off and the residue dissolved in 90 ml IN HCl. The aqueous phase was extracted twice with ethyl acetate and the pooled organic extracts washed twice with water and once with brine. The organic layer was dried with Na2SO , filtered and evaporated to yield the title compound 1J0. MS (m/e): 273J (MH", 100%).
Example 1.11 Preparation of 5-Cyano-2- (2-methoxy-ethoxy)-benzoic acid
(a) 2-Bromo-5-cvano-benzoic acid
To a suspension of 7J mmol copper (II) bromide in acetonitrile (30 ml) was added dropwise 8.63 mmol tert-butylnitrite at 0°C within 2 minutes. 6J7 mmol 2-Amino-5- cyano-benzoic acid (CAS: 99767-45-0; WO9518097) was added portionwise within 10 minutes at 0°C. The mixture was stirred at 0°C for 2 hours and then at room temperature overnight. Half of the solvent was removed in vacuo. The residue was taken in HCl IN (15 ml) and ethyl acetate (30 ml). The organic layer was extracted with NaOH IN (3x10 ml). The aqueous layer was acidified with HCl 2N. The resulting solid was filtered, washed with water and dried (high vacum, 50°C) to provide the title compound MS (m/e): 227J(M+H+J00%)
(b) 5-Cyano-2-(2-methoxy-ethoxy)-benzoic acid
To a solution of 0J6 mmol 2-bromo-5-cyano-benzoic acid in 6 ml 2-methoxyethanol and 1.2 ml triethylamine were added 23 mg copper (I) bromide and the reaction mixture heated to 120°C for 4 h. The solvent was distilled off and the residue dissolved in 20 ml IN HCl. The aqueous phase was extracted twice with ethyl acetate and the pooled organic extracts washed twice with water and once with brine. The organic layer was dried with Na2SO , filtered and evaporated to yield the title compound 1.11. MS (m/e): 220.4 (MH", 100%).
Example 1J2 Preparation of 5-Cyano-2-(2,2,2-trifluoro-ethoxy)-benzoic acid A mixture of 11.3 mmol sodium in 66 mmol 2,2,2-trifluoroethanol was heated to 100°C until all sodium was dissolved (20 min.). Then a solution of 5.5 mmol 5-cyano-2-iodo- benzoic acid [CAS: 219841-92-6; WO9901455] in 2 ml N-methyl-2-pyrrolidone and 0.5 mmol copper (I) bromide were added and the reaction mixture heated to 120° C for 2 h. The reaction mixture was poured onto water, acidified to pH 2 with cone. HCl and extracted 3x with ethyl acetate. The pooled organic extracts were washed with brine, dried over Na2SO and evaporated. Flash chromatography on silica gel with heptane/ethyl acetate provided the title compound 1J2. MS (El) (m/e): 245J (M+', 94%), 146.0 ([M-CF3CH2O]+', 100%). In analogy to Example 1J2 compounds 1.13 to 1.16 of the following table were prepared from 5-cyano-2-iodo-benzoic acid and the appropriate alcohol:
Figure imgf000045_0001
In analogy to Example 5 compounds 55 to 61 of the following table were prepared from the acid derivatives and piperazine derivatives:
Figure imgf000046_0001
Figure imgf000047_0001
Example 2.1
Preparation of (2-Hydroxy-5-nitro-phenyl)-[4-(4-trifluoromethyl- phenyl)-piperazin- 1 - yl] -methanone Compound 2J was prepared in analogy to Example 5 using 2-hydroxy-5-nitrobenzoic acid [96-97-9] and l-(4-trifluoromethyl-phenyl)-piperazine. MS (m/e): 394.0 (M-H, 100%)
Example 2.2
Preparation of (2-Hydroxy-5-methanesulfonyl-phenyl)- [4-(4-trifluoromethyl-phenyl)- piperazin- l-yl]-methanone
Compound 2.2 was prepared in analogy to Example 5 using 2-hydroxy-5- (methylsulfonyl)benzoic acid [68029-77-6] and l-(4-trifluoromethyl-phenyl) -piperazine. MS (m/e): 427.5 (M-H, 100%)
Example 66 Preparation of (2-Butoxy-5-nitro-phenyl)-[4-(4-trifluoromethyl-phenyl)-piperazin-l- yl] -methanone
A solution of (2-Hydroxy-5-nitro-phenyl)-[4-(4-trifluoromethyl-phenyl)-piperazin-l- yl]-methanone (50 mg), potassium carbonate (87 mg) and 1-bromobutane (0J5 mL) in dimethylacetamide (0.3 mL) was heated at 150°C for 15 minutes in a microwave oven. The reaction mixture was then concentrated and purified by column chromatography (SiO2) to give the title compound (55 mg).
In analogy to Example 66, compounds 62 to 97 of the following table were prepared from the acid derivatives and piperazine derivatives:
Figure imgf000048_0001
Figure imgf000049_0001
Figure imgf000050_0001
Figure imgf000051_0001
Figure imgf000052_0001
Figure imgf000053_0001
Figure imgf000054_0001
Example 98 Preparation of (2-Difluoromethoxy-5-nitro-phenyl)-[4-(4-trifluoromethyl- phenyl) -piperazin- 1-yl] -methanone
In analogy to a procedure published in WO9749710, a solution of (2-Hydroxy-5-nitro- phenyl)-[4-(4-trifluoromethyl-phenyl)-piperazin-l-yl]-methanone (50 mg), potassium carbonate (1 eq), and ethyl chlorofluoroacetate (1 eq) in DMF (1 mL) was stirred at 65°C for 16 hours. After such time the reaction mixture was concentrated in vacuo and purified by column chromatography (SiO2) to yield the title compound (26 mg). MS (m/e): 446.0 (M+H+, 100%).
Example 99 Preparation of 5-Nitro-2-(2,2,3,3-tetrafluoro-cyclobutylmethoxy)-phenyl]-[4-(4- trifluoromethyl-phenyl)-piperazin- 1-yl] -methanone
Example 99 was prepared in analogy to Example 66 using l-(chloromethyl)-2,2,3,3- tetrafluorocyclobutane [356-80-9]. MS (m/e): 536.3 (M+H\ 100%).
Example 100 Preparation of [5-Nitro-2-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-[4-(4- trifluoromethyl-phenyl)-piperazin-l-yl]-methanone
To a refluxing solution of 50 mg of (2-hydroxy-5-nitro-phenyl)-[4-(4-trifluoromethyl- phenyl)-piperazin-l-yl]-methanone in acetone (2 mL) containing potassium carbonate (35 mg) was added 2,2,3,3,3-pentafluoropropyl trifluoromethanesulfonate (54 mg) over 10 min. The reaction mixture was refluxed for 20 hours before being concentrated in vacuo and purified by column chromatography (SiO2, CH2Cl2/MeOH) to yield the title compound as a colorless solid (66 mg). MS (m/e): 569.0 (M+H+, 100%). Example 101 Preparation of [2- (2-Fluoro- 1 -fluoromethyl-ethoxy)-5-nitro-phenyl] - [4- (4- trifluoromethyl-phenyl)-piperazin- 1-yl] -methanone A solution of (2-hydroxy-5-nitro-phenyl)-[4-(4-trifluoromethyl-phenyl)-piperazin-l- yl] -methanone (50 mg), l,3-difluoro-2-propanol [453-13-4] (27 mg), triphenylphosphine (76 mg) and diisopropylazodicarboxylate (48mg) was refluxed overnight, concentrated in vacuo and purified by column chromatography (SiO2) to yield the title compound as a colorless solid (68 mg). MS (m/e): 474J (M+H+, 100%).
In analogy to Example 48, compounds 102 to 104 of the following table were prepared from (2-Iodo-5-methanesulfonyl-phenyl)-[4-(4-trifluoromethyl-phenyl)-piperazin-l- yl] -methanone (compound 1.9) and an alcohol:
Figure imgf000055_0001
Example 2.3
Preparation of (2-Fluoro-5-methanesulfonyl-phenyl)-[4-(5-trifluoromethyl-pyridin-2- yl) -piperazin- 1-yl] -methanone Compound 2.3 was prepared in analogy to Example 5 using 2-fluoro-5- (methylsulfonyl)benzoic acid [247569-56-8] and l-(5-trifluoromethyl-2- pyridyl)piperazine [132834-58-3]. MS (m/e): 432.4 (M+H+, 100%).
Example 105 Preparation of [5-Methanesulfonyl-2-(2,2,2-trifluoro-lJ-dimethyl-ethoxy)- phenyl] - [4- (5-trifluoromethyl-pyridin-2-yl)-piperazin- 1 -yl] -methanone
A solution of (2-fluoro-5-methanesulfonyl-phenyl)- [4-(5-trifluoromethyl-pyridin-2-yl)- piperazin- 1-yl] -methanone (compound 2.3) (20 mg), 2-trifluoromethyl-2-propanol (0.053 mL), potassium carbonate or cesium carbonate (3 equivalents) in dimethylacetamide was heated at 150°C for 30 min and then at 180°C for lh in a microwave oven. After such time the reaction mixture was concentrated and purified by column chromatography (SiO2) to yield the title compound as a light yellow solid (4.9 mg). MS (m/e): 540.3 (M+H+, 100%).
Example 2.4 Preparation of (2-Isopropoxy-5-methanesulfbnyl-phenyl)-piperazin- 1 -yl-methanone trifluoro-acetic acid
A solution of 2-isopropoxy-5-methanesulfonyl-benzoic acid (compound 1.2, 1.0 g), tert- butyl 1-piperazinecarboxylate (0.78 g), TBTU (1.4 g) and JV-ethyldiisopropylamine (4 mL) was stirred at room temperature for 2 hours. After such time, the reaction mixture was concentrated in vacuo and purified by column chromatography (SiO2) to give 4-(2- Isopropoxy-5-methanesulfonyl-benzoyl)-piperazine-l-carboxylic acid tert-butyl ester as a colorless foam (1.6 g ). The latter was dissolved in dichloromethane (11 mL) and treated with trifluroacetic acid (4.2 mL) for 30 minutes. After such time the reaction mixture was concentrated in vacuo to yield the title compound (1.6 g) as light yellow oil. MS (m/e): 327J (M+H+, 100%).
Example 2.5
Preparation of 4-Chloro-6-trifluoromethyl-pyrimidine
6-Trifluoromethyl-pyrimidin-4-ol ([1546-78-7], 5 g) was refluxed in phosphorus oxychloride (17 mL) for 2 hours. The reaction mixture was carefully concentrated in vacuo and the residue was distilled (Kugelrohr) under reduced pressure (bp = 30-55°C @ 10 mbar) to yield the title compound ([37552-81-1], 1.4 g). MS (El): 182.0 (M). Example 106 Preparation of (2-Isopropoxy-5-methanesulfonyl-phenyl)- [4- (5-nitro-pyri din-2- yl)-piperazin- 1 -yl] -methanone
A solution of ( 2-isopropoxy-5-methanesulfonyl-phenyl) -piperazin- 1 -yl-methanone trifluoro-acetic acid (compound 2.4, 80 mg) 2-chloro-5-nitro-pyridine (29 mg), potassium carbonate (50 mg) in 1-butanol (3 mL) was stirred at 120°C for 20 hours. After such time the solution was concentrated in vacuo, and purified by column chromatography (SiO2) to yield the title compound as white foam (81 mg). MS (m/e): 449.1 (M+H+, 100%). Example 107 Preparation of (2-Isopropoxy-5-methanesulfonyl-phenyl)-[4-(6-trifluoromethyl- pyrimidin-4-yl)-piperazin-l-yl]-methanone
Example 107 was prepared in analogy to example 106 using 4-chloro-6-trifluoromethyl- pyrimidine [37552-81-1]. MS (m/e): 473.1 (M+H+, 100%). Example 2.6
Preparation of 2-(4-fluorophenoxy)-5-nitrobenzoic acid
2-(4-Fluoro-phenoxy)-5-nitro-benzoic acid can be prepared by a similar method to that described in the literature (e.g. WO9938845) by reaction of 2-Chloro-5-nitro-benzoic acid ethyl ester [16588-17-3] with 4-Fluoro-phenol [371-35-7] yielding 2-(4-Fluoro- phenoxy)-5-nitro-benzoic acid ethyl ester. 2-(4-Fluoro-phenoxy)-5-nitro-benzoic acid ethyl ester can then be hydrolysed with sodium hydroxide for example to yield the title compound. MS (m/e): 276.1 (M+H+, 100%).
Example 2.7
Preparation of 2,3-Dif_uoro-4-piperazin-l-y_-benzonitrile- trifluoro-acetic acid (a) 4-(4-Cyano-2,3-difluoro-phenyl)-piperazine-l-carboxylic acid tert-butyl ester
To a solution of N-Boc-Piperazine (0.65 g) in DMA (20 mL) was slowly added a solution of 2,3,4-trifluorobenzonitrile (0.49 g) in DMA (10 mL). The reaction mixture was stirred for 2 hours at 80°C. After such time the solvent was removed in vacuo and purified by column chromatography (SiO2) to yield the title compound as white solid (0.76 g).
(b) 2-3-Difluoro-4-piperazin-l-yl-benzonitrile- trifluoro-acetic acid To a solution of 4-(4-Cyano-2,3-difluoro-phenyl)-piperazine-l-carboxylic acid tert-butyl ester (0.72 g) in dichloromethane (5 mL) was added trifluoroacetic acid and the reaction mixture was stirred at room temperature for 30 minutes. After such time the reaction mixture was concentrated in vacuo to yield the title compound (0.63 g). MS (m/e): 224.3 (M+H+, 100%).
Example 2.8
Preparation of 2,5-Difluoro-4-piperazin- 1 -yl-benzonitrile-trifluoro-acetic acid
Example 2.8 was prepared in analogy to Example 2.7 using 2,4,5-trifluorobenzonitrile. MS (m/e): 224.3 (M+H+, 100%). Example 2.9
Preparation of 5-Methylsulfamoyl-2-trifluoromethoxy-benzoic acid
(a) 5-Chlorosulfonyl-2-trifluoromethoxy-benzoic acid
A solution of 2-trifluoromethoxy benzoic acid [1979-29-9] (1.0 g) was added in small batches to chlorosulfonic acid (3.2 mL) at 0°C. After completion of the addition, the reaction mixture was stirred at 70°C for 4 hours then left at room temperature overnight and heated at 75°C for another 3 hours. After such time the reaction was slowly poured onto ice, and the precipitate was then filtered, washed with water and dried to yield the title compound as a white solid (1.2 g). MS (m/e): 303.3 (M-H, 100%).
(b . 5-MethylsulfamoyI-2-trifluoromethoxy-benzoic acid
To a solution of 5-CMorosulfonyl-2-trifluoromethoxy-benzoic acid (0J5 g) in dichloromethane (1.5 ml) was added a solution of methylamine in methanol (8M, 0.31 mL) and the reaction mixture was stirred for 2 minutes after precipitation was compele. The reaction mixture was then concentrated in vacuo and the residue was dissolved in IN NaOH (2 mL) and extracted with diethylether. The aqueous phase was then acidified using 3 N hydrochloric acid solution (2 mL) and the solution was extracted with dichloromethane (2 x 10 mL). The combined organic phases were dried with sodium sulfate and concentrated in vacuo to yield the title compound as a white solid (0J2 g). MS (m/e): 298.0 (M-H, 100%).
Example 2J0 Preparation of 5-Methanesulfonyl-2-(3,3,3-trifluoro-propoxy)-benzoic acid (a) 5-Methanesulfonyl-2-(3,3,3-trifluoro-propoxy.-benzoic acid methyl ester
A solution of methyl 5-(methanesulfonyl)-salicylate [101371-44-2] (50 mg), triphenylphosphine (65 mg) 3,3,3-trifluoro-l-propanol and di-tert-butyl azodicarboxylate (55 mg) in THF (3 mL) was stirred at room temperature for 1 hour. The reaction mixture was then concentrated in vacuo purified by column chromatography (SiO2) to yield the title compound as a white solid (65 mg). MS (m/e): 327.5 (M+H+, 100%).
(b) 5-Methanesulfonyl-2-(3,3,3-trifluoro-propoxy)-benzoic acid
To 5-methanesulfonyl-2-(3,3,3-trifluoro-propoxy)-benzoic acid methyl ester (620 mg) in ethanol at 60°C was added IN NaOH solution (3.8 mL) and the reaction mixture was stirred for 15 minutes. After such time 3.8 ml of IN HCl was slowly added to the reaction mixture and the ethanol was evaporated in vacuo. The precipitate was then washed with water several times to give the title compound (497 mg). MS (m/e): 311.0, M-H+, 100%).
Example 2J1 Preparation of 5-Methanesulfonyl-2- (tetrahydro-pyran-4-yloxy)-benzoic acid
Compound 2J1 was prepared in analogy to compound 2J0 using tetrahydro-2H-pyran- 4-ol. MS (m/e): 299.4 (M-H, 100%).
Example 2J2
Preparation of 2-Cyclobutylmethoxy-5-methanesulfonyl-benzoic acid
Compound 2J2 was prepared in analogy to compound 2J0 using cyclobutyl methanol. MS (m/e): 299.4 (M-H, 100%).
Example 2J 3
Preparation of 3,5-Difluoro-4-piperazin-l-yl-benzonitrile trifluoro-acetic acid
Compound 2J3 was prepared in analogy to compound 2.7 using 3,4,5- trifluorobenzonitrile. MS (m/e): 224J (M+H+, 100%).
Example 2J4
Preparation of 2,6-Difluoro-4-piperazin-l-yl-benzonitrile trifluoro-acetic acid Compound 2J4 was prepared in analogy to compound 2.7 using 2,4,6- trifluorobenzonitrile. MS (m/e): 224.1 (M+H+, 100%).
Example 2J5
Preparation of 5-Methanesulfonyl-2-trifluoromethoxy-benzoic acid
(a) 5-Sulfino-2-trifluoromethoxy-benzoic acid
5-chlorosulfonyl-2-trifluoromethoxy-benzoic acid (1.0 g, compound 2.9.a) was added portionwise onto a solution of sodium sulfite (3J g) in 16 mL of water. The reaction mixture was kept under basic conditions by the addition of the proper amount of 20% NaOH and was stirred at room temperature for 45 minutes. After such time the reaction mixture was cooled down with an ice bath and was then acidified by the addition of 20% H2SO solution until reaching pH 2. The solution was then extracted several times with diethyl ether and ethyl acetate. The combined organic phases were dried (sodium sulfate) and concentrated in vacuo to yield the title compound as a white solid (0.88 g).
(b) 5-Methanesulfonyl-2-trifluoromethoxy-benzoic acid
To 5-Sulfino-2-trifluoromethoxy-benzoic acid (0.82 g) in DMF (5 mL) was added 1.3 g of potassium carbonate and the reaction mixture was stirred for 5 minutes before methyl iodide (0.66 mL) was added. The reaction mixture was then stirred at room temperature for 60 hours. After such time the reaction mixture was concentrated in vacuo and the residue was treated with IN NaOH (10 mL) and THF (4 mL). The reaction mixture was stirred for a further 2 hours at room temperature. After such time the solution was acidified with concentrated HCl solution. THF was then removed in vacuo and the precipitate was isolated by filtration and washed several times with water to yield the title compound. MS (m/e): 283.0 (M-H, 100%).
Example 2J6 Preparation of 2,4-Difluoro-6-piperazin-l-yl-benzonitrile trifluoro-acetic acid
Compound 2J6 was prepared in analogy to compound 2.7 using 2,4,6- trifluorobenzonitrile of . MS (m/e): 224.1 (M+H+, 100%).
Example 2J7
Preparation of 2-(2-Fluoro-l-fluoromethyl-ethoxy)-5-methanesulfonyl-benzoic acid Compound 2J7 was prepared in analogy to compound 2J0 using l,3-difluoro-2- propanol. MS (m/e): 293.1 (M-H, 100%).
Example 2J8
Preparation of 5-Methanesulfonyl-2-(2,2,3,3,3-pentafluoro-propoxy)-benzoic acid
(a) 5-MethanesulfonvI-2-(2,2,3.3,3-pentafluoro-propoxy)-benzoic acid methyl ester
A solution of methyl 5-(methanesulfonyl)salicylate [101371-44-2] (0.50 g), trifluoro- methanesulfonic acid 2,2,3,3,3-pentafluoro-propyl ester (0.67 g) and potassium carbonate (0.60 g) in acetone was stirred at 60°C for 5 hours. The reaction mixture was then concentrated in vacuo and purified by column chromatography (SiO2) to yield the title compound as a white solid (0.44 g). MS (m/e): 363J (M+H+, 100%).
(b) 5-Methanesulfonyl-2-(2.2,3,3.3-pentafluoro-propoxy .-benzoic acid
To 5-methanesulfonyl-2-(2,2,3,3,3-pentafluoro-propoxy)-benzoic acid methyl ester (414 mg) in THF (5 mL) was added a solution of lithium hydroxide monohydrate (72 mg) in water (5 mL), and the reaction mixture was stirred at room temperature for 1 hour. After such time 1.72 mL of IN aqueous hydrochloric acid solution was added. The reaction mixture was then concentrated in vacuo and the resulting precipitate was then washed several times with water to yield the title compound as a white solid (367 mg). MS (m/e): 347.1 (M-H, 100%).
Example 2J9 Preparation of 2-tert-Butoxy-5-methanesulfonyl-benzoic acid
(a) 2-tert-Butoxy-5-methanesulfonyl-benzoic acid methyl ester
To a solution of methyl 5-(methanesulfonyl)-salicylate [101371-44-2] (0.50 g) in toluene (5 mL) was added N,N-dimethylformamide-di-tert-butylacetal and the reaction mixture was strirred at 80°C for 1 hour. After such time the reactiom mixture was concentrated in vacuo and purified by column chromatography to yield the title compound as colourless oil (258 mg). MS (m/e): 304.4 (M+NH4 +, 100%).
(b) 2-tert-Butoxy-5-methanesulfonyl-benzoic acid
To 2-tert-Butoxy-5-methanesulfonyl-benzoic acid methyl ester (1.58 g) in THF (25 mL) was added a solution lithium hydroxide monohydrate (0.35 g) in water (25 mL) and the reaction mixture was stirred at room temperature for 4 hours. After such time the THF was removed in vacuo and to the remaining aqueous solution was added 8 mL of IN HCl solution leading to precipitation of the compound. The precipitate was filtered off and washed several times with water to yield the title compound (1.00 g) as a white solid. MS (m/e): 289.9 (M+NH4 +).
Example 2.20
Preparation of l-(2,5-Difluoro-4-methanesulfonyl-phenyl)-piperazine trifluoro-acetic acid
(a) 2,4.5-Trifluoro-benzenesulfinic acid
2,4,5-Trifluoro-benzenesulfonyl chloride ([220227-21-4], 2.5 g) was added portionwise onto a solution of sodium sulfite (10.3 g) in 50 ml of water. The reaction mixture was kept under basic conditions by the addition of the proper amount of 20% NaOH and was stirred at room temperature for 1 hour. Methanol was added to the reaction mixture and the reaction mixture was stirred at room temperature for another hour. After such time the reaction mixture was cooled down with an ice bath and was then acidified by the addition of 20% H2SO solution until reaching pH 2. The aqueous solution was then extracted several times with diethyl ether and ethyl acetate. The aqueous solution was further extracted with etyl acetate using a Kutscher-Steudel apparatus (continuous extraction). The combined organic phases were dried (sodium sulfate) an concentrated in vacuo to yield the title compound as a white solid (2J g).
(b) l,2J-Trifluoro-5-methanesulfonyl-benzene
To 2,4,5-trifluoro-benzenesulfinic acid (2.0 g) in DMF (17 mL) was added 4.3 g of potassium carbonate and the reaction mixture was stirred for 5 minutes before methyl iodide (2.2 mL) was added. The reaction mixture was then stirred at room temperature for 60 hours. After such time water (30 mL) was poured onto the reaction mixture and the reaction mixture was extracted with diethylether several times. The combined organic phases were dried with sodium sulfate and the remaining mixture was distilled to yield the title compound as a light yellow oil (2.1 g).
(c) l-(2,5-Difluoro-4-methanesulfonyl-phenyl)-piperazine trifluoro-acetic acid
The title compound was obtained in analogy to example 2.7 using l,2,4-Trifluoro-5- methanesulfonyl-benzene. MS (m/e): 277J (M+H+). Example 2.21
Preparation of l-(3,5-Difluoro-4-methanesulfonyl-phenyl)-piperazine trifluoro-acetic acid
Compound 2.21 was prepared in analogy to compound 2.20 using 2,4,6-trifluoro- benzenesulfonyl chloride [172326-59-9]. MS (m/e): 277.1 (M+H+).
Example 2.22
Preparation of 5-Methanesulfonyl-2-(2,2,3,3-tetrafluoro-propoxy)-benzoic acid
Compound 2.22 was prepared in analogy to compound 2J8 using 2,2,3,3-tetrafluoro-l- propyl triflate. MS (m/e): 329J (M-H). Example 2.23
Preparation of l-(2,6-Difluoro-4-methanesulfonyl-phenyl)-piperazine trifluoro-acetic acid
Compound 2.23 was prepared in analogy to compound 2.20 using 3,4,5-trifluoro- benzenesulfonyl chloride [351003-43-5]. MS (m/e): 277.1 (M+H+). Example 2.24
Preparation of 4- Piperazin- l-yl-6-trifluoromethyl-pyrimidine trifluoro-acetic acid
Compound 2.24 was prepared in analogy to compound 2.7 using 4-chloro-6- trifluoromethyl-pyrimidine [37552-81-1]. MS (m/e): 233.1 (M+H+).
Example 2.25 Preparation of 2-Piperazin-l-yl-5-trifluoromethyl-pyrimidine
(a) 2-(4-Benzyl-piperazin-l-yl)-5-trifluoromethyl-pyrimidine
To a solution of (3-Dimethylamino-2-trifluoromethyl-aUylidene)-dimethyl-ammonium chloride ([176214-18-9], 0.60 g) in acetonitrile (10 mL) was added 4-Benzyl-piperazine- 1-carboxamidine hydrochloride ([7773-69-5], 0.66 g) and triethylamine (0.87 mL) and the reaction mixture was stirred for 3 hours at room temperature. After such time the reaction mixture was concentrated in vacuo and purified by column chromatography to yield the title compound as a light yellow solid (0.79 g). MS (m/e): 323.4 (M+H+). (b) 2-Piperazin-l-yl-5-trifluoromethyl-pyrimidine
To a solution of 2-(4-Benzyl-piperazin-l-yl)-5-trifluoromethyl-pyrimidine (0.63 g) in methanol was added Palladium-C (Degussa E101N; 5%) and the reaction mixture was heated at 60°C under hydrogen atmosphere. The reaction mixture was then allowed to cool down to room temperature, the catalyst was filtered of and solvent was removed in vacuo to yield the title compound as a colorless solid (0.41 g). MS (m/e): 233J (M+H+).
In analogy to Example 5 compounds 108 to 280 of the following table were prepared from the acid derivatives and piperazine derivatives:
Figure imgf000064_0001
Figure imgf000065_0001
Figure imgf000066_0001
Figure imgf000067_0001
Figure imgf000068_0001
Figure imgf000069_0001
Figure imgf000070_0001
Figure imgf000071_0001
Figure imgf000072_0001
Figure imgf000073_0001
Figure imgf000074_0001
Figure imgf000075_0001
Figure imgf000076_0001
Figure imgf000077_0001
Figure imgf000078_0001
Figure imgf000079_0001
Figure imgf000080_0001
Figure imgf000081_0001
Figure imgf000082_0001
Figure imgf000083_0001
Figure imgf000084_0001
Figure imgf000085_0001
Figure imgf000086_0001
l-(4-Chloro-2-fluoro- phenyl)-pipera [4-(4-Chloro-2-fluoro- zine hydrochloride phenyl) -piperazin- 1 -yl] - (commercial) and 5-
224 [5-methanesulfonyl-2- 495.4 Methanesulfonyl-2-(2,2,2- (2,2,2-trifluoro-ethoxy)- trifluor phenyl] -methanone o-ethoxy)-benzoic acid (compound 1.5) l-(4-Chloro-3- [4-(4-Chloro-3- trifluoromethyl-pheny trifluoromethyl-phenyl) - 1) -piperazine (commercial) piperazin- 1-yl] -[5-
225 and 5-Methanesulfonyl-2- 545.3 methanesulfonyl-2- (2,2,2-trifluor ( 2,2,2-trifluoro-e thoxy) - o-ethoxy) -benzoic acid phenyl] -methanone (compound 1.5) l-(2,5-Difluoro-4- [4-(2,5-Difluoro-4- methanesulfonyl-phenyl) - methanesulfonyl- piperazine trifluoro-acetic phenyl) -piperazin- 1 -yl] - acid (compound 2.20) and 574.3
226 [5-methanesulfonyl-2- 5-Methanesulfonyl-2-(2,2,2- (M+NH4 +) (2,2,2-trifluoro-ethoxy)- trifluor phenyl] -methanone o-ethoxy)-benzoic acid (compound 1.5) l-(2,6-Difluoro-4- methanesulfonyl-phenyl)- piperazine trifluoro-acetic [4-(2,6-Difluoro-4- acid (compound 2.23) and methanesulfonyl- 5-Methanesulfonyl-2-(2,2,2- phenyl) -piperazin- 1 -yl] -
227 trifluor 557.4 [5-methanesulfonyl-2- o-ethoxy) -benzoic acid (2,2,2-trifluoro-ethoxy)- (compound 1.5) phenyl] -methanone
Figure imgf000088_0001
Figure imgf000089_0001
Figure imgf000090_0001
Figure imgf000091_0001
Figure imgf000092_0001
Figure imgf000093_0001
Figure imgf000094_0001
Figure imgf000095_0001
Figure imgf000096_0001
Figure imgf000097_0001
Figure imgf000098_0001
Figure imgf000099_0001
In analogy to Example 1.2 (b) compounds 3J to 3.5 o t e o owing ta e were prepared from 2-chloro-5-methanesulfonyl-benzoic acid and the appropriate alcohol:
Figure imgf000099_0002
Figure imgf000100_0001
In analogy to Example 5 compounds 281 to 326 of the following table were prepared from the acid derivatives and piperazine derivatives.
Figure imgf000100_0002
Figure imgf000101_0001
Figure imgf000102_0001
Figure imgf000103_0001
Figure imgf000104_0001
Figure imgf000105_0001
Figure imgf000106_0001
Figure imgf000107_0001
Figure imgf000108_0001
Figure imgf000109_0001
Example 4.1 Preparation of 6-Ethoxy-2-fluoro-3-methanesulfonyl-benzoic acid
(a) 3-Chlorosulfonyl-2.6-difluoro-benzoic acid
95 mmol of 2,6-difluorobenzoic acid in 19 ml of chlorosulfonic acid was stirred for 2 h at 150°. The mixture was poured into 200 ml of ice and stirred for 20 min. The resulting slurry was filtered, washed with water and dried (20° overnight in the dessicator) to yield the title compound as a colorless solid. MS (m/e): 279.4 (MNa+, 81%)
(b 2,6-Difluoro-3-sulfino-benzoic acid
41 mmol of 3-chlorosulfonyl-2,6-difluoro-benzoic acid was slowly added over 20 min. to a solution of 310 mmol sodium sulfite in 200 ml of water. The resulting mixture was stirred for one hour at room temperature, cooled to 0° C and acidified with 20% aqueous sulfuric acid. The sulfinic acid was extracted with ethyl acetate, dried over MgSO and concentrated to yield the title compound as a colorless solid. MS (m/e): 220.9 (M-H, 100%)
(c) 6-Ethoxy-2-fluoro-3-methanesulfonyl-benzoic acid
A mixture of 27 mmol 2,6-difluoro-3-sulfino-benzoic acid and 9 mmol Na2CO3 in 110 ml methanol was treated with 72 mmol of methyl iodide. The resulting mixture was stirred overnight at 60°, concentrated and the dark residue dissolved in 100 ml of ethanol. 100 ml of 2 molar aqueous NaOH is added and the mixture was refluxed for 2 hours. Concentration to about 100 ml precipitated a yellowish solid which was filtered and triturated with diethyl ether to give the crude title compound, which was used without further purification.
Example 4.2 Preparation of l-(4-Trifluoromethanesulfonyl-phenyl)-piperazine
A mixture of 1 mmol l-Bromo-4-trifluoromethanesulfonyl-benzene [Nodiff et al.,
J.Org.Chem. 25, 60 (I960)], 3 mmol of piperazine and 2 mmol of potassium carbonate in 5 ml of acetonitrile was refluxed for 2 hours. The resulting mixture was poured into water, extracted with ethyl acetate, dried, concentrated and purified by column chromatography (SiO2; Et2O / cyclohexane) to yield the title compound as a colorless solid. MS (m/e): 295.2 (MH\ 100%)
Example 4.3 Preparation of l-(2,4-Bis-trifluoromethyl-phenyl)-piperazine hydrochloride
(a) 4-(2J-Bis-trifluoromethyl-phenyl)-piperazine-l-carboxylic acid tert-butyl ester
A mixture of 5 mmol 2,4-bis(trifluoromethyl)bromobenzene, 6 mmol N-BOC- piperazine, 8 mmol NaOtBu, 0.5 mmol rac-2,2'-bis(diphenylphosphino)-lJ'-binaphthyl and 1 mmol tris-(dibenzylideneacetone)dipa_ladium chloroform complex in 20 ml toluene was stirred at 80° C for 3 hours. The mixture was then diluted with water, extracted with ethyl acetate, dried and purified by column chromatography (SiO2; cyclohexane / ethyl acetate 9:1) to yield the title compound as a yellowish oil.
MS (m/e): 399J (MH+, 100%)
(b) l-(2J-Bis-trifluoromethyl-phenyl)-piperazine hydrochloride
3 mmol of 4-(2,4-Bis-trifluoromethyl-phenyl)-piperazine-l-carboxylic acid tert-butyl ester was stirred in 10 ml of 1,4-dioxane saturated with gaseous HCl. After 4 h at room temperature, the reaction mixture was evaporated to dryness to yield the title compound as a colorless solid. MS (m/e): 299.3 (MH+, 100%)
Example 4.4
Preparation of l-[4-(5-Methyl-[l,2,4]oxadiazol-3-yl)-phenyl]-piperazine hydrochloride
(a) 4-[4-(5-Methyl-f l,2-4loxadiazol-3-yl)-phenyl1-piperazine-l-carboxylic acid tert- butyl ester A well stirred mixture of 0.015 mmol of bis(tri-t-butylphosphine)palladium, 0.01 mmol of cetyltrimethylammonium bromide, 2 mmol of powdered potassium hydroxide, 2mmol of 3-(4-bromo-phenyl)-5-methyl-[l,2,4]oxadiazole and 2J mmol of N-BOC- piperazine in 1 ml of toluene was heated under Ar to 90° C for 17 hours. The resulting reaction mixture was diluted with water, extracted with ethyl acetate and the product purified by column chromatography (SiO2; cyclohexane / ethyl acetate 7:3 ) to yield the title compound as a yellowish solid. MS (m/e): 345.3 (MH+, 100%)
(b) l-[4-(5-Methyl-[ 1,2.41 oxadiazol-3-yl)-phenvn-piperazine hydrochloride
1 mmol of 4-[4-(5-Methyl-[l,2,4]oxadiazol-3-yl)-phenyl]-piperazine-l-carboxylic acid tert-butyl ester was stirred in 3 ml of 1,4-dioxane saturated with gaseous HCl. After 2 h at room temperature, the reaction mixture was evaporated to dryness to yield the tide compound as a colorless solid. MS (m/e): 245J (MH+, 100%)
Example 4.5
Preparation of l-(4-Oxazol-2-yl-phenyl)-piperazine hydrochloride
(a) 4-Bromo-N-(2,2-dimethoxy-ethyl)-benzamide
A solution of 24 mmol aminoacetaldehyde dimethylacetal was dissolved in 30 ml of water and treated with 25 mmol of potassium hydrogen carbonate. A solution of 23 mmol of 4- bromobenzoyl chloride in 50 ml of acetone was slowly added under stirring over a period of 30 min. The acetone was evaporated and the aqueous phase extracted 3 times with ethyl acetate to yield the crude tide compound as a slightly brown solid.
MS (m/e): 287.1 (M-H, 43%)
(b) 2-(4-Bromo-phenyl)-oxazole
A solution of 21 mmol of phosphorous pentoxide in 20 ml of methylsulfonic acid was treated with 7 mmol of 4-Bromo-N-(2,2-dimefhoxy-ethyl)-benzamide. The reaction mixture was heated for 5 hours at 130°, cooled to room temperature and poured into ice- water. The resulting solid was filtered off and dried to yield the crude tide compound as a brownish solid. MS (m/e): 224.0 (MH+, 24%)
(c) 4-(4-Oxazol-2-yl-phenyl.-piperazine-l-carboxylic acid tert-butyl ester
Prepared in analogy to example 4.4 (a) from 2-(4-Bromo-phenyl)-oxazole and N-BOC- piperazine. MS (m/e): 330.3 (MH\ 100%) - Ill -
(d) l-(4-Oxazol-2-yI-phenyl)-piperazine hydrochloride
Prepared in analogy to example 4.4 (b) from 4- (4-Oxazol-2-yl-phenyl) -piperazine- 1- carboxylic acid tert-butyl ester and hydrochloric acid in dioxane. MS (m/e): 230J (MH+, 100%) Example 4.6
Preparation of 1- [4- (5-Methyl-[l, 3,4] oxadiazol-2-y_)-phenyl] -piperazine hydrochloride
(a) 2J4-Bromo-phenyl)-f 1,3,41 oxadiazole
12.3 mmol of 4-bromo-benzoic acid hydrazide were dissolved in 26 ml of triethyl orthoformate. The reaction mixture was stirred overnight at 140°, evaporated and the residue crystallized from ethanol to give the title compound as a colorless solid. MS (m/e): 225.0 (MH+, 100%)
(b) 4-(4-f l,3,4]Oxadiazol-2-yl-phenyl)-piperazine-l-carboxylic acid tert-butyl ester
Prepared in analogy to example 4.4 (a) from 2-(4-Bromo-phenyl)-[l,3,4]oxadiazole and N-BOC-piperazine.
MS (m/e): 342.2 (MH+, 100%)
(c . 1 - [4-(5-Methyl- [1,3,41 oxadiazol-2-yl)-phenyl1 -piperazine hydrochloride
Prepared in analogy to example 4.4 (b) from 4-(4-[l,3,4]Oxadiazol-2-yl-phenyl)- piperazine-1 -carboxylic acid tert-butyl ester and hydrochloric acid in dioxane. MS (m/e): 245.3 (MH+, 100%) Example 4.7
Preparation of l-[4-(2-Methyl-2H-tetrazol-5-yl)-phenyl]-piperazine hydrochloride
(a) 5-(4-Bromo-phenyl)-2-methyl-2H-tetrazole
A mixture of 3.5 mmol of 5-(4-bromo-phenyl)-2H-tetrazole, 0.2 mmol of tetrabutyl ammonium bromide, 4.4 mmol of methyl iodide, 6 ml of IM aqueous sodium hydroxide and 6 ml of dichloromethane were stirred at room temperature for 24 hours. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic phase was dried, evaporated and the product purified by column chromatography (SiO2; cyclohexane / ethyl acetate 7:3). MS (m/e): 239.1 (MH+, 29%) (b) 4-[4-(2-Methyl-2H-tetrazol-5-yl)-phenyl1-piperazine-l-carboxylic acid tert-butyl ester
Prepared in analogy to example 4.4 (a) from 5-(4-Bromo-phenyl)-2-methyl-2H-tetrazole and N-BOC-piperazine. MS (m/e): 345.1 (MH+, 41%)
(c) l-[4-(2-Methyl-2H-tetrazol-5-yl)-phenyl1 -piperazine hydrochloride
Prepared in analogy to example 4.4 (b) from 4-[4-(2-Methyl-2H-tetrazol-5-yl)-phenyl]- piperazine-1 -carboxylic acid tert-butyl ester and hydrochloric acid in dioxane. MS (m/e): 245.1 (MH\ 100%)
Example 4.8 Preparation of 3,4,5,6-Tetrahydro-2H-[l,2']bipyrazinyl-5'-carboxylic acid methyl ester hydrochloride
(a) 23,5,6-Tetrahydro-[l,2'1bipyrazinyl-4,5'-dicarboxylic acid 4-tert-butyl ester 5'- methyl ester
A mixture of 17 mmol methyl- 5-chloropyrazine-2-carboxylate, 18 mmol of N-BOC- piperazine and 20 mmol of K2CO3 in 20 ml of acetonitrile was heated under reflux for 3 hours. The reaction mixture was concentrated, diluted with water and extracted with ethyl acetate. The tide compound was recrystallized from ethyl acetate to yield a colorless solid. MS (m/e): 323.4 (MH+, 100%)
(b) 3.4,5,6-Tetrahydro-2H-[l,2'1bipyrazinyl-5'-carboxyric acid methyl ester hydrochloride
Prepared in analogy to example 4.4 (b) from 2,3,5,6-Tetrahydro-[l,2']bipyrazinyl-4,5'- dicarboxylic acid 4-tert-butyl ester 5' -methyl ester and 1,4-dioxane saturated with gaseous HCl. MS (m/e): 223.1 (MH+, 100%)
Example 4.9 Preparation of 6'-Chloro-3,4,5,6-tetrahydro-2H-[l,2']bipyrazinyl trifluoroacetate
(a) 6'-Chloro-2,3,5,6-tetrahydro-[l,2'1bipyrazinyl-4-carboxylic acid tert-butyl ester
A mixture of 10 mmol 2,6-dichloropyrazine and 21 mmol of N-BOC-piperazine in 15 ml acetonitrile was heated under reflux for 1.5 hours. The reaction mixture was concentrated and purified by chromatography (SiO2; dichloromethane / methanol 95:5) to yield the title compound as a colorless solid. MS (m/e): 299.2 (MH+, 100%) (b) 6'-Chloro-3J,5,6-tetrahydro-2H-[l,2'1bipyrazinyl trifluoroacetate
A solution of 2 mmol 6'-Chloro-2,3,5,6-tetrahydro-[l,2']bipyrazinyl-4-carboxylic acid tert-butyl ester in 10 ml of dichloromethane was treated with 3 mmol of trifluoroacetic acid and stirred at room temperature for 17 hours. Concentration and crystallisation from diethylether yielded the title compound as a colorless solid.
MS (m/e): 198.0 (M\ 100%)
Example 4J0
Preparation of 3,4,5,6-Tetrahydro-2H-[l,2']bipyrazinyl-5'-carboxylic acid amide hydrochloride
(a) 5'-Carbamoyl-2,3,5,6-tetrahydro-[l,2'1bipyrazinyl-4-carboxylic acid tert-butyl ester
3 mmol of 2,3,5,6-Tetrahydro-[l,2']bipyrazinyl-4,5'-dicarboxylic acid 4-tert-butyl ester 5'-methyl ester (example 1J3 (a)) was dissolved in a 7 molar solution of gaseous ammonia in methanol. The reaction vessel was tightly closed and heated overnight at 60° C. Cooling of the reaction mixtures led to crystallisation of the title compound. MS (m/e): 308.4 (MH+, 100%)
(b) 3,4,5,6-Tetrahydro-2H-[1.2'1bipyrazinyl-5'-carboxylic acid amide hydrochloride
0.25 mmol of 5'-Carbamoyl-2,3,5,6-tetrahydro-[l,2']bipyrazinyl-4-carboxylic acid tert- butyl ester was stirred for 1 hour in 1 ml of dioxane saturated with gaseous HCl. Concentration of the reaction mixture led to the title compound, as a colorless solid. MS (m/e): 208.3 (MH+, 100%)
Example 4.11
Preparation of Dimethyl-(4-piperazin-l-yl-[l,3,5]triazin-2-yl)-amine
(a) 4J4-CMoro-f 1.3.5ltriazin-2-yl)-piperazine-l-carboxylic acid tert-butyl ester
A solution of 11 mmol of 2,4-dichlorotriazine (WO 02/083654) in 20ml of acetonitrile was chilled and treated with 11 mmol of triethylamine and 11 mmol of N-BOC- piperazine. The reaction mixture was stirred for 2 hours at 0° C then for 2 hours at room temperature. Addition of 100ml brine and extraction with ethyl acetate yielded the crude product which was purified through trituration in ethyl acetate. MS (m/e): 300.3 (MH+, 100%) (b) 4-(4-Dimethylamino-[l,3,5ltriazin-2-yl)-piperazine-l-carboxylic acid tert-butyl ester
A solution of 2 mmol of 4-(4-Chloro-[l,3,5]triazin-2-yl)-piperazine-l-carboxylic acid tert-butyl ester in 15 ml of 2M dimethylamine in methanol was stirred at room temperature for 1 hour. Concentration and purification by chromatography (SiO2; ethyl acetate / cyclohexane 1:1) yielded the tide compound as a colorless solid. MS (m/e): 309J (MH+, 100%)
(c) Dimethyl-(4-piperazin-l-yl-[l,3,5]triazin-2-yl. -amine
A solution of 1 mmol of 4-(4-Dimethylamino-[l,3,5]triazin-2-yl)-piperazine-l- carboxylic acid tert-butyl ester in 10 ml dichloromethane was chilled and treated with 14 mmol of trifluoroacetic acid. The reaction mixture was heated to 40° C for 30 min. After cooling, 50ml of 2M aqueous sodium hydroxide is added. The organic layer was separated, dried and concentrated to yield the title compound as a yellowish oil. MS (m/e): 267.0 (M+CH3COO+, 100%)
Example 4J 2 Preparation of 6'-Methoxy-3,4,5,6-tetrahydro-2H-[l,2']bipyrazinyl
(a) 6'-Methoxy-2,3,5-6-tetrahydro-[l,2Hbipyrazinyl-4-carboxylic acid tert-butyl ester
1 mmol of 6'-Chloro-2,3,5,6-tetrahydro-[l,2']bipyrazinyl-4-carboxylic acid tert-butyl ester [example 4.9 (a)] was dissolved in a solution of sodium methanolate (prepared by dissolving 1 mmol of sodium in 10 ml of methanol). The mixture was heated overnight to 70°, concentrated and the product purified by chromatography (SiO2; dichloromethane / methanol 99:1) to yield the tide compound as a colorless foam. MS (m/e): 295.3 (MH+, 100%)
(b) 6'-Methoxy-3J,5,6-tetrahydro-2H-[l,2'1bipyrazinyl
Prepared in analogy to example 4J0 (c) from 6'-Methoxy-2,3,5,6-tetrahydro- [ l,2']bipyrazinyl-4-carboxylic acid tert-butyl ester and trifluoroacetic acid. MS (m/e): 195.1 (MH+, 80%)
Example 4J3
Preparation of 2-Methoxy-4-piperazin- 1-yl- [ 1 ,3,5] triazine
(a) 4-(4-Methoxy-[l,3-5]triazin-2-yl)-piperazine-l-carboxylic acid tert-butyl ester 1 mmol of 4-(4-Chloro-[l,3,5]triazin-2-yl)-piperazine-l-carboxylic acid tert-butyl ester [example 4J1 a)] was dissolved in a solution of sodium methanolate (prepared by dissolving 1 mmol of sodium in 5 ml of methanol). The mixture was stirred at room temperature for 1 hour, concentrated and the the tide compound purified by recrystallisation from ethyl acetate / cyclohexane. MS (m/e): 296.3 (MH+, 100%)
(b) 2-Methoxy-4-piperazin-l-yl-[l,3,5]triazine
Prepared in analogy to example 4J0 (c) from 4-(4-Methoxy-[l,3,5]triazin-2-yl)- piperazine-1 -carboxylic acid tert-butyl ester and trifluoroacetic acid. MS (m/e): 196.4 (MH\ 100%) Example 4J 4
Preparation of 2-Dimethylcarbamoyloxy-5-methanesulfonyl-benzoic acid
(a) 2-Hydroxy-5-methanesulfonyl-benzoic acid benzyl ester
5 mmol of N-(3-dimethylaminopropyl)-N'-ethyl-carbodiimid-hydrochloride was slowly added to a stirred suspension of 5 mmol 2-hydroxy-5-methanesulfonyl-benzoic acid, 5 mmol of benzyl alcohol and 0.5 mmol of 4-dimethylaminopyridine in 10 ml acetonitrile . The mixture was stirred overnight at room temperature, concentrated and treated with 10 ml of water. A few drops of diluted hydrochloric acid were added to acidify the solution. The resulting solid was filtered and the purified by chromatography (SiO2; ethyl acetate / cyclohexane 3:7) to yield the tide compound as a colorless solid. MS (m/e): 305.0 (M-H, 100%)
(b) 2-Dimethylcarbamoyloxy-5-methanesulfonyl-benzoic acid benzyl ester
A mixture of 1 mmol 2-hydroxy-5-methanesulfonyl -benzoic acid benzyl ester, 1.5 mmol of N-methylmorpholine and 0.2 mmol of 4-dimethylaminopyridine in 4 ml of dimethylformamide was treated with 1.3 mmol of N,N-dimethyl-carbamoylchloride. The reaction mixture was stirred at 60° for 48 hours, concentrated in vacuo and the residue taken up in 5 ml of water. Acidification with diluted hydrochloric acid and extraction with ethyl acetate yielded a crude product which was purified by chromatography (SiO2; ethyl acetate / cyclohexane 1.1). MS (m/e): 378.3 (MH+, 100%)
(c) 2-Dimethylcarbamoyloxy-5-methanesulfonyl-benzoic acid 1 mmol of 2-dimethylcarbamoyloxy-5-methanesulfonyl-benzoic acid benzyl ester was dissolved in 5 ml of methanol. 25 mg of palladium 10% on charcoal was added and the reaction mixture hydrogenated at room temperature to yield the title compound as a slightly yellowish solid. MS (m/e): 288.0 (MH\ 66%) In analogy to Example 5 compounds 327 to 355 of the following table were prepared from the acid derivatives and piperazine derivatives:
Figure imgf000117_0001
Figure imgf000118_0001
Figure imgf000119_0001
Figure imgf000120_0001
Figure imgf000121_0001
Figure imgf000122_0001
Figure imgf000123_0001
Example 356 Preparation of l-{3-Fluoro-4- [4-(2-isopropoxy-5-methanesu_fonyl-benzoyl)- piperazin- 1-yl] -phenyl}-ethanone oxime
0J2 mmol of l-{3-Fluoro-4-[4-(2-isopropoxy-5-methanesulfonyl-benzoyl)-piperazin-l- yl] -phenyl} -ethanone was dissolved in 1 ml of a 1:1 mixture of ethanol and water. 0.8 mmol of hydroxylamine hydrochloride was added, followed by 8.4 mmol of sodium acetate. The resulting mixture was stirred overnight at room temperature, diluted with water, filtered, washed and dried to yield the title compound as a colorless solid.
MS (m/e): 478.2 (MH+, 100%)
Example 357 Preparation of l-{3-Fluoro-4- [4-(2-isoproρoxy-5-methanesulfonyl-benzoyl)- piperazin- 1 -yl] -phenyl}-ethanone O-methyl-oxime
0J2 mmol of l-{3-Fluoro-4-[4-(2-isopropoxy-5-methanesulfonyl-benzoyl)-piperazin-l- yl] -phenyl} -ethanone was dissolved in 1 ml of a 1:1 mixture of ethanol and water. 0.8 mmol of O-methyl-hydroxylamine hydrochloride was added, followed by 8.4 mmol of sodium acetate. The slurry was stirred overnight at room temperature, diluted with water, extracted with ethyl acetate, dried and concentrated. The resulting gum was triturated with diethyl ether / heptane to yield the tide compound as a colorless solid. MS (m/e): 492.3 (MH+, 100%)
Example 4J 5
Preparation of (2,6-Difluoro-3-methanesulfonyl-phenyl)- [4- (2-fluoro-4- methanesulfonyl-phenyl)-piper azin- 1 -yl] -methanone
(a) 3-ChlorosuIfonyl-2,6-difluoro-benzoic acid
77 mmol of 2,6-difluorobenzoic acid were dissolved in 15.5 ml of chlorosulfonic acid and stirred for 2 h at 150° C. The reaction mixture was cooled to room temperature and poured into 100 ml of ice / water. The solid was filtered and dried to yield the tide compound as a colorless solid. MS (m/e): 255J (M-H, 44%)
(b) 2,6-Difluoro-3-sulfino-benzoic acid
240 mmol of sodium sulfite were dissolved in 150 ml of water. 32 mmol of 3- Chlorosulfonyl-2,6-difluoro-benzoic acid was added under stirring over a period of about 20 min. After stirring for an additional hour at room temperature, the mixture was chilled and acidified with 20% aqueous sulfuric acid. The product was extracted with ethyl acetate to yield the tide compound as a colorless solid. MS (m/e): 221.3 (M-H, 34%)
(c) 2,6-Difluoro-3-mefhanesulfonyl-benzoic acid
A suspension of 18 mmol sodium carbonate and 9 mmol 2,6-Difluoro-3-sulfino-benzoic acid in 30 ml of methanol was stirred at room temperature for 30 min, then heated to 60° C. 24 mmol of methyl iodide were added and the reaction mixture heated overnight at 60° C. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic phase was discarded and the aqueous phase acidified by addition of concentrated hydrochloric acid. Extraction with ethyl acetate yielded the title compound as a slightiy brownish solid. MS (m/e): 235.1 (M-H, 16%)
(d) (2,6-Difluoro-3-methanesulfonyl-phenyl)-[4-(2-fluoro-4-methanesulfonyl-phenyl)- piperazin- 1-yll -methanone
This compound was prepared in analogy to example 5 from l-(2-fluoro-4- methanesulfonyl-phenyl) -piperazine and 2,6-difluoro-3-methanesulfonyl -benzoic acid. MS (m/e): 477.0 (MH\ 67%) Example 4J6
Preparation of 4- [4- (2,6-Difluoro-3-methanesulfonyl-benzoyl)-piperazin- 1 -yl] - benzonitrile
Prepared in analogy to example 5 from 4-piperazin- 1-yl-benzonitrile and 2,6-difluoro-3- methanesulfonyl-benzoic acid. MS (m/e): 406.3 (MH+, 84%)
Example 358 Preparation of (2-Cyclopentyloxy-6-ethxy-3-methanesulfonyl-phenyl)-[4-(4- methanesulfonyl-phenyl)-piperazin- 1-yl] -methanone
0J2 mmol of (6-Ethoxy-2-fluoro-3-methanesulfonyl-phenyl)- [4-(4-methanesulfonyl- phenyl) -piperazin- 1-yl] -methanone (example 55) was added to a solution of sodium cyclopentanolate (prepared from 1 mmol sodium dissolved in 1 ml of cyclopentanol). The mixture was heated for 1 hour at 80° C, poured on ice / water and extracted with ethyl acetate. Chromatography (SiO2; ethyl acetate) yielded the tide compound as a slighdy yellow solid. MS (m/e): 551.1 (MH+, 29%) Example 359 Preparation of (2, 6-diisopropoxy-3-methanesulfonyl-phenyl)-[4-(2-fluoro-4- methanesulfonyl-phenyl)-piperazin-l-yl]-methanone
0.27 mmol of 2,6-difluoro-3-methanesulfonyl- phenyl)- [4-(2-fluoro-4-methanesulfonyl- phenyl)-piperazin-l-yl]-methanone (example 4J5) was added to a solution of sodium isopropanolate (prepared by dissolving 3 mmol of sodium in 2 ml of isopropanol). The reaction mixture was heated under reflux for 5 hours, cooled, diluted with water and extracted with ethyl acetate, yielding the tide compound as a slighdy yellow solid.
MS (m/e): 557.3 (MH+, 66%)
Example 360 Preparation of (2-Fluoro-6-isopropoxy-3-methanesulfonyl-phenyl)-[4-(2-fluoro-4- methanesulfonyl-phenyl)-piperazin-l-yl]-methanone
0.2 mmol of£2,6-difluoro-3-methanesulfonyl-phenyl)-[4-(2-fluoro-4-methanesulfonyl- phenyl) -piperazin- 1-yl] -methanone were dissolved in a solution of sodium isopropanolate (prepared by dissolving 0.2 mmol of sodium in 1 ml of isopropanol). The reaction mixture was heated to 50° C for 2 hours, then stirred at room temperature for 48 hours. The solution was diluted with water and extracted with ethyl acetate. The product was purified by chromatography (SiO2, ethyl acetate / cyclohexane 9:1) to yield the tide compound as a colorless solid. MS (m/e): 517J (MH+, 100%)
Example 361 Preparation of (6-Cydopentyloxy-2-fluoro-3-methanesulfonyl-phenyl)-[4-(2-fluoro-4- methanesulfonyl-phenyl)-piperazin- 1 -yl] -methanone
The compound was prepared in analogy to example 358 from £2,6-difluoro-3- methanesulfonyl-phenyl) - [4- (2-fluoro-4-methanesulfonyl-phenyl) -piperazin- 1 -yl] - methanone and sodium cyclopentanolate. MS (m/e): 560.5 (MNH4 +, 43%)
Example 362 Preparation of 4- [4- (2-Fluoro-6-isopropoxy-3-methanesulfonyl-benzoyl)-piperazin- 1- yl] -benzonitrile
The compound was prepared in analogy to example 359 from 4-[4-(2,6-difluoro-3- methanesulfonyl-benzoyl) -piperazin- 1-yl] -benzonitrile and sodium isopropanolate. MS (m/e): 446.0 (MH+, 49%) Example 5J Preparation of l-(3-Fluoro-4-trifluoromethyl-phenyl)-piperazine
(a) 4-(3-Fluoro-4-trifluoromethyl-phenyl)-piperazine-l-carboχylic acid tert-butyl ester
A mixture of 4.9 mmol 4-chloro-2-fluorobenzotrifluoride, 5.9 mmol n-Boc-piperazine, 0.05 mmol palladium acetate, 6.9 mmol sodium-t-butoxide and 0.49 mmol 2-(di-t- butylphosphino)biphenyl in 10 ml toluene was heated for 16 h at 80 °C. After cooling to RT, the mixture was diluted with ether, the suspension was filtered over decalite and the filtrate evaporated. The residue was purified on sihca eluting with a gradient of heptane / EtO Ac to yield after evaporation the tide compound.
(b) l-(3-Fluoro-4-trifluoromethyl-phenyl)-piperazine
A mixture of 2.87 mmol 4-(3-Fluoro-4-trifluoromethyl-phenyl)-piperazine-l -carboxylic acid tert-butyl ester in 10 ml dichloromethane was treated with 14.4 mmol trifluoroacetic acid and refluxed for 3 h. The mixture was concentrated and treated with 10 ml water, NaOH and extracted with dichloromethane. The combined organic phases were dried with MgSO and evaporated to yield the tide compound 5J. MS (m/e): 249.2 (MH+, 100%) Example 5.2 Preparation of 2-Piperazin- l-yl-5-trifluoromethyl-benzonitrile
The compound was prepared in analogy to compound 5J from 2-Chloro-5- trifluoromethyl-benzonitrile (DE2550262). MS (m/e): 256.0 (MH\ 100%) Example 5.3 Preparation of l-(2,3-Difluoro-4-methanesulfonyl-phenyl)-piperazine
The compound was prepared in analogy to compound 2.20 from 2,3,4-Trifluoro- benzenesulfonyl chloride (commercial). MS (m/e): 277.2 (MH+, 100%)
Example 5.4 Preparation of l-(2-Fluoro-4-methyl-phenyl) -piperazine
The compound was prepared in analogy to compound 1J from 4-bromo-3- fluorotoluene (commercial). MS (m/e): 195.3 (MH\ 100%)
Example 5.5 Preparation of l-(3-Fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazine
The compound was prepared in analogy to compound 2.7 from 2,3-Difluoro-5- trifluoromethyl-pyridine (EP0104715). MS (m/e): 250.2 (MH+, 100%)
Example 5.6 Preparation of 5-Methanesulfonyl-2-((S)-2,2,2-trifluoro-l-methyl-ethoxy)-benzoic acid
(a) rac-5-Methanesulfonyl-2-(2,2,2-trifluoro-l-methyl-ethoxy)-benzoic acid methyl ester
A mixture of 21.7 mmol 2-Hydroxy-5-methanesulfonyl-benzoic acid methyl ester
[68029-77-6], 32.5 mmol trifluoro-methanesulfonic acid 2,2,2-trifluoro- 1 -methyl-ethyl ester [212556-43-9], 43.4 mmol potassium carbonate in 87 ml DMF was stirred at 80 °C for 48 hours . After cooling to RT, the mixture was concentrated in vacuo, taken in water and stirred for 1 hour. Filtration yielded the tide compound.
(b) 5-Methanesulfonyl-2-((S.-2,2,2Jrifluoro-l-methyl-ethoxy.-benzoic acid methyl ester
The tide compound was obtained by separation of rac-5-Methanesulfonyl-2-(2,2,2- trifluoro-l-methyl-ethoxy)-benzoic acid methyl ester by chiral HPLC (Chiralcel OD, 15 % ethanol/ Heptane, flow 35 ml, 220 nm, retention time: 86 min.). (c) 5-Methanesulfonyl-2-((S)-2,2,2-trifluoro-l-methyl-ethoxy)-benzoic acid
The compound was prepared in analogy to compound 2.10(b) from 5-Methanesulfonyl- 2-((S)-2,2,2-trifluoro-l-methyl-ethoxy)-benzoic acid methyl ester MS (m/e): 311.0 (M- H, 100%) Example 5.7
Preparation of 5-Methanesulfonyl-2-((R)-2,2,2-trifluoro-l-methyl-ethoxy)-benzoic acid
(a) 5-Methanesulfonyl-2-((R)-2,2,2-trifluoro-l-methyl-ethoxy)-benzoic acid methyl ester
The tide compound was obtained by separation of rac-5-Methanesulfonyl-2- (2,2,2- trifluoro-1 -methyl-ethoxy) -benzoic acid methyl ester by chiral HPLC (Chiralcel OD, 15 % ethanol/ Heptane, flow 35 ml, 220 nm, retention time: 74 min.).
(c. 5-Methanesulfonyl-2-((R)-2,2,2-trifluoro-l-methyl-ethoxy)-benzoic acid
The compound was prepared in analogy to compound 2.10(b) from 5-Methanesulfonyl- 2- ((R) -2,2,2-trifluoro- 1 -methyl-ethoxy) -benzoic acid methyl ester MS (m/e): 311.0 (M- H, 100%)
Example 5.8 Preparation of 2-Chloro-4-piperazin- 1-yl-benzonitrile
A mixture of 7.0 mmol 2-chloro-4-fluorobenzonitrile (commercial), 10.5 mmol piperazine in 4 ml N,N-dimethylacetamide was heated for 1 h at 85 °C. After cooling to RT and evaporation in vacuo, the mixture was diluted with dichloromethane and purified on silica eluting with a gradient of dichloromethane / MeOH to yield after evaporation the tide compound.MS (m/e): 222J (MH\ 100%)
Example 5.9 Preparation of l-(2-Fluoro-4-piperazin-l-yl-phenyl)-ethanone
The compound was prepared in analogy to compound 5.8 from 2,4- difluoroacetophenone (commercial). MS (m/e): 223.2 (M-H, 100%)
Example 5J0 Preparation of l-(3-Fluoro-4-methanesulfonyl-phenyl)-piperazine The compound was prepared in analogy to compound 2.20 from 2,4- difluorobenzenesulfonylchloride (commercial). MS (m/e): 259J (MH+, 100%)
Example 5.11 Preparation of l-(4-Fluoro-2-piperazin-l-yl-phenyl)-ethanone
The compound was prepared in analogy to compound 5.8 from 2,4- difluoroacetophenone (commercial). MS (m/e): 223.2 (M-H, 100%)
Example 5J2 Preparation of 6-Isopropoxy-isophthalamic acid
The compound was prepared in analogy to compound 2J0 from 6-Hydroxy- isophthalamic acid methyl ester [89366-34-7]. MS (m/e): 222J (M-H, 100%)
Example 5J 3 Preparation of 5-Ethanesulfonyl-2-isopropoxy-benzoic acid
(a) 5-Ethanesulfonyl-2-hydroxy-benzoic acid methyl ester
The compound was prepared in analogy to compound 2.20(b) from 2-Hydroxy-5- sulfino-benzoic acid [19479-88-0] and ethyliodide
(b) 5-Ethanesulfonyl-2-isopropoxy-benzoic acid
The compound was prepared in analogy to compound 2J0 from 5-Ethanesulfonyl-2- hydroxy-benzoic acid methyl ester. MS (m/e): 271J (M-H, 100%)
Example 5J4 Preparation of 1 - (4-Difluoromethyl-2-fluoro-phenyl)-piperazine
(a) l-Chloro-4-difluoromethyl-2-fluoro-benzene
24.7 mmol 4-Chloro-3-fluorobenzaldehyde was dissolved in DAST (5J ml) under nitrogen. The mixture was stirred at room temperature for 3 hours, at 50°C for 2 hours and then at room temperature for 65 hours. The solution was added dropwise to a saturated.bicarbonate solution (150 ml) under cooling. The aqueous layer was extracted 3 times with ethyl acetate. The combined extracts were dried over Na2SO , filtered and the solvent was removed in vacuo. The residue was purified on silica eluting with heptane to yield after evaporation the tide compound. (b) l-(4-Difluoromethyl-2-fluoro-phenyl)-piperazine
The compound was prepared in analogy to compound 1J from l-Chloro-4- difluoromethyl-2-fluoro-benzene. MS (m/e): 231.2 (M+H+, 100%)
Example 5J5 Preparation of 1 - (6-Trifluoromethyl-pyridin-3-yl)-piperazine
The compound was prepared in analogy to compound 1J from 5-Bromo-2- trifluoromethyl-pyridine [436799-32-5]. MS (m/e): 232J (M+H+, 100%) Example 5J6 Preparation of 3-Fluoro-4-piperazin-l-yl-benzoic acid ethyl ester
The compound was prepared in analogy to compound 5.8 from Ethyl-3,4- difluorobenzoate (commercial). MS (m/e): 253.2 (M+H+, 100%) Example 5J7 Preparation of l-(2-Trifluoromethyl-pyridin-4-yl)-piperazine
The compound can be prepared from 4-Nitro-2-trifluoromethyl-pyridine 1-oxide [ 147149-97- 1 ] in analogy to the procedure used for the preparation of 4-Bromo-2- methyl-6-trifluoromethyl-pyridine [615579-78-1] (WO03087056). MS (m/e): 227 (M+H+, 100%) Example 5J8 Preparation of l-(6-Methyl-pyridin-3-yl)-piperazine
The compound was prepared in analogy to compound 1J from 5-Bromo-2-methyll- pyridine (commercial). MS (m/e): 178J (M+H+, 100%)
In analogy to Example 5 compounds 363 to 461 of the following table were prepared from the acid derivatives and piperazine derivatives:
Figure imgf000131_0001
Figure imgf000132_0001
Figure imgf000133_0001
Figure imgf000134_0001
Figure imgf000135_0001
Figure imgf000136_0001
Figure imgf000137_0001
Figure imgf000138_0001
(2- 1 - ( 5 -Trifluoromethyl-pyridin - Cyclopropylmethoxy- 5- 2-yl)- methanesulfonyl- piperazine (commercial) and
405 phenyl)-[4-(5- 2-Cyclopropylmethoxy-5- 484.5 trifluoromethyl- methanesulfo pyridin-2-yl)-piperazin- nyl-benzoic acid (compound 1-yl] -methanone 1J) l-(3-Chloro-5- [4-(3-Chloro-5- trifluoromethyl-pyrid trifluoromethyl- in-2-yl) -piperazine pyridin-2-yl)-piperazin- (commercial) and 2-
406 l-yl]-(2- 518.3 Cyclopropylmethoxy-5- cyclopropylmethoxy-5- methanesulfo methanesulfonyl- nyl-benzoic acid (compound phenyl) -methanone 1.4) rac-[4-(3-Chloro-5- l-(3-Chloro-5- trifluoromethyl- trifluoromethyl-pyrid pyridin-2-yl)-piperazin- in-2-yl) -piperazine l-yl]-[5- (commercial) and rac-5-
407 560.3 methanesulfonyl-2- Methanesulfonyl-2-(2,2,2- (2,2,2-trifluoro-l- trifluor methyl-ethoxy)- o-l -methyl-ethoxy) -benzoic phenyl] -methanone acid (compound 3J)
1 - ( 5 -Trifluoromethyl-pyridin - 2-yD- rac-[5- piperazine (commercial) and Methanesulfonyl-2- rac-5-Methanesulfonyl-2- (2,2,2-trifluoro-l- (2,2,2-trifluor methyl-ethoxy)- o-l -methyl-ethoxy) -benzoic
408 526.2 phenyl]-[4-(5- acid (compound 3J) trifluoromethyl- pyridin-2-yl)-piperazin- 1-yl] -methanone
Figure imgf000140_0001
Figure imgf000141_0001
1 - (5-Chloro-pyridin-2-yl) -
[4-(5-Chloro-pyridin- piperazin 2-yl)-piperazin-l-yl] - e (WO01062751) and 2- (2-cyclopentyloxy-5- 464.3 Cyclopentyloxy-5- methanesulfonyl- methanesulfonyl- phenyl) -methanone benzoic acid (compound 1.6) l-(5-Chloro-pyridin-2-yl)-
[4- ( 5-Chloro-pyridin- piperazin
2-yl)-piperazin- 1 -yl] - e (WOO 1062751) and 2-
(2- Cyclopropylmethoxy-5- 450.4 cyclopropylmethoxy-5- methanesulfo methanesulfonyl- nyl-benzoic acid (compound phenyl)-methanone 1.4) l-(5-Chloro-pyridin-2-yl)-
[4-(5-Chloro-pyridin- piperazin
2-yl) -piperazin- 1 -yl] - e (WOO 1062751) and 5-
[5-methanesulfonyl-2- Methanesulfonyl-2-(2,2,2- 478.2
(2,2,2-trifluoro- trifluor ethoxy)-phenyl]- o-ethoxy)-benzoic acid methanone (compound 1.5) l-(5-Chloro-pyridin-2-yl)-
[4-(5-Chloro-pyridin- piperazin 2-yl)-piperazin- 1 -yl] - e (WO01062751) and 2- (2-isopropoxy-5- 438.3 Isopropoxy-5- methanesulfonyl- methanesulfonyl-benzoic acid phenyl) -methanone (compound 1.2)
3-Chloro-6-piperazin-l-yl-
Rac-[4-(6-Chloro- pyridazine (WO02030405) and pyridazin-3-yl)- rac-5-Methanesulfonyl-2- piperazin-l-yl]-[5- (2,2,2-trifluor methanesulfonyl-2- o-l-methyl-ethoxy)-benzoic 493.3
(2,2,2-trifluoro-l- acid (compound 3J) methyl-ethoxy)- phenyl] -methanone
Figure imgf000143_0001
Figure imgf000144_0001
-I44.
Figure imgf000145_0001
Figure imgf000146_0001
(2-Cyclopentyloxy-5- l-(6-Methyl-pyridin-3-yl)- methanesulfonyl- piperazine (compound 5J8)
444 phenyl)-[4-(6-methyl- and 2-Cyclopentyloxy-5- 444.4 pyridin-3-yl)-piperazin- methanesulfonyl- 1-yl] -methanone benzoic acid (compound 1.6)
(2- l-(6-Methyl-pyridin-3-yl)- Cyclopropylmethoxy-5- piperazine (compound 5J8) methanesulfonyl- and 2-Cyclopropylmethoxy-5-
445 430.5 phenyl)- [4-(6-methyl- methanesulfo pyridin-3-yl)-piperazin- nyl-benzoic acid (compound 1-yl] -methanone 1.4)
[5-Methanesulfonyl-2- l-(5-Methyl-pyridin-2-yl)- (2,2,2-trifluoro- piperazine (WO03032996) and ethoxy)-phenyl]-[4-(5- 5-Methanesulfonyl-2-(2,2,2-
446 458.0 methyl-pyridin-2-yl)- trifluor piperazin-1-yl]- o-ethoxy)-benzoic acid methanone (compound 1.5)
(2-Isopropoxy-5- l-(5-Methyl-pyridin-2-yl)- methanesulfonyl- piperazine (WO03032996) and
447 phenyl)-[4-(5-methyl- 2-Isopropoxy-5- 418.3 pyridin-2-yl)-piperazin- methanesulfonyl-benzoic acid 1-yl] -methanone (compound 1.2)
1 - ( 5-Methyl-pyridin-2-yl) - piperazine (WO03032996) and 2-Cyclopropylmethoxy-5- methanesulfo (2- Cyclopropylmethoxy- 5- nyl-benzoic acid (compound methanesulfonyl- 1.4)
448 430.5 phenyl)-[4-(5-methyl- pyridin-2-yl)-piperazin- 1-yl] -methanone
Figure imgf000148_0001
Figure imgf000149_0001
Figure imgf000150_0001
Example 462 Preparation of rac-{4-[2-Fluoro-4-(l-hydroxy-ethyl)-phenyl]-piperazin-l-yl}-(2- isopropoxy-5-methanesulfonyl-phenyl)-methanone
0.086 mmol of l-{3-Fluoro-4-[4-(2-isopropoxy-5-methanesulfonyl-benzoyl)-piperazin- l-yl]-phenyl}-ethanone was dissolved in 1 ml ethanol and 0.26 mmol sodium borohydride was added. The mixture was refluxed for 40 min., cooled to room temperature, quenched with water, acidified with HCl IN and extracted with ethyl acetate. The combined extracts were dried over Na2SO , filtered and the solvent was removed in vacuo. The residue was purified on silica eluting with heptane/ethylacetate to yield after evaporation the tide compound. MS (m/e): 465.4 (M+H+, 100%)
Example 463 Preparation of {4- [2-Fluoro-4- ( 1-hydroxy- 1 -methyl-ethyl)-phenyl] -piperazin- 1- yl}-(2-isopropoxy-5-methanesulfonyl-phenyl)-methanone To a solution of 0J73 mmol l-{3-Fluoro-4-[4-(2-isopropoxy-5-methanesulfonyl- benzoyl)-piperazin-l-yl]-phenyl}-ethanone in tetrahydrofuran (2 ml) was added dropwise 0J90 mmol 1.6M Methylhthium solution in ether at -75°C. The mixture was stirred for 2 hours and then allowed to warm to 0°C. The mixture was quenched with a 20% NH C1 solution and extracted 3 times with ethyl acetate. The combined extracts were dried over Na SO , filtered and the solvent was removed in vacuo. The residue was purified on silica eluting with dichloromethane/MeOH to yield after evaporation the tide compound. MS (m/e): 479.5 (M+H+, 100%)
The examples 464-471 have been prepared by separation of the racemic material by chiral HPLC:
Figure imgf000151_0001
Figure imgf000152_0001
Figure imgf000153_0001
Example 6.1 Preparation of 2-isobutoxy-5-methylsulfamoyl-benzoic acid
(a) 5-Chlorosulfonyl-2-hydroxy-benzoic acid
To 3.26 mol chlorosulfonic acid at 0 °C was added 652 mmol salicylic acid in small portions and the mixture was then allowed to stir at RT for 1 h, then at 50 °C for 1 h, and finally at 70 °C for 1 h. The mixture was then added dropwise to 1000 ml ice- water with stirring and stirring continued for an additional 30 min. The ensuing white crystals were collected by filtration, washed three times with water, and then dried in vacuo at 45 °C for 16 h to yield the tide compound. MS (m/e): 236.8 ([{37C1}M-H]\ 33%), 235.0 ([{37C1}M- H]', 100%)
(b) 2-Hydroxy-5-methylsulfamoyl-benzoic acid
To 63 mmol 5-chlorosulfonyl-2-hydroxy-benzoic acid in 120 ml dichloromethane at RT was added dropwise 317 mmol methylamine (8 M solution in ethanol) and the mixture was allowed to stir at RT for 1 h. The mixture was then concentrated in vacuo. The residue was suspended in 1 M aq NaOH solution and extracted twice with ether. The aqueous phase was acidified with 5 M aq HCl, saturated with NaCl, and extracted 3 times with THF. The combined THF extracts were washed twice with saturated aqueous NaCl solution and dried with Na SO . Evaporation in vacuo yielded the tide compound. MS (m/e): 249.0 (M+NH4\ 100%), 231.9 (M+H+, 63%)
(c) 2-Hydroxy-5-methylsulfamoyl-benzoic acid methyl ester
To 11 mmol 2-hydroxy-5-methylsulfamoyl-benzoic acid in 300 ml THF was added 85 mmol CDI and the mixture heated at 70 °C for 1 h. 770 mmol methanol was then added and the mixture was heated at 70 °C for 16 h. The mixture was then cooled to room temperature and concentrated in vacuo. The residue was chromatographed on silica gel (eluant: ethyl acetate/heptane/ dichloromethane 45:45:10) to afford the tide compound. MS (m/e): 244.1 ([M-H]', 100%)
(d . 2-Isobutoxy-5-methylsulfamoyl-benzoic acid methyl ester
To 2.9 mmol 2-hydroxy-5-methylsulfamoyl-benzoic acid methyl ester, 3J mmol 2- methyl-1-propanol and 3.3 mmol triphenylphosphine in 10 ml THF was added 3J mmol di- tert-butyl azodicarboxylate and the mixture was stirred at RT for 2 h. The mixture was then concentrated in vacuo. The residue was chromatographed on silica gel (eluant: ethyl acetate/heptane 2:3) to afford the tide compound. MS (m/e): 300.2 ([M-H]", 100%)
(e) 2-Isobutoχy-5-methylsulfamoyl-benzoic acid
To 3.3 mmol 2-isobutoxy-5-methylsulfamoyl-benzoic acid methyl ester in 10 ml THF was added 20 mmol 2 M aq NaOH and the mixture was heated at 50 °C for 2 h. The mixture was then cooled to RT and extracted twice with ether. The aqueous phase was acidified with 10% aq citric acid and extracted 3 times with ethyl acetate. The combined organic phases were dried with Na2SO . Evaporation in vacuo followed by trituration in ether afforded the tide compound. MS (m/e): 286.2 ([M-H]', 100%)
In analogy to Example 6.1(d) and (e), compounds 6.2 to 6J0 of the following table were prepared from 2-hydroxy-5-methylsulfamoyl-benzoic acid methyl ester and the appropriate alcohol, followed by hydrolysis with aqueous sodium hydroxide:
Figure imgf000155_0001
Example 6.11 Preparation of 5-methylsulfamoyl-2-(2,2,2-trifluoro-ethoxy)-benzoic acid (a) 5-Methylsulfamoyl-2-(2-2,2-trifluoro-ethoxy. -benzoic acid methyl ester
To 3.3 mmol 2-hydroxy-5-methylsulfamoyl-benzoic acid methyl ester and 3.3 mmol potassium carbonate in 50 ml acetone was added dropwise 4.9 mmol 2,2,2-trifluoro-ethyl trifluoromethanesulfonate and the mixture was heated at 60 °C for 16 h. The mixture was then concentrated in vacuo. The residue was suspended in dichloromethane and filtered. The filtrate was concentrated in vacuo and the residue was chromatographed on silica gel (eluant: ethyl acetate/heptane 3:7) to afford the tide compound. MS (m/e): 328.0 (M+H+, 100%)
(b) 5-Methylsulfamoyl-2-(2,2,2-trifluoro-ethoxy)-benzoic acid
To 2.3 mmol 5-methylsulfamoyl-2-(2,2,2-trifluoro-ethoxy)-benzoic acid methyl ester in 10 ml THF was added 20 mmol 2 M aq NaOH and the mixture was heated at 50 °C for 2 h. The mixture was then cooled to RT and extracted twice with ether. The aqueous phase was acidified with 10% aq citric acid and extracted 3 times with ethyl acetate. The combined organic phases were dried with Na2SO . Evaporation in vacuo followed by trituration in ether afforded the tide compound. MS (m/e): 312.0 ( [M-H] ", 100%)
Example 6J 9 Preparation of rac-5-methylsulfamoyl-2-(2,2,2-trifluoro-l-methyl-ethoxy)-benzoic acid
(a) rac-5-Methylsulfamoyl-2-(212,2-trifluoro-l-methyl-ethoxy)-benzoic acid methyl ester
To 4J mmol 2-hydroxy-5-methylsulfamoyl-benzoic acid methyl ester and 4J mmol potassium carbonate in 5 ml DMF was added dropwise 6J mmol trifluoro- methanesulfonic acid 2,2,2-trifluoro- 1 -methyl-ethyl ester and the mixture was heated at 90 °C for 16 h. The mixture was then cooled to RT, poured onto water and extracted 3 times with ethyl acetate. The combined organic phases were dried with Na2SO4. Evaporation in vacuo followed by chromatography on silica gel (eluant: dichloromethane) afforded the title compound.
MS (m/e): 359.2 (M+NH4 +, 80%), 342.0 (M+H+, 100%)
(b) rac-5-Methylsulfamoyl-2-(2,2,2-trifluoro-l-methyl-ethoxy)-benzoic acid
To 1.6 mmol 5-methylsulfamoyl-2-(2,2,2-trifluoro-l-methyl-ethoxy)-benzoic acid methyl ester in 10 ml THF was added 20 mmol 2 M aq NaOH and the mixture was heated at 50 °C for 2 h. The mixture was then cooled to RT and extracted twice with ether. The aqueous phase was acidified with 10% aq citric acid and extracted twice with ethyl acetate. The combined organic phases were dried with Na2SO . Evaporation in vacuo followed by trituration in ether and hexane afforded the tide compound. MS
(m/e): 326.2 ([M-H]", 100%)
Example 6J4 Preparation of 5-cyclopropanesulfonyl-2-isopropoxy-benzoic acid
(a) 2-Hydroxy-5-sulfino-benzoic acid
To 317 mmol sodium sulfite in 200 ml water at RT was added dropwise over 30 min a solution of 42.3 mmol 5-chlorosulfonyl-2-hydroxy-benzoic acid in 80 ml dioxane and stirring continued for a further 30 min. 5 M aq NaOH was then added dropwise until the reaction mixture was pH 14 and the mixture was then allowed to stir at RT for a further 2 h. The mixture was then cooled to 0 °C and concentrated H2SO4 added until the reaction mixture was pH 1. Ethyl acetate was added and the phases were separated. The organic phase was dried with Na2SO . Evaporation in vacuo yielded the tide compound.
MS (m/e): 201.0 ([M-H]", 100%)
(b) 5-(3-Chloro-propane-l-sulfonyl.-2-hydroxy-benzoic acid
To 16.7 mmol 2-hydroxy-5-sulfino-benzoic acid and 41.7 mmol triethylamine in 40 ml DMF was added 18.3 mmol l-chloro-3-iodopropane and the mixture heated at 40 °C for 1 h. The mixture was then cooled to room temperature and concentrated in vacuo. The residue was chromatographed on silica gel (eluant: dichloromethane/methanol/acetic acid gradient) to afford the tide compound. MS (m/e): 279.1 ( [{37C1}M-H]\ 33%), 277.0 ([{35C1}M-H]\ 100%)
(c) 5-Cyclopropanesulfonyl-2-hydroxy-benzoic acid
To 8.0 mmol 5-(3-chloro-propane-l-sulfonyl)-2-hydroxy-benzoic acid in 30 ml THF at - 78 °C was added dropwise over 30 min 23.9 mmol of a 0.9 M solution of potassium bis (trimethylsilyl) amide in toluene. The reaction mixture was then allowed to warm to RT and stirring continued for a further 30 min at RT. The mixture was then diluted with THF/ethyl acetate (1:1) and washed sequentially with 1 M aq HCl and saturated aqueous NaCl solution, dried with Na2SO4, and concentrated in vacuo. The residue was triturated in ether/pentane to afford the tide compound. MS (m/e): 241.2 ([M-H]", 100%)
(d) 5-Cyclopropanesulfonyl-2-hydroxy-benzoic acid methyl ester To 7.2 mmol 5-cyclopropanesulfonyl-2-hydroxy-benzoic acid in 20 ml dichloroethane containing a few drops of DMF was added dropwise 8.7 mmol oxalyl chloride. After stirring for 90 min at RT, the reaction mixture was cooled to 0 °C and then 144 mmol methanol was added followed by 72 mmol pyridine and stirring continued at RT for 1 h. The mixture was then washed with 1 M aq HCl, dried with Na2SO , and concentrated in vacuo. The residue was chromatographed on silica gel (eluant: ethyl acetate/heptane gradient) to afford the tide compound. MS (m/e): 255.2 ([M-H]", 100%)
(e) 5-Cyclopropanesulfonyl-2-isopropoxy-benzoic acid
To 0.6 mmol 5-cyclopropanesulfonyl-2-hydroxy-benzoic acid methyl ester, 3.7 mmol 2- propanol and 0.9 mmol diphenyl-2-pyridylphosphine in 8 ml THF was added 0.9 mmol di-tert-butyl azodicarboxylate and the mixture was stirred at RT for 3 h. 4 mmol 5 M aq NaOH solution was then added and the mixture heated at 60 °C for 1 h. The mixture was then concentrated in vacuo. The residue was resuspended in ethyl acetate and washed twice with 1 M aq NaOH solution. The combined aqueous phases were then acidified to pH 1 by addition of 25% aq HCl and extracted three times with ethyl acetate. The combined organic extracts were then dried with Na2SO , and concentrated in vacuo to afford the tide compound. MS (m/e): 282.9 ([M-H]', 100%)
In analogy to Example 6J4 (e), compounds 6J5 to 6J8 of the following table were prepared from 5-cyclopropanesulfonyl-2-hydroxy-benzoic acid methyl ester and the appropriate alcohol, followed by hydrolysis with aqueous sodium hydroxide:
Figure imgf000158_0001
Figure imgf000159_0001
Example 6J 2 Preparation of l-(4-ethanesulfonyl-2-fluoro-ρhenyl)-piperazine
(a) 3,4-Difluoro-benzenesulfinic acid
To 2.47 mol sodium sulfite in 1120 ml water at RT was added dropwise over 20 min a solution of 329 mmol 3,4-difluoro-benzenesulfonyl chloride in 560 ml dioxane and stirring continued for a further 30 min. 1 M aq NaOH was then added dropwise until the reaction mixture was pH 14 and the mixture was then allowed to stir at RT for a further 16 h. The mixture was then cooled to 0 °C and concentrated H2SO4 added until the reaction mixture was pH 1. The mixture was extracted three times with ethyl acetate and the combined organic phases washed with saturated aq NaCl solution and then dried with Na2SO . Evaporation in vacuo yielded the tide compound. MS (m/e): 177J ([M-H]" , 100%)
(b) 4-EthanesulfonyI-l,2-difluoro-benzene
To 3.0 mmol 3,4-difluoro-benzenesulfinic acid and 3.0 mmol triethylamine in 10 ml DMF was added 7.5 mmol iodoethane and the mixture heated at 90 °C for 9 h. The reaction mixture was then poured onto water and extracted three times with ethyl acetate. The combined organic phases were then washed twice with saturated aq. NaCl solution, dried over Na2SO , and concentrated in vacuo. The residue was chromatographed on silica gel (eluant: ethyl acetate/heptane 1:7) to afford the tide compound. MS (m/e): 206.9 (M+H+, 100%)
(c) l-(4-Ethanesulfonyl-2-fluoro-phenyl -piperazine
To 2.0 mmol 4-ethanesulfonyl-l,2-difluoro-benzene in 5 ml N,N-dimethylacetamide was added 5.6 mmol piperazine and the mixture was heated at 80 °C for 45 min. The mixture was then concentrated in vacuo to afford the tide compound. MS (m/e): 273.0 (M+H+, 100%) In analogy to Example 6J2 (b) and (c), compounds 6J3, and 6.21 to 6.23 of the following table were prepared from 3,4-difluoro-benzenesulfinic acid and the indicated alkyl halides, followed by reaction with piperazine:
Figure imgf000160_0001
Example 6.20 Preparation of 1 - (4-Cycloρropanesulfonyl-2-fluoro-phenyl)-piperazine
(a) 4-(3-Chloro-propane-l-sulfonyl)-l,2-difluoro-benzene
To 28.3 mmol 3,4-difluoro-benzenesulfinic acid and 36.8 mmol triethylamine in 100 ml DMF was added 70.7 mmol l-chloro-3-iodopropane and the mixture stirred at RT for 1 h. The reaction mixture was then poured onto water and extracted three times with ethyl acetate. The combined organic phases were then washed with saturated aq. NaCl solution, dried over Na2SO , and concentrated in vacuo. The residue was chromatographed on silica gel (eluant: ethyl acetate/heptane gradient) to afford the tide compound.
MS (m/e): 257.2 ({37C1}M+H+, 33%), 255J({35C1}M+H÷, 100%),
(b) 4-Cvclopropanesulfonyl-l,2-difluoro-benzene To 11.8 mmol 4-(3-chloro-propane-l-sulfonyl)-l,2-difluoro-benzene in 400 ml THF at - 78 °C was added dropwise over 30 min 14.2 mmol of a 0.9 M solution of potassium bis(trimefhylsilyl)amide in THF. The reaction mixture was then allowed to warm to RT and stirring continued for a further 30 min at RT. The mixture was then quenched by addition of 1 M aq HCl and extracted three times with ethyl acetate. The combined organic phases were dried with Na2SO , and concentrated in vacuo. The residue was chromatographed on silica gel (eluant: ethyl acetate/heptane 1:5) to afford the tide compound. MS (m/e): 219.2 (M+H+, 100%)
(c) l-(4-Cvclopropanesulfonyl-2-fluoro-phenyl. -piperazine
To 0.2 mmol 4-cyclopropanesulfonyl-l,2-difluoro-benzene in 5 ml N,N- dimethylacetamide was added 0.5 mmol piperazine and the mixture was heated at 80 °C for 90 min. The mixture was then concentrated in vacuo to afford the title compound. MS (m/e): 285.0 (M+H\ 100%)
Example 6.24 Preparation of l-(4-cyclobutanesulfonyl-2-fluoro-phenyl)-piperazine hydrochloride
(a) 4-Cyclobutanesulfonyl- 1,2-difluoro-benzene
To 5.6 mmol 3,4-difluoro-benzenesulfinic acid and 6.2 mmol triethylamine in 10 ml DMF were added 8.4 mmol bromocyclobutane and 0.2 mmol sodium iodide and the mixture heated at 100 °C for 48 h. The reaction mixture was then poured onto water and extracted three times with ethyl acetate. The combined organic phases were then washed with saturated aq. NaCl solution, dried over Na2SO , and concentrated in vacuo. The residue was chromatographed on silica gel (eluant: ethyl acetate/heptane gradient) to afford the tide compound. MS (m/e): 233J (M+H+, 100%)
(b) l-(4-Cyclobutanesulfonyl-2-fluoro-phenyl. -piperazine hydrochloride
To 2.8 mmol 4-cyclobutanesulfonyl- 1,2-difluoro-benzene in 20 ml N,N- dimethylacetamide was added 8.3 mmol piperazine and the mixture was heated at 80 °C for 45 min. The mixture was then concentrated in vacuo and the residue was chromatographed on silica gel (eluant: ethyl acetate/methanol gradient). The product- containing fractions were combined and concentrated in vacuo. The residue was resuspended in 100 ml dioxane and 6.0 mmol HCl (as a 4 M solution in dioxane) was added. After stirring for 10 min, the ensuing white crystals were collected by filtration, washing twice with ether, to afford the tide compound. MS (m/e): 299.1 (M+H+, 100%)
In analogy to Example 6.24 (a) and (b), compound 6.25 of the following table was prepared from the 3,4-difluoro-benzenesulfinic acid, bromocyclobutane and sodium iodide, followed by reaction with piperazine and subsequent treatment with HCl in dioxane:
Figure imgf000162_0001
Example 6.26 Preparation of 1 - [ 2-fluoro-4- (3 ,3 ,3-trifluoro-propane- 1 -sulfonyl) -phenyl] -piperazine
(a) l,2-Difluoro-4-(3.3-3-trifluoro-propylsulfanyl)-benzene
To 3.4 mmol 3,4-difluoro-thiophenol and 5J mmol l-iodo-3,3,3-trifluoropropane in 5 ml acetone was added 3.7 mmol potassium carbonate and the mixture heated at 140 °C for 3 h under microwave irradiation. The reaction mixture was then poured onto water and extracted three times with ethyl acetate. The combined organic phases were then washed with saturated aq. NaCl solution, dried over Na2SO4, and concentrated in vacuo to afford the tide compound. MS (m/e): 243J (M+H+, 100%)
(b) l,2-Difluoro-4J3,3,3-trifluoro-propane-l-sulfonyl)-benzene
To 3.0 mmol l,2-difluoro-4-(3,3,3-trifluoro-propylsulfanyl)-benzene in 5 ml dichloromethane was added 8.3 mmol m-chloroperbenzoic acid and the mixture heated at 50 °C for 48 h.. The reaction mixture was then cooled to room temperature and diluted with dichloromethane and washed three times with saturated aq NaHCO3 solution. The organic phase was then washed with saturated aq. NaCl solution, dried over Na2SO , and concentrated in vacuo. The residue was chromatographed on silica gel (eluant: ethyl acetate/heptane gradient) to afford the tide compound. MS (m/e): 275J (M+H+, 100%)
(c) l-[2-Fluoro-4-(3.3,3-trifluoro-propane-l-sulfonyl.-phenyl1-piperazine To 0.5 mmol l,2-difluoro-4-(3,3,3-trifluoro-propane-l-sulfonyl)-benzene in 5 ml N,N- dimethylacetamide was added 1.5 mmol piperazine and the mixture was heated at 80 °C for 90 min. The mixture was then concentrated in vacuo and the residue was chromatographed on silica gel (eluant: methanol/dichloromethane gradient) to afford the tide compound. MS (m/e): 341.2 (M+H+, 100%)
In analogy to Example 6.26 (a) to (c), compounds 6.27 and 6.28 of the following table were prepared from 3,4-difluoro-thiophenol and the indicated alkylating agent, followed by oxidation with m-chloroperbenzoic acid and reaction with piperazine:
Figure imgf000163_0001
Example 6.29 Preparation of 1- [2,3-difluoro-4-(propane-2-sulfonyl)-phenyl] -piperazine hydrochloride
(a) l,23-Trifluoro-4-(propane-2-sulfonyl)-benzene
To 20.4 mmol 2,3,4-trifluoro-benzenesulfinic acid (prepared in analogy to example 2.20(a) from 2,3,4-trifluoro-benzenesulfonyl chloride) and 61.2 mmol triethylamine in 20 ml DMF was added 40.8 mmol 2-iodopropane and the mixture stirred at room temperature for 16 h. The reaction mixture was then poured onto water and extracted three times with ethyl acetate. The combined organic phases were then washed twice with saturated aq. NaCl solution, dried over Na2SO , and concentrated in vacuo. The residue was chromatographed on silica gel (eluant: ethyl acetate/heptane 1:4) to afford the tide compound. MS (m/e): 239.1 (M+H+, 100%) (b) 4-f2,3-Difluoro-4-(propane-2-sulfonyl -phenyl]-piperazine-l-carboχylic acid tert- butyl ester
To 7.6 mmol l,2,3-trifluoro-4-(propane-2-sulfonyl)-benzene in 20 ml N,N- dimethylacetamide was added 15.9 mmol tert-butyl- 1 -piperazine carboxylate and the mixture was heated at 90 °C for 1 h. The mixture was then cooled to room temperature and concentrated in vacuo. The residue was chromatographed on silica gel (eluant: ethyl acetate/heptane 1:2) to afford the tide compoundJVIS (m/e): 405.2 (M+H+, 100%)
(c) l-[23-Difluoro-4-(propane-2-sulfonyl)-phenyll -piperazine hydrochloride
To 7.5 mmol 4- [2,3-difluoro-4-(propane-2-sulfonyl)-phenyl] -piperazine- 1-carboxylic acid tert-butyl ester in 100 ml dioxane was added 30.2 mmol HCl (as a 4 M solution in dioxane) and the mixture was heated at 80 °C for 1 h. The mixture was then cooled to room temperature and the ensuing white crystals were collected by filtration, washing twice with ether, to afford the tide compound.
MS (m/e): 305.2 (M+H+, 100%)
In analogy to Example 6.29 (a) to (c), compounds 6.30, 6.32 and 6.33 of the following table were prepared from the indicated sulfinic acids and alkyl halides, followed by reaction with tert-butyl- 1 -piperazine carboxylate and hydrolysis with HCl in dioxane:
Figure imgf000164_0001
Example 6.31 Preparation of l-(4-cyclopropanesulfonyl-2,3-difluoro-phenyl)-piperazine hydrochloride
(a) l-(3-Chloro-propane- l-sulfonyl)-2.3J-trifluoro-benzene
To 30.6 mmol 2,3,4-trifluoro-benzenesulfinic acid (acid (prepared in analogy to example 2.20(a) from 2,3,4-trifluoro-benzenesulfonyl chloride) and 91.8 mmol triethylamine in 20 ml DMF was added 61.2 mmol l-chloro-3-iodoρropane and the mixture stirred at room temperature for 1 h. The reaction mixture was then poured onto water and extracted three times with ethyl acetate. The combined organic phases were then washed twice with saturated aq. NaCl solution, dried over Na2SO , and concentrated in vacuo. The residue was chromatographed on silica gel (eluant: ethyl acetate/heptane 1:4) to afford the tide compound. MS (m/e): 275.2 ({37C1}M+H+, 33%), 273J({35C1}M+H+, 100%),
(b) l-Cyclopropanesulfonyl-2,3.4-trifluoro-benzene
To 5.9 mmol l-(3-chloro-propane-l-sulfonyl)-2,3,4-trifluoro-benzene in 200 ml THF at -78 °C was added dropwise over 30 min 7.0 mmol of a 0.9 M solution of potassium bis(trimethylsilyl)amide in THF. The reaction mixture was then allowed to warm to RT and stirring continued for a further 30 min at RT. The mixture was then quenched by addition of 1 M aq HCl and extracted three times with ethyl acetate. The combined organic phases were dried with Na2SO , and concentrated in vacuo. The residue was chromatographed on silica gel (eluant: ethyl acetate/heptane 1:4) to afford the tide compound. MS (m/e): 237.2 (M+H+, 100%)
(c) 4-(4-Cyclopropanesulfonyl-2,3-difluoro-phenyl)-piperazine-l-carboxylic acid tert- butyl ester
To 4.2 mmol l-cyclopropanesulfonyl-2,3,4-trifluoro-benzene in 20 ml N,N- dimethylacetamide was added 8.9 mmol tert-butyl- 1 -piperazine carboxylate and the mixture was heated at 90 °C for 1 h. The mixture was then cooled to room temperature and concentrated in vacuo. The residue was chromatographed on silica gel (eluant: dichloromethane/ethyl acetate gradient) to afford the tide compound. MS (m/e): 403.3 (M+H+, 100%)
(d) 1 -(4-Cyclopropanesulfonyl-2,3-difluoro-phenyl)-piperazine hydrochloride To 3.7 mmol 4- (4-Cyclopropanesulfonyl-2,3-difluoro-phenyl)-piperazine-l -carboxylic acid tert-butyl ester in 100 ml dioxane was added 14.9 mmol HCl (as a 4 M solution in dioxane) and the mixture was heated at 80 °C for 1 h. The mixture was then cooled to room temperature and the ensuing white crystals were collected by filtration, washing twice with ether, to afford the tide compound. MS (m/e): 303.2 (M+H+, 100%)
In analogy to Example 6.31 (a) to (d), compound 6.34 of the following table was prepared from the indicated sulfinic acid and alkyl halide, followed by treatment with potassium bis(trimethylsilyl)amide, reaction with tert-butyl- 1 -piperazine carboxylate and deprotection with HCl in dioxane:
Figure imgf000166_0001
Example 6.35 Preparation of rac-2-Methyl- l-(4-trifluoromethyl-phenyl)-piperazine hydrochloride
(a) rac-3-Methyl-4-(4-trifluoromethyl-phenyl)-piperazine-l-carboxylic acid tert-butyl ester
To l-bromo-4-trifluoromethyl-benzene (1 g), rac-3-Methyl-piperazine-l -carboxylic acid tert-butyl ester (1 g), in toluene (10 mL) was added sodium tert-butylate (0.6 g), 2- (dicyclohexylphosphino)biphenyl (31 mg), and tris(dibenzylideneacetone)Pd-CHCl3 (23 mg). The reaction mixture was then stirred at 80°C overnight. Ethyl acetate was then added to the reaction mixture. Solids were filtered off. The filtrate was then concentrated in vacuo and the residue was purified by column chromatography to yield 0.46 g of the tide compound.MS (m/e): 345.2 (M+H+, 100%)
(b) rac-2-Methyl-l-(4-trifluoromethyl-phenyl. -piperazine hydrochloride
To 0.58 mmol rac-3-methyl-4-(4-trifluoromethyl-phenyl)-piperazine-l-carboxylic acid tert-butyl ester in 3 ml dioxane was added 8.7 mmol HCl (as a 4 M solution in dioxane) and the mixture was heated at 90 °C for 3 h. The mixture was then cooled 0 °C and diluted with 10 ml ether. The ensuing white crystals were collected by filtration, washing with ether, and dried in vacuo to afford the tide compound.
MS (m/e): 245.1 (M+H+, 100%)
Example 6.36 Preparation of 5-Acetyl-2-isopropoxy-benzoic acid
(a) 5-Acetyl-2-isopropoxy-benzoic acid methyl ester
To 25.8 mmol methyl-5-acetyl-2-hydroxybenzoate, 28.3 mmol 2-propanol and 29.6 mmol triphenylphosphine in 100 ml THF was added 28.3 mmol di-tert-butyl azodicarboxylate and the mixture was stirred at RT for 90 min. The mixture was then concentrated in vacuo to afford the tide compound. MS (m/e): 237J (M+H+, 100%)
(b) 5-Acetyl-2-isopropoxy-benzoic acid
To 25.8 mmol 5-acetyl-2-isopropoxy-benzoic acid methyl ester in 100 ml THF was added 400 mmol 2 M aq NaOH and the mixture was heated at 80 °C for 2 h. The mixture was then cooled to RT and extracted twice with ether. The aqueous phase was acidified with 15% aq hydrochloric acid and extracted 3 times with ethyl acetate. The combined organic phases were dried with Na2SO . Evaporation in vacuo followed by trituration in ether afforded the tide compound. MS (m/e): 221.2 ([M-H]", 100%)
In analogy to Example 5 compounds 472 to 619 of the following table were prepared from the acid derivatives and piperazine derivatives:
Figure imgf000167_0001
Figure imgf000168_0001
Figure imgf000169_0001
Figure imgf000170_0001
Figure imgf000171_0001
Figure imgf000172_0001
Figure imgf000173_0001
Figure imgf000174_0001
Figure imgf000175_0001
Figure imgf000176_0001
Figure imgf000177_0001
Figure imgf000178_0001
Figure imgf000179_0001
Figure imgf000180_0001
Figure imgf000181_0001
Figure imgf000182_0001
Figure imgf000183_0001
Figure imgf000184_0001
Figure imgf000185_0001
Figure imgf000186_0001
Figure imgf000187_0001
Figure imgf000188_0001
Figure imgf000189_0001
Figure imgf000190_0001
Figure imgf000191_0001
{4-[2,3-Difluoro-4- l-[2,3-Difluoro-4-(propane-2- (propane-2-sulfonyl)- sulfonyl) -phenyl] -piperazine 602.2 phenyl] -piperazin- 1-yl}- hydrochloride (compound 6.29) and
604 [5-methanesulfonyl-2- 5-Methanesulfonyl-2-(2,2,2-trifluor (M+NH4 (2,2,2-trifluoro-ethoxy)- o-ethoxy)-benzoic acid (compound +) phenyl] -methanone 1.5)
[4-(4-Ethanesulfonyl- 1 -(4-Ethanesulfonyl-2,3-difluoro- 2,3-difluoro-phenyl)- phenyl)-piperazine hydrochloride piperazin- 1 -yl] - [5- (compound 6.30) and 5-
605 571.2 methanesulfonyl-2- Methanesulfonyl-2-(2,2,2-trifluor (2,2,2-trifluoro-ethoxy)- o-ethoxy)-benzoic acid (compound phenyl] -methanone 1.5)
[4-(4- l-(4-Cyclopropanesulfonyl-2,3- Cyclopropanesulfonyl- difluoro-phenyl) -piperazine 600.2 2,3-difluoro-phenyl)- hydrochloride (compound 6.31) and
606 piperazin-l-yl]-[5- 5-Methanesulfonyl-2-(2,2,2-trifluor (M+NH4 methanesulfonyl-2- o-ethoxy) -benzoic acid (compound +) (2,2,2-trifluoro-ethoxy)- 1.5) phenyl] -methanone
{4-[2,5-Difluoro-4- l-[2,5-Difluoro-4-(propane-2- (propane-2-sulfonyl)- sulfonyl) -phenyl] -piperazine 602.3 phenyl ] -piperazin- 1 -yl } - hydrochloride (compound 6.32) and
607 [5-methanesulfonyl-2- 5-Methanesulfonyl-2-(2,2,2-trifluor (M+NH4 (2,2,2-trifluoro-ethoxy)- o-ethoxy)-benzoic acid (compound +) phenyl] -methanone 1.5) l-(4-Ethanesulfonyl-2,5-difluoro- phenyl) -piperazine hydrochloride [4-(4-Ethanesulfonyl- (compound 6.33) and 5- 2,5-difluoro-phenyl)- Methanesulfonyl-2-(2,2,2-trifluor 588.3 piperazin-l-yl]-[5-
608 o-ethoxy) -benzoic acid (compound methanesulfonyl-2- (M+NH4 1-5) (2,2,2-trifluoro-ethoxy)- +) phenyl] -methanone
Figure imgf000193_0001
Figure imgf000194_0001
Figure imgf000195_0001
Example 6.37 Preparation of 4-isopropoxy-3-[4-(4-trifluoromethyl-phenyl)-piperazine-l-carbonyl]- benzoic acid
(a) 4-Isopropoxy-3-[4-(4-trifluoromethyl-phenyl)-piperazine-l-carbonyl1 -benzonitrile
To a solution of 3.6 mmol 5-cyano-2-isopropoxy-benzoic acid (compound 1J3) in 20 ml THF were added 4.0 mmol TBTU, 21.6 mmol N-ethyldiisopropylamine and 4.0 mmol 1- (4-trifluoromethyl-phenyl)-piperazine (commercial). The reaction was then stirred at RT for 16 h, concentrated in vacuo, and purified by chromatography on silica gel (eluant: ethyl acetate/heptane 1:1) to afford the tide compound. MS (m/e): 418.3 (M+H+, 100%)
(b) 4-Isopropoxy-3-[4-(4-trifluoromethyl-phenyl)-piperazine-l-carbonyn -benzoic acid
To 3.2 mmol 4-isopropoxy-3-[4-(4-trifluoromethyl-phenyl)-piperazine- 1-carbonyl] - benzonitrile in 15 ml ethanol was added 30 mmol 2 M aq NaOH and the mixture was heated at 85 °C for 16 h. The mixture was then cooled to RT, diluted with water and acidified to pH 1 with cone HCl, and then extracted three times with ethyl acetate. The combined organic phases were dried with Na2SO4, concentrated in vacuo, and the residue purified by chromatography on silica gel (eluant: methanol/dichloromethane 5:95) to afford the tide compound.MS (m/e): 435.3 ([M-H]", 100%)
Example 620 Preparation of 4-isopropoxy-3- [4- (4-trifluoromethyl-phenyl)-piperazine- 1 - carbonyl] -benzoic acid methyl ester
To 0.3 mmol 4-isopropoxy-3-[4-(4-trifluoromethyl-phenyl)-piperazine-l-carbonyl]- benzoic acid in 2 ml DMF was added 0.4 mmol CDI and the mixture heated at 50 °C for 30 min. 5.2 mmol methanol was then added and the mixture was stirred at RT for 16 h. The mixture was then cooled to room temperature, concentrated in vacuo, and the residue chromatographed on silica gel (eluant: ethyl acetate/heptane 1:4) to afford the tide compound. MS (m/e): 451.2 (M+H+, 100%)
Example 621 Preparation of 4-isopropoxy-N-methyl-3-[4-(4-trifluoromethyl-phenyl)- piperazine-l-carbonyl]-benzamide
To 0.3 mmol 4-isopropoxy-3-[4-(4-trifluoromethyl-phenyl)-piperazine-l-carbonyl]- benzoic acid in 2 ml DMF was added 0.4 mmol CDI and the mixture heated at 50 °C for 30 min. 5.2 mmol methylamine (41% aq solution) was then added and the mixture was stirred at RT for 16 h. The mixture was then cooled to room temperature, concentrated in vacuo, and the residue chromatographed on silica gel (eluant: ethyl acetate) to afford the tide compound. MS (m/e): 450J (M+H+, 100%)
Example 6.38 Preparation of 3-[4-(4-Cyano-3-fluoro-phenyl)-piperazine-l-carbonyl]-4-hydroxy- benzenesulfonamide
(a) 2-Hydroxy-5-sulfamoyl-benzoic acid
Ammonia gas was bubbled through a solution of 107 mmol 5-chlorosulfonyl-2-hydroxy- benzoic acid in 250 ml acetone at 0 °C for 2 h. Argon gas was then bubbled through the reaction mixture for 1 h to purge excess ammonia. The mixture was then diluted with water, the pH adjusted to pH 14 by addition of 5 M aq NaOH solution, and the mixture was then extracted with ether/ ethyl acetate (1:1). The aqueous phase was acidified with concentrated HCl, saturated with NaCl, and extracted twice with THF. The combined THF extracts were dried with Na2SO . Evaporation of the solvent in vacuo followed by drying of the residue by heating at 60 °C overnight in vacuo yielded the tide compound. MS (m/e): 216.1 ([M-H]", 100%)
(b) 2-Hydroxy-5-sulfamoyl-benzoic acid methyl ester
To 62 mmol 2-hydroxy-5-sulfamoyl-benzoic acid in 80 ml THF was added 80 mmol CDI and the mixture heated at 50 °C for 1 h. 616 mmol methanol was then added and the mixture was heated at 50 °C for 16 h. The mixture was then cooled to room temperature, concentrated in vacuo, and the residue chromatographed on silica gel (eluant: dichloromethane/methanol 20:1). The product containg fractions were concentrated in vacuo and the residue suspended in ethyl acetate and washed with aq NaHCO3 solution. The organic phase was dried dried with Na2SO and concentrated in vacuo to afford the title compound. MS (m/e): 230.2 ([M-H]", 100%)
(c) 2-(4-Methoxy-benzyloxy)-5-sulfamoyl-benzoic acid methyl ester
To 4.8 mmol 2-hydroxy-5-sulfamoyl-benzoic acid methyl ester, 5.2 mmol 4- methoxybenzyl alcohol and 5.2 mmol triphenylphosphine in 8 ml THF was added 5.2 mmol di-tert-butyl azodicarboxylate and the mixture was stirred at RT for 2 h. The mixture was then concentrated in vacuo. The residue was chromatographed on silica gel (eluant: ethyl acetate/heptane gradient) to afford the tide compound. MS (m/e): 350.2 ([M-H]", 100%)
(d) 2-(4-Methoxy-benzyloxy)-5-sulfamoyl-benzoic acid
To 2.5 mmol 2-(4-methoxy-benzyloxy)-5-sulfamoyl-benzoic acid methyl ester in 6 ml THF was added 5 mmol 2 M aq NaOH and the mixture was heated at 60 °C for 30 min. The mixture was then cooled to RT and extracted twice with ethyl acetate. The aqueous phase was acidified to pH 1 with 5 M aq HCl and extracted with ethyl acetate. The combined organic phases were washed with saturated aq NaCl and dried with Na2SO4. Evaporation in vacuo afforded the tide compound. MS (m/e): 336J ( [M-H]", 100%)
(e) (3-[4-(4-Cyano-3-fluoro-phenyl)-piperazine-l-carbonyl]-4-(4-methoxy-benzyloxy)- benzenesulfonamide
To a solution of 3.5 mmol 2-(4-methoxy-benzyloxy)-5-sulfamoyl-benzoic acid in 4 ml dimethylformamide and 12 ml THF were added 5.3 mmol TBTU, 17.5 mmol N- ethyldiisopropylamine and 3.5 mmol 3-fluoro-4-piperazin- 1-yl-benzonitrile
(WO9625414). The reaction was then stirred at RT for 1 h, concentrated in vacuo, and purified by chromatography on silica gel (eluant: ethyl acetate/heptane gradient) to afford the tide compound. MS (m/e): 525.1 (M+H+)
(f) (3- [4-(4-Cyano-3-fluoro-phenyI.-piperazine-l-carbonyl] -4-hydroxy- benzenesulfonamide
Hydrogen gas was bubbled through a solution of 1.0 mmol (3-[4-(4-Cyano-3-fluoro- phenyl)-piperazine-l-carbonyl]-4-(4-methoxy-benzyloxy)-benzenesulfonamide in 40 ml THF containing 50 mg 10% palladioum on charcoal and a few drops of acetic acid for 6 h at RT. The reaction mixture was then purged with argon, filtered through celite, and the filtrate was concentrated in vacuo. The residue was purified by chromatography on silica gel (eluant: methanol/dichloromethane gradient) to afford the tide compound. MS (m/e): 403.1 ([M-H]-, 100%)
In analogy to Example 6.38(e) and (f), compounds 6.39 and 6.40 of the following table were prepared from 2-(4-methoxy-benzyloxy)-5-sulfamoyl-benzoic acid and the appropriate piperazine, followed by hydrogenolysis with catalytic palladium on charcoal:
Figure imgf000198_0001
Example 622 Preparation of 3- [4- (4-cyano-3-fluoro-phenyl)-piperazine- 1 -carbonyl] -4-isobutoxy- benzenesulfonamide
To 0J mmol (3-[4-(4-cyano-3-fluoro-phenyl)-piperazine-l-carbonyl]-4-hydroxy- benzenesulfonamide (compound 6.38), 0.5 mmol 2-methyl-l -propanol and 0.3 mmol diphenyl-2-pyridylphosphine in 4 ml THF was added 0.3 mmol di-tert-butyl azodicarboxylate and the mixture was stirred at 60 °C for 4 h. The mixture was then diluted with ethyl acetate and washed twice with 5 M aq HCl and then with saturated aq NaCl solution. The organic phase was then dried with Na2SO4, and concentrated in vacuo. The residue was triturated in ether to afford the tide compound. MS (m/e): 459.2 ([M-H]", 100%)
In analogy to Example 622, compounds 623 to 632 of the following table were prepared from compounds 6.38 to 6.40 and the appropriate alcohol:
Figure imgf000199_0001
Figure imgf000200_0001
Example 7J: Preparation of 3-Piperazin- l-yl-5-trifluoromethyl-pyridazine
(a)-3-Chloro-5-trifluoromethyl-pyridazine
5-Trifluoromethyl-pyridazin-3-ol [244268-34-6 (lg) was added to a stirred solution of phosphoryloxychloride and the reaction mixture was stirred at 80°C for 1 hour. After such time, the reaction mixture was allowed to cool to room temperature, poured onto ice and after 5 minutes was extracted twice from the aqueous solution with dichloromethane. The combined organic phases were dried with sodium sulfate and concentrated in vacuo. The residue was distilled in a Kugelrohr apparatus (bp = 80-100°C @ 12 mBar) to yield the tide compound (0.26g). MS (m/e): 182.0
(b) 4-(5-Trifluoromethyl-pyridazin-3-yl)-piperazine-l-carboxylic acid tert-butyl ester
3-Chloro-5-trifluoromethyl-pyridazine (200mg) was added to piperazine- 1 -carboxylic acid tert-butyl ester (231mg) in dimethylacetamide (3mL) and the reaction mixture was stirred at 100°C for 3 hours. After such time the reaction mixture was allowed to cool down to room temperature and diluted with ethyl acetate. The solid was filtered off and washed with ethyl acetate. The filtrate was then concentrated in vacuo and then purified by column chromatography (SiO2, Heptane/EtOAc) to yield the tide compound as a white solid (364mg). MS (m/e): 333.4 (M+H+, 100%)
(c) 3-Piperazin-l-yl-5-trifluoromethyl-pyridazine
4-(5-Trifluoromethyl-pyridazin-3-yl)-piperazine-l-carboxylic acid tert-butyl ester (45mg) was dissolved in dichloromethane (0.5 mL) and trifluoroacetic acid was added (0.5 mL). The reaction mixture was stirred for 30 minutes before being concentrated in vacuo to afford the crude tide compound which was used direcdy in the next step without further purification or analysis. Example 7.2:
Preparation of 5-Methanesulfonyl-2- (2,2,2-trifluoro- 1 , 1 -dimethyl-ethoxy)-benzoic acid
To 2-Fluoro-5-methanesulfonyl-benzoic acid (247569-56-8) (600 mg) in dimethylacetamide (10 mL) was added cesium carbonate at 170°C. 2-trifluoromethyl- propanol (0.94 mL) was first added to the reaction mixture followed by additionally 0.47 mL every 24 hours. After a total of 72 hours, the reaction mixture was acidified by addition of formic acid, concentrated in vacuo and purified by preparative HPLC to yield the tide compound as a light brown solid (897 mg). MS (m/e): 325.3. (M-H, 100%)
Example 7.3:
Preparation of 5-Methanesulfonyl-2-piperazin- 1-yl-pyrimidine (a. 3-Dimethylamino-2-methanesulfonyl-allylidene-dimethyl-ammonium; chloride
To sulfonyl-acetic acid (1.5g) in dimethylformamide was slowly added phosphorus oxychloride over 5 minutes and the reaction was then stirred at 70°C for 1 hour and then at room temperature overnight. The reaction mixture was then directly poured over a short column chromatography (SiO2, 100 g) eluting successively with 500 mL of EtO Ac, THF, EtOAc/EtOH (50/50), EtOH and finally MeOH to yield the tide compound (1.58g). MS (m/e): 204.9 (M+).
(b. 5-Methanesulfonyl-2-piperazin- 1-yl-pyrimidine
The tide compound was prepared in analogy to Example 2.25 using 3-Dimethylamino-2- methanesulfonyl-allylidene-dimethyl-ammonium; chloride as starting material. MS (m/e): 243.1 (M+H+, 100%).
Example 7.4:
Preparation of l-(5-Methanesulfonyl-pyridin-2-yl)-piperazine trifluoro-acetic acid
The tide compound was prepared in analogy to Example 7J (b-c) from 2-bromo-5- (methanesulfonyl) pyridine and piperazine- 1-carboxylic acid tert-butyl ester. MS (m/e): 242.1 (M+H+, 100%)
In analogy to Example 5, compounds 633 to 644 of the following table were prepared from the acid derivatives and piperazine derivatives: MW
Expl.- Systematic Name Starting materials found No. (MH+)
3-Piperazin-l-yl-5- rac- [ 5-Methanesulfonyl-2- trifluoromethyl- (2,2,2- trifluoro- 1 -methyl- pyridazine (compound 7J) and ethoxy) -phenyl]- [4-(5- 633 rac-5-Methanesulfonyl-2-(2,2,2- 527.0 trifluoromethyl-pyridazin- trifluor 3 -yl) -piperazin- 1 -yl] - o-l -methyl-ethoxy) -benzoic methanone acid (compound 3J)
[5-Methanesulfonyl-2- 2-Piperazin-l-yl-5- (2,2,2-trifluoro-lJ- trifluoromethyl-pyrimidine dimethyl-ethoxy)-phenyl] - (compound 2.25) and 5- 634 541.0 [4- ( 5-trifluoromethyl- Methanesulfonyl-2-(2,2,2- pyrimidin-2-yl)-piperazin- trifluoro- 1 ,1 -dimethyl-ethoxy) - 1-yl] -methanone benzoic acid (compound 7.2)
[ 5-Methanesulfonyl-2- 2-Piperazin- l-yl-5- ((S)-2,2,2-trifluoro-l- trifluoromethyl-pyrimidine methyl-ethoxy) -phenyl] - (compound 2.25) and 5- 635 527.2 [4- ( 5-trifluoromethyl- Methanesulfonyl-2-((S)-2,2,2- pyrimidin-2-yl)-piperazin- trifluoro- 1-methyl-ethoxy)- 1-yl] -methanone benzoic acid (compound 5.6)
2-Piperazin-l-yl-5- trifluoromethyl-pyrimidine (compound 2.25) and 5- [5-Methanesulfonyl-2- Methanesulfonyl-2-( (R)-2,2,2- ((R)-2,2,2-trifluoro-l- trifluoro-1 -methyl-ethoxy) - methyl-ethoxy)-phenyl] - 636 benzoic acid (compound 5.7) 527.2 [4-(5-trifluoromethyl- pyrimidin-2-yl)-piperazin- 1-yl] -methanone
Figure imgf000204_0001
Figure imgf000205_0001
Example 645 Preparation of (2-AUyloxy-5-nitro-phenyl)-[4-(4-trifluoromethyl-phenyl)- piperazin- 1-yl] -methanone
The tide compound was prepared in analogy to example 62 from (2-Hydroxy-5-nitro- phenyl)-[4-(4-trifluoromethyl-phenyl)-piperazin-l-yl]-methanone (compound 2J) and cyclopropyl bromide. MS (m/e): 436.5 (MH+, 100%)
Example 7.5:
Preparation of 2-Benzyloxy-5-methanesulfonyl-benzoic acid
The tide compound was prepared in analogy to example 2.10 from methyl 5- (methanesulfonyl)salicylate and benzylalcohol. MS (m/e): 305.3 (M-H, 100%) Example 646 Preparation of (2-Benzyloxy-5-methanesulfonyl-phenyl)-[4-(3-fluoro-5- trifluoromethyl-ρyridin-2-yl)-piperazin- 1 -yl] -methanone
The tide compound was prepared in analogy to example 5 from l-(3-Fluoro-5- trifluoromethyl-pyridin-2-yl)-piperazine (compound 5.5) and 2-Benzyloxy-5- methanesulfonyl-benzoic acid (compound 7.5). MS (m/e): 538.4 (MH+, 100%)
Example 647 Preparation of (2-Benzyloxy-5-met anesu_fonyl-phenyl)-[4-(2-fluoro-4- methanesulfonyl-phenyl) -piperazin- 1 -yl] -methanone
The tide compound was prepared in analogy to example 5 from l-(2-Fluoro-4- methanesulfonyl-pheny
l)-piperazine (commercial) and 2-Benzyloxy-5-methanesulfonyl-benzoic acid (compound 7.5). MS (m/e): 547.4 (MH+, 100%)
Example 648 Preparation of [4-(2-Fluoro-4-methanesιdfonyl-phenyl)-piperazin-l-yl]-(2- hydroxy-5-methanesulfonyl-phenyl)-methanone
A mixture of 0.915 mmol (2-benzyloxy-5-methanesulfonyl-phenyl)-[4-(2-fluoro-4- methanesulfonyl-phenyl)-piperazin-l-yl]-methanone,0.05 mmol palladium on charcoal (10%) in 12.5 ml methanol was hydrogenated at atmospheric pressure at room temperature for 2 hours. After addition of chloroform, the mixture was filtered and the solvent was evaporated to provide the tide compound. MS (m/e): 474.3 (M+NH4+, 100%)
Example 1.6 Preparation of 5-Piperazin- l-yl-2-trifluoromethyl-pyrimidine
(a) 5-Chloro-2-trifluoromethyI-pyrimidine
To a solution of 38 mmol trifluoroacetamidine in 70 ml acetonitrile was added 37.92 mmol ((Z)-2-Chloro-3-dimethylamino-allylidene)-dimethyl-ammonium hexafluoro phosphate (CAS: 291756-76-8) followed by 45.5 mmol triethylamine. The yellow solution was stirred at room temperature for 5 hours, then poured onto water and extracted 3 times with ether. The combined extracts were dried over sodium sulfate, filtered and distilled at 760 mm Hg to provide the tide compound. MS (m/e): 182.2 (M\ 100%)
(b) 4-(2-Trifluoromethyl-p imidin-5-yl .-piperazine-1-carboxylic acid tert-butyl ester
0.26 mmol 5-Chloro-2-trifluoromethyl-pyrimidine was added to 0.26 mmol piperazine- 1-carboxylic acid tert-butyl ester in 1.5 ml dimethylacetamide and the reaction mixture was stirred at 150°C for 10 min. in a microwave oven. After such time the reaction mixture was concentrated and the residue was then purified by column chromatography (SiO2, Heptane/EtOAc) to yield the tide compound. MS (m/e): 333.2 (M+H+, 100%)
(c) 5-Piperazin-l-yI-2-trifluoromethyl-pyrimidine
The tide compound was prepared in analogy to Example 7J (c) from 4-(2- trifluoromethyl-pyrimidin-5-yl)-piperazine-l-carboxylic acid tert-butyl ester MS (m/e): 233.0 (M+H\ 100%)
Example 7.7 Preparation of 5'-Trifluoromethyl-3,4,5,6-tetrahydro-2H-[l,2']bipyrazinyl
(a) 2-Bromo-5-trifluoromethyl-pyrazine
To a suspension of 0.423 mmol copper (II) bromide in THF (1 ml) was added dropwise 0.51 mmol tert-butylnitrite at 0°C within 2 minutes. 0.37 mmol 5-Trifluoromethyl- pyrazin-2-ylamine (CAS: 69816-38-2; WO9518097) in solution in THF (0.5 ml) was added dropwise within 5 minutes at 0°C. The mixture was stirred at 0°C for 1 hour, at room temperature for 21 hours and quenched with water. The aqueous phase was extracted with ether. The combined extracts were dried over sodium sulfate and filtered and concentrated at atmospheric pressure. The residue was then purified by column chromatography (SiO2, ether) to yield the tide compound.
(b. 5'-Trifluoromethyl-3J,5,6-tetrahvdro-2H-[ 2'1bipyrazinyl
The tide compound was prepared in analogy to Example 7.6 (b-c) from 2-Bromo-5- trifluoromethyl-pyrazine MS (m/e): 233.0 (M+H+, 100%)
Example 7.8 Preparation of 3-Piperazin- l-yl-6-trifluoromethyl-pyridazine
The title compound was prepared in analogy to Example 7.6 (b-c) from 3-Chloro-6- trifluoromethyl-pyridazine (CAS: 258506-68-2). MS (m/e): 233.0 (M+H+, 100%) In analogy to Example 5, compounds 649 to 660 of the following table were prepared from the acid derivatives and piperazine derivatives:
Figure imgf000208_0001
Figure imgf000209_0001
Figure imgf000210_0001
The compounds of formula I and their pharmaceutically usable addition salts possess valuable pharmacological properties. Specifically, it has been found that the compounds of the present invention are good inhibitors of the glycine transporter I (GlyT-1).
The compounds were investigated in accordance with the test given hereinafter.
Solutions and materials
DMEM complete medium: Nutrient mixture F-12 (Gibco Life- technologies), fetal bovine serum (FBS) 5 %, (Gibco life technologies), Penicillin/Streptomycin 1 % (Gibco life technologies), Hygromycin 0.6 mg/ml (Gibco life technologies), Glutamine 1 mM Gibco life technologies) Uptake buffer .UB .: 150 mM NaCl, 10 mM Hepes-Tris, pH 7.4, 1 mM CaCl2, 2.5 mM
KC1, 2.5 mM MgSO4, 10 mM (+) D-glucose.
Flp-in™-CHO (Invitrogen Cat n° R758-07)cells stably transfected with mGlyTlb cDNA.
Glycine uptake inhibition assay (mGlyT-lb.
On day 1 mammalian cells, (Flp-in™-CHO), transfected with mGlyT-lb cDNA , were plated at the density of 40,000 cells/well in complete F-12 medium, without hygromycin in 96-well culture plates. On day 2, the medium was aspirated and the cells were washed twice with uptake buffer (UB). The cells were then incubated for 20 min at 22°C with either (i) no potential competitor, (ii) 10 mM non-radioactive glycine , (iii) a concentration of a potential inhibitor. A range of concentrations of the potential inhibitor was used to generate data for calculating the concentration of inhibitor resulting in 50 % of the effect (e.g. ICSQ, the concentration of the competitor inhibiting glycine uptake of 50 %). A solution was then immediately added containing [3H] -glycine 60 nM (11-16 Ci/mmol) and 25 μM non-radioactive glycine. The plates were incubated with gende shaking and the reaction was stopped by aspiration of the mixture and washing (three times) with ice-cold UB. The cells were lysed with scintillation liquid, shaken 3 hours and the radioactivity in the cells was counted using a scintillation counter.
The prepared compounds show an IC5Q (μM) at GlyT-1 in the range of 0.006 - 5.0. The preferred compounds show an ICs0 (μM) at GlyT-1 in the range of 0.006 - 0.05, as shown in the table below.
Figure imgf000211_0001
Figure imgf000212_0001
Figure imgf000213_0001
Figure imgf000214_0001
The compounds of formula I and the pharmaceutically acceptable salts of the compounds of formula I can be used as medicaments, e.g. in the form of pharmaceutical preparations. The pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions. The administration can, however, also be effected rectally, e.g. in the form of suppositories, parenterally, e.g. in the form of injection solutions.
The compounds of formula I can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical preparations. Lactose,corn starch or derivatives thereof, talc, stearic acids or its salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragees and hard gelatine capsules. Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like. Depending on the nature of the active substance no carriers are however usually required in the case of soft gelatine capsules. Suitable carriers for the production of solutions and syrups are, for example, water, polyols, glycerol, vegetable oil and the like. Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.
The pharmaceutical preparations can, moreover, contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
Medicaments containing a compound of formula I or a pharmaceutically acceptable salt thereof and a therapeutically inert carrier are also an object of the present invention, as is a process for their production, which comprises bringing one or more compounds of formula I and/or pharmaceutically acceptable acid addition salts and, if desired, one or more other therapeutically valuable substances into a galenical administration form together with one or more therapeutically inert carriers.
The most preferred indications in accordance with the present invention are those, which include disorders of the central nervous system, for example the treatment or prevention of schizophrenia, cognitive impairment and Alzheimer's disease.
The dosage can vary within wide limits and will, of course, have to be adjusted to the individual requirements in each particular case. In the case of oral administration the dosage for adults can vary from about 0.01 mg to about 1000 mg per day of a compound of general formula I or of the corresponding amount of a pharmaceutically acceptable salt thereof. The daily dosage may be administered as single dose or in divided doses and, in addition, the upper limit can also be exceeded when this is found to be indicated.
Tablet Formulation (Wet Granulation)
Ingredients mg/tablet 5 mg 25 mg 100 mg 500
1. Compound of formula I 5 25 100 500
2. Lactose Anhydrous DTG 125 105 30 150
3. Sta-Rx 1500 6 6 6 30
4. Microcrystalline Cellulose 30 30 30 150 5. Magnesium Stearate 1 1 1 1 Total 167 167 167 831 Manufacturing Procedure
1. Mix items 1, 2, 3 and 4 and granulate with purified water.
2. Dry the granules at 50°C.
3. Pass the granules through suitable milling equipment. 4. Add item 5 and mix for three minutes; compress on a suitable press.
Capsule Formulation
Item Ingredients mg/capsulle 5mg 25 mg 100 mg 500
1. Compound of formula I 5 25 100 500 2. Hydrous Lactose 159 123 148 —
3. Corn Starch 25 35 40 70
4. Talc 10 15 10 25
5. Magnesium Stearate 1 2 2 5 Total 200 200 300 600
Manufacturing Procedure
1. Mix items 1, 2 and 3 in a suitable mixer for 30 minutes.
2. Add items 4 and 5 and mix for 3 minutes.
3. Fill into a suitable capsule.

Claims

Claims
1. Compounds of general formula
Figure imgf000217_0001
wherein
Ar is unsubstituted or substituted aryl or 6-membered heteroaryl, containing one, two or three nitrogen atoms, and wherein the aryl and the heteroaryl groups may be substituted by one or more substituents selected from the group consisting of hydroxy, halogen, NO2, CN, (Cι-C6)-alkyl, (Cι-C6)-alkyl substituted by halogen, (Cι-C6)-alkyl substituted by hydroxy, (CH2)n-(C1-C6)-alkoxy, (CrC6)-alkoxy substituted by halogen, NR7R8, C(O)R9, SO2R10, -C(CH3)=NOR7, or by a 5- membered aromatic heterocycle, containing 1 - 4 heteroatoms, selected from N and O, which is optionally substituted by (Cι-C6)-alkyl;
R1 is hydrogen or (Q-C^-alkyl;
R2 is hydrogen, (Cι-C6)-alkyl, (C2-C6)-alkenyl, (C C6)-alkyl substituted by halogen, ( - )-alkyl substituted by hydroxy, (CH2)n-(C3-C7)-cycloalkyl optionally substituted by ( -C^-alkoxy or by halogen, or is CH(CH3)-(C3-C7)-cycloalkyl, (CH2)n+1-C(O)-R9, (CH2)n+rCN, bicyclo[2.2J]heptyl, (CH2)n+ι-O-(CrC6)-alkyl, (CH2)n-heterocycloalkyl, (CH2)n-aryl or (CH2)n-5 or 6-membered heteroaryl containing one, two or three heteroatoms, selected from the group consisting of oxygen, sulphur or nitrogen wherein aryl, heterocycloalkyl and heteroaryl are unsubstituted or substituted by one or more substituents selected from the group consisting of hydroxy, halogen, (Cι-C6)-alkyl or (CrC6)-alkoxy;
R3, R4 and R6 independentiy from each other are hydrogen, hydroxy, halogen, (C1-C6)-alkyl, (CrC6)-alkoxy or O-(C3-C6)-cycloalkyl; R5 is NO2, CN, C(O)R9 or SO2R10;
R7 and R8 independentiy from each other are hydrogen or (C1-C6)-a_kyl;
R9 is hydrogen, (C_-C_)-alkyl- (C C6)-alkoxy or NR7R8;
R10 is (Ci-C6)-alkyl optionally subtituted by halogen, (CH2)n-(C3-C6)-cycloalkyl, (CH2)n-(C3-C6)-alkoxy, (CH2)n-heterocycloalkyl or NR7R8;
n is 0, 1, or 2; and to pharmaceutically acceptable acid addition salts thereof, with the proviso that l-[5-(aminosulfonyl)-2-methoxybenzoyl]-4-(3-chlorophenyl)-piperazine, 1- [5-(aminosulfonyl)-2-methoxybenzoyl] -4-(4-fluorophenyl)-piperazine,
1 - [5-(aminosulfonyl)-2-methoxybenzoyl] -4- [3-(trifluoromethyl)phenyl] -piperazine, 4-(3-amino-4-nitrophenyl)-l-[4-(dimethylamino)-2-methoxy-5-nitrobenzoyl]-2- methyl-piperazine, l-[4-(dimethylamino)-2-methoxy-5-nitrobenzoyl]-2-methyl-4-(4-nitrophenyl)- piperazine,
4-[4-(dimethylamino)-2-methoxy-5-nitrobenzoyl]-2-methyl-l-(4-nitrophenyl)- piperazine, l-(2-chloro-4-nitrophenyl)-4-[4-(dimethylamino)-2-methoxy-5-nitrobenzoyl]- piperazine, l-[4-(dimethylamino)-2-methoxy-5-nitrobenzoyl]-4-(2,4-dinitrophenyl)-2-methyl- piperazine, l-(4-chloro-2-nitrophenyl)-4-[4-(dimethylamino)-2-methoxy-5-nitrobenzoyl]- piperazine and 4-[4-(dimethylamino)-2-methoxy-5-nitrobenzoyl]-l-(2,4-dinitrophenyl)-2-methyl- piperazine are excluded.
2. Compounds of formula
Figure imgf000219_0001
wherein
Ar is substituted aryl or unsubstituted or substituted 6-membered heteroaryl, containing one, two or three nitrogen atoms, and wherein the aryl and the heteroaryl groups are substituted by one or more substituents selected from the group consisting of hydroxy, halogen, NO2, CN, (Cι-C6)-alkyl, (Cι- )-alkyl substituted by halogen, (Cι-C6)-alkoxy, (C C6)-alkoxy substituted by halogen, NR7R8, C(O)R9 or SO2R10;
R1 is hydrogen or (CrC6)-alkyl;
R2 is ( -C6)-alkyl, ( -Ce^alkyl substituted by halogen, (C3-C6)-cycloalkyl, heterocycloalkyl, (C]-C6)-alkyl-(C3-C6)-cydoalkyl, (C1-C6)-alkyl-heterocycloalkyl, (C1-C6)-alkyl-C(O)-R9, (CrC6)-alkyl-CN, (C2-C6)-alkyl-O-R13, (C2-C6)-alkyl- NR7R8, aryl or 6-membered heteroaryl containing one, two or three nitrogen atoms, (CrC6)-alkyl-aryl or (Cι-C6)-alkyl-5 or-6-membered heteroaryl containing one, two or three heteroatoms, selected from the group consisting of oxygen, sulphur or nitrogen wherein aryl, heterocycloalkyl and heteroaryl are unsubstituted or substituted by one or more substituents selected from the group consisting of hydroxy, halogen, (Cι-C6)-alkyl or (d-C6)-alkoxy,
R3, R4 and R6 independentiy from each other are hydrogen, hydroxy, halogen, CN, ( -Q -alkyl, (C C6)-alkoxy or NR7R8;
R5 is NO2, CN, C(O)R9, SO2R10 or NRUR12;
R7 and R8 independentiy from each other are hydrogen or (CrC6)-alkyl;
R9 is hydroxy, (C1-C6)-alkyl, (C3-C6)-cycloalkyl, (C C6)-alkoxy or NR7R8; R10 is (C1-C6)-alkyl, (C3-C6)-cycloalkyl or NR7R8;
Ru and R12 independentiy from each other are hydrogen, C(O)-(Cι-C6)-alkyl, SO2-(Cι-C6)-alkyl, or form together with the N-atom a 5-membered heteroaryl group, optionally substituted by halogen, (Cι-C6)-alkyl, (C1-C6)-alkyl substituted by halogen or (C3-C6)-cycloalkyl;
R13 is hydroxy, (C_-C_)-alkyl or (C3-C6)-cycloalkyl;
and pharmaceutically acceptable acid addition salts thereof, with the proviso that l-[5-(aminosulfonyl)-2-methoxybenzoyl]-4-(3-chlorophenyl)-piperazine, l-[5-(aminosulfonyl)-2-methoxybenzoyl]-4-(4-fluorophenyl)-piperazine, l-[5-(aminosulfonyl)-2-methoxybenzoyl]-4-[3-(trifluoromethyl)phenyl] -piperazine, 4-(3-amino-4-nitrophenyl)-l-[4-(dimethylamino)-2-methoxy-5-nitrobenzoyl]-2- methyl-piperazine, l-[4-(dimethylamino)-2-methoxy-5-nitrobenzoyl]-2-methyl-4-(4-nitrophenyl)- piperazine, 4-[4-(dimethylamino)-2-methoxy-5-nitrobenzoyl]-2-methyl-l-(4-nitrophenyl)- piperazine, l-(2-chloro-4-nitrophenyl)-4-[4-(dimethylamino)-2-methoxy-5-nitrobenzoyl]- piperazine, l-[4-(dimethylamino)-2-methoxy-5-nitrobenzoyl]-4-(2,4-dinitrophenyl)-2-methyl- piperazine, l-(4-chloro-2-nitrophenyl)-4-[4-(dimethylamino)-2-methoxy-5-nitrobenzoyl]- piperazine and 4-[4-(dimethylamino)-2-methoxy-5-nitrobenzoyl]-l-(2,4-dinitrophenyl)-2-methyl- piperazine are excluded.
3. Compounds of formula I according to claim 1, wherein Ar is substituted phenyl,
R2 is ( -Q -alkyl and R5 is S(O)2CH3 or S(O)2CH2CH3.
4. Compounds of formula I according to claim 3, wherein the compounds are:
l-{3-fluoro-4-[4-(2-isopropoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-phenyl}- ethanone, 3-fluoro-4-[4-(2-isopropoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl] -benzonitrile,
2-Fluoro-4- [4-(2-isopropoxy-5-methanesulfonyl-benzoyl)-piperazin- 1-yl] -benzonitrile,
[4-(2-fluoro-4-trifluoromethyl-phenyl)-piperazin-l-yl]-(2-isopropoxy-5- methanesulfonyl-phenyl)-methanone, l-{3-fluoro-4-[4-(2-isobutoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-phenyl}- ethanone,
4- [4-(2-isobutoxy-5-methanesulfonyl-benzoyl)-piperazin- 1-yl] -benzonitrile,
3-fluoro-4- [4-(2-isobutoxy-5-methanesulfonyl-benzoyl)-piperazin- 1-yl] -benzonitrile,
2-fluoro-4- [4-(2-isobutoxy-5-methanesulfonyl-benzoyl)-piperazin- 1-yl] -benzonitrile, (2-isobutoxy-5-methanesulfonyl-phenyl)-[4-(4-trifluoromethyl-phenyl)-piperazin-l-yl]- methanone,
[4-(2-fluoro-4-trifluoromethyl-phenyl)-piperazin-l-yl]-(2-isobutoxy-5- methanesulfonyl-phenyl) -methanone,
[4-(3-fluoro-4-trifluoromethyl-phenyl)-piperazin-l-yl]-(2-isobutoxy-5- methanesulfonyl-phenyl)-methanone,
[4-(2-fluoro-4-methanesulfonyl-phenyl)-piperazin-l-yl]-(2-isobutoxy-5- methanesulfonyl-phenyl)-methanone,
[4-(2-fluoro-4-methanesulfonyl-phenyl)-piperazin-l-yl]-(2-isopropoxy-5- methanesulfonyl-phenyl)-methanone, 2,3-difluoro-4-[4-(2-isopropoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]- benzonitrile,
2,3-difluoro-4- [4-(2-isobutoxy-5-methanesulfonyl-benzoyl)-piperazin- 1-yl] - benzonitrile,
2,5-difluoro-4-[4-(2-isobutoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]- benzonitrile,
2,6-difluoro-4-[4-(2-isobutoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]- benzonitrile,
3,5-difluoro-4-[4-(2-isobutoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]- benzonitrile, 4-[4-(2-tert-butoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-2,3-difluoro- benzonitrile,
5-chloro-2-[4-(2-isopropoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-benzonitrile,
4-[4-(2-tert-butoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-2,5-difluoro- benzonitrile, 4-[4-(2-tert-butoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-3-fluoro-benzonitrile,
(2-tert-butoxy-5-methanesulfonyl-phenyl)-[4-(2-fluoro-4-trifluoromethyl-phenyl)- piperazin- 1 -yl] -methanone, (2-tert-butoxy-5-methanesulfonyl-phenyl)-[4-(2,5-difluoro-4-methanesulfonyl-phenyl)- piperazin- 1 -yl] -methanone, l-(4-{4-[2-(2,2-dimethyl-propoxy)-5-methanesulfonyl-benzoyl]-piperazin-l-yl}-3- fluoro-phenyl)-ethanone, 4-{4-[2-(2,2-dimethyl-propoxy)-5-methanesulfonyl-benzoyl]-piperazin-l-yl}- benzonitrile,
4-{4-[2-(2,2-dimethyl-propoxy)-5-methanesulfonyl-benzoyl]-piperazin-l-yl}-3-fluoro- benzonitrile,
4-{4-[2-(2,2-dimethyl-propoxy)-5-methanesulfonyl-benzoyl]-piperazin-l-yl}-2-fluoro- benzonitrile,
[2-(2,2-dimethyl-propoxy)-5-methanesulfonyl-phenyl]-[4-(4-trifluoromethyl-phenyl)- piperazin- 1-yl] -methanone,
[2-(2,2-dimethyl-propoxy)-5-methanesulfonyl-phenyl]-[4-(2-fluoro-4-trifluoromethyl- phenyl)-piperazin-l-yl]-methanone, [2-(2,2-dimethyl-propoxy)-5-methanesulfonyl-phenyl] - [4-(3-fluoro-4-trifluoromethyl- phenyl) -piperazin- 1-yl] -methanone,
[2-(2,2-dimethyl-propoxy)-5-methanesulfonyl-phenyl]-[4-(2-fluoro-4-ethanesulfonyl- phenyl) -piperazin- 1-yl] -methanone, rac-l-{4-[4-(2-sec-butoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-3-fluoro- phenyl} -ethanone, rac-4-[4-(2-sec-butoxy-5-methanesulfonyl-benzoyl)-piperazin- 1-yl] -3-fluoro- benzonitrile, rac-4-[4-(2-sec-butoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl] -2-fluoro- benzonitrile, rac-(2-sec-butoxy-5-methanesulfonyl-phenyl)-[4-(2-fluoro-4-trifluoromethyl-phenyl)- piperazin-l-yl]-methanone, rac-(2-sec-butoxy-5-methanesulfonyl-phenyl)-[4-(3-fluoro-4-trifluoromethyl-phenyl)- piperazin- 1-yl] -methanone,
(2-isopropoxy-5-methanesulfonyl-phenyl)-[4-(4-trifluoromethanesulfonyl-phenyl)- piperazin- 1-yl] -methanone,
(2-isobutoxy-5-methanesulfonyl-phenyl)-[4-(4-trifluoromethanesulfonyl-phenyl)- piperazin- 1 -yl] -methanone,
2-[4-(2-isopropoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-5-trifluoromethyl- benzonitrile, l-{2-fluoro-4-[4-(2-isopropoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-phenyl}- ethanone,
[4-(3-fluoro-4-methanesulfonyl-phenyl)-piperazin-l-yl]-(2-isobutoxy-5- methanesulfonyl-phenyl)-methanone, l-{2-fluoro-4-[4-(2-isobutoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-phenyl}- ethanone,
2-[4-(2-isobutoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-5-trifluoromethyl- benzonitrile,
(5-ethanesulfonyl-2-isopropoxy-ρhenyl)-[4-(2-fluoro-4-trifluoromethyl-phenyl)- piperazin- 1 -yl] -methanone,
[4-(4-difluoromethyl-2-fluoro-phenyl)-piperazin-l-yl]-(2-isopropoxy-5- methanesulfonyl-phenyl)- methanone, [4-(3-chloro-5-trifluoromethyl-pyridin-2-yl)-piperazin-l-yl]-(2-isopropoxy-5- methanesulfonyl-phenyl)-methanone,
3-fluoro-4- [4-(2-isoproρoxy-5-methanesulfonyl-benzoyl)-piperazin- 1-yl] -benzaldehyde,
[4-(4-ethanesulfonyl-2-fluoro-phenyl)-piperazin-l-yl]-(2-isobutoxy-5-methanesulfonyl- phenyl) -methanone, rac-(2-sec-butoxy-5-methanesulfonyl-phenyl)-[4-(4-ethanesulfonyl-2-fluoro-phenyl)- piperazin- 1 -yl] -methanone,
[4-(4-cyclobutanesulfonyl-2-fluoro-phenyl)-piperazin-l-yl]-(2-isopropoxy-5- methanesulfonyl-phenyl)-methanone,
[4-(4-cyclopentanesulfonyl-2-fluoro-phenyl)-piperazin-l-yl]-(2-isopropoxy-5- methanesulfonyl-phenyl)-methanone,
[4-(4-cyclopropanesulfonyl-2-fluoro-phenyl)-piperazin-l-yl]-(2-isobutoxy-5- methanesulfonyl-phenyl)-mefhanone and
[4-(4-cyclopropanesulfonyl-2,5-difluoro-phenyl)-piperazin-l-yl]-(2-isopropoxy-5- methanesulfonyl-phenyl)-methanone. 5. Compounds of formula I acoording to claim 1, wherein Ar is substituted phenyl,
R2 is (CH_)n-(C3-C7)-cyc_oalkyl and R5 is S(O)2CH3.
6. Compounds of formula I according to claim 5, wherein the compounds are: l-{4-[4-(2-cyclopropylmethoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-3-fluoro- phenyl} -ethanone, 4-[4-(2-cyclopropylmethoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl] -benzonitrile, 4-[4-(2-cyclopropylmethoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl] -3-fluoro- benzonitrile,
4-[4-(2-cyclopropylmethoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl] -2-fluoro- benzonitrile, (2-cyclopropylmethoxy-5-methanesulfonyl-phenyl)-[4-(4-trifluoromethyl-phenyl)- piperazin- 1 -yl] -methanone,
(2-cyclopropylmethoxy-5-methanesulfonyl-phenyl)-[4-(2-fluoro-4-trifluoromethyl- phenyl)-piperazin- 1 -yl] -methanone,
(2-cyclopropylmethoxy-5-methanesulfonyl-phenyl)-[4-(3-fluoro-4-trifluoromethyl- phenyl)-piperazin-l-yl]-methanone, l-{4-[4-(2-cyclopentyloxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-3-fluoro- phenyl}-ethanone,
4-[4-(2-cyclopentyloxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl] -benzonitrile,
4-[4-(2-cyclopentyloxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-3-fluoro- benzonitrile,
4-[4-(2-cyclopentyloxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl] -2-fluoro- benzonitrile,
(2-cyclopentyloxy-5-methanesulfonyl-phenyl)-[4-(2-fluoro-4-trifluoromethyl-phenyl)- piperazin- 1 -yl] -methanone, (2-cyclopentyloxy-5-methanesulfonyl-phenyl)-[4-(3-fluoro-4-trifluoromefhyl-phenyl)- piperazin- 1 -yl] -methanone,
(2-cyclopentyloxy-5-methanesulfonyl-phenyl)-[4-(4-trifluoromethyl-phenyl)-piperazin-
1-yl] -methanone,
Rac- [2-( l-cyclopropyl-ethoxy)-5-methanesulfonyl-phenyl] - [4-(4-trifluoromethyl- phenyl) -piperazin- 1-yl] -methanone,
4-[4-(2-cyclopentyloxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-2,3-difluoro- benzonitrile,
4- [4-(2-cyclopentyloxy-5-methanesulfonyl-benzoyl)-piperazin- 1-yl] -2,5-difluoro- benzonitrile, 4-[4-(2-cyclobutylmethoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl] -benzonitrile, 4-[4-(2-cyclobutylmethoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl] -2-fluoro- benzonitrile,
4- [4-(2-cyclobutylmethoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl] -3-fluoro- benzonitrile, (2-cyclobutylmethoxy-5-methanesulfonyl-phenyl)-[4-(4-trifluoromethyl-phenyl)- piperazin- 1 -yl] -methanone, l-{4-[4-(2-cyclobutylmethoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-3-fluoro- phenyl}-ethanone, 2-[4-(2-cyclobutylmethoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-5- trifluoromethyl-benzonitrile,
4- [4-(2-cyclobutylmethoxy-5-methanesulfonyl-benzoyl)-piperazin- 1-yl] -2,3-difluoro- benzonitrile, 4-[4-(2-cydobutylmethoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-2,5-difluoro- benzonitrile,
4-[4-(2-cyclobutylmethoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-3,5-difluoro- benzonitrile, 4-[4-(2-cydobutylmethoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-2,6-difluoro- benzonitrile,
4-[4-(2-cyclopropylmethoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-3,5-difluoro- benzonitrile,
4- [4-(2-cyclopentyloxy-5-methanesulfonyl-benzoyl)-piperazin- 1-yl] -3,5-difluoro- benzonitrile,
4-[4-(2-cyclopropylmethoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-2,6-difluoro- benzonitrile,
4-[4-(2-cyclopentyloxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-2,6-difluoro- benzonitrile, 5-chloro-2-[4-(2-cyclopropylmethoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]- benzonitrile,
4-[4-(2-cyclohexyloxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-benzonitrile,
4-[4-(2-cyclohexyloxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-3-fluoro- benzonitrile, 4-[4-(2-cyclohexyloxy-5methanesulfonyl-benzoyl)-piperazin-l-yl]-2-fluoro- benzonitrile,
(2-cyclohexyloxy-5-methanesulfonyl-phenyl)-[4-(4-trifluoromethyl-phenyl)-piperazin-
1-yl] -methanone,
(2-cyclohexyloxy-5-methanesulfonyl-phenyl)-[4-(3-fluoro-4-trifluoromethyl-phenyl)- piperazin- 1-yl] -methanone,
(2-cyclohexyloxy-5-methanesulfonyl-phenyl)-[4-(2-fluoro-4-methanesulfonyl-phenyl)- piperazin- 1 -yl] -methanone, l-{4-[4-(2-cyclobutoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-3-fluoro-phenyl}- ethanone, 4-[4-(2-cyclobutoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-3-fluoro-benzonitrile,
(2-cyclobutoxy-5-methanesulfonyl-phenyl)-[4-(3-fluoro-4-trifluoromethyl-phenyl)- piperazin- 1-yl] -methanone,
(2-cyclopentyloxy-5-methanesulfonyl-phenyl)-[4-(4-trifluoromethanesulfonyl-phenyl)- piperazin- 1 -yl] -methanone, l-{4-[4-(2-cyclopropylmethoxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-2-fluoro- phenyl } -ethanone,
2-[4-(2-cyclopentyloxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl]-5-trifluoromethyl- benzonitrile,
(2-cyclopropylmethoxy-5-methanesulfonyl-phenyl)-[4-(4-ethanesulfonyl-2-fluoro- phenyl)-piperazin- 1-yl] -methanone,
(2-cyclopentyloxy-5-methanesulfonyl-phenyl)-[4-(4-ethanesulfonyl-2-fluoro-phenyl)- piperazin- 1-yl] -methanone,
(2-cyclohexyloxy-5-methanesulfonyl-phenyl)-[4-(4-ethanesulfonyl-2-fluoro-phenyl)- piperazin- 1 -yl] -methanone,
(2-cyclopentyloxy-5-methanesulfonyl-phenyl)-[4-(4-cyclopropanesulfonyl-2-fluoro- phenyl) -piperazin- 1 -yl] -methanone, (2-cyclohexyloxy-5-methanesulfonyl-phenyl)-[4-(4-cyclopropanesulfonyl-2-fluoro- phenyl) -piperazin- 1-yl] -methanone,
(2-cyclobutoxy-5-methanesulfonyl-phenyl)-[4-(4-cyclopropanesulfonyl-2-fluoro- phenyl) -piperazin- 1-yl] -methanone
7. Compounds of formula I according to claim 1, wherein Ar is substituted phenyl, R2 is (C C6)-alkyl substituted by halogen and R5 is S(O)2CH3.
8. Compounds of formula I according to claim 7, wherein the compounds are:
l-(3-fluoro-4-{4-[5-methanesulfonyl-2-(2,2,2-trifluoro-ethoxy)-benzoyl]-piperazin-l- yl } -phenyl) -ethanone,
3-fluoro-4-{4-[5-methanesulfonyl-2-(2,2,2-trifluoro-ethoxy)-benzoyl]-piperazin-l-yl}- benzonitrile,
[4-(2-fluoro-4-trifluoromethyl-phenyl)-piperazin- 1 -yl] - [5-methanesulfonyl-2-(2,2,2-tri- fluoro-ethoxy)-phenyl] -methanone,
[4-(3-fluoro-4-trifluoromethyl-phenyl)-piperazin- 1 -yl] - [5-methanesulfonyl-2-(2,2,2-tri- fluoro-ethoxy)-phenyl] -methanone, [4-(2-fluoro-4-methanesulfonyl-phenyl)-piperazin-l-yl]-[5-methanesulfonyl-2-(2,2,2- trifluoro-ethoxy) -phenyl] -methanone,
3-fluoro-4-{4-[5-methanesulfonyl-2-(3,3,3-trifluoro-propoxy)-benzoyl]-piperazin-l-yl}- benzonitrile,
[4-(3-fluoro-4-trifluoromethyl-phenyl)-piperazin-l-yl]-[5-methanesulfonyl-2-(3,3,3- trifluoro-propoxy)-phenyl] -methanone,
[4-(2-fluoro-4-trifluoromethyl-phenyl)-piperazin-l-yl]-[5-methanesulfonyl-2-(3,3,3- trifluoro-propoxy)-phenyl] -methanone, l-(3-fluoro-4-{4-[5-methanesulfonyl-2-(3,3,3-trifluoro-propoxy)-benzoyl]-piperazin-l- yl} -phenyl) -ethanone, 2,5-difluoro-4-[4-(5-methanesulfonyl-2-trifluoromethoxy-benzoyl)-piperazin-l-yl]- benzonitrile,
2,3-difluoro-4-{4-[2-(2-fluoro-l-fluoromethyl-ethoxy)-5-methanesulfonyl-benzoyl]- piperazin- 1 -yl} -benzonitrile,
2-fluoro-4-{4-[5-methanesulfonyl-2-(2,2,3,3,3-pentafluoro-propoxy)-benzoyl]- piperazin- 1-yl} -benzonitrile,
[5-methanesulfonyl-2-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-[4-(4-trifluoromethyl- phenyl)-piperazin- 1-yl] -methanone,
2,3-difluoro-4-{4-[5-methanesulfonyl-2-(2,2,3,3,3-pentafluoro-propoxy)-benzoyl]- piperazin- 1 -yl} -benzonitrile, 3,5-difluoro-4-{4-[5-methanesulfonyl-2-(2,2,3,3,3-pentafluoro-propoxy)-benzoyl]- piperazin- 1 -yl} -benzonitrile,
2-{4- [2-(2-fluoro- l-fluoromethyl-ethoxy)-5-methanesulfonyl-benzoyl] -piperazin- 1-yl}-
5 -trifluoromethyl-benzonitrile, rac-2,3-difluoro-4-{4-[5-methanesulfonyl-2-(2,2,2-trifluoro-l-methyl-ethoxy)-benzoyl]- piperazin-l-yl}-benzonitrile,
2-Fluoro-4-{4-[5-methanesulfonyl-2-(2,2,3,3-tetrafluoro-propoxy)-benzoyl]-piperazin-
1-yl} -benzonitrile,
3-fluoro-4-{4-[5-methanesulfonyl-2-(2,2,3,3-tetrafluoro-propoxy)-benzoyl]-piρerazin-
1 -yl} -benzonitrile, [5-methanesulfonyl-2-(2,2,3,3-tetrafluoro-propoxy)-phenyl] - [4-(4-trifluoromethyl- phenyl) -piperazin- 1-yl] -methanone,
[4-(2-fluoro-4-trifluoromethyl-phenyl)-piperazin-l-yl]-[5-methanesulfonyl-2-(2,2,3,3- tetrafluoro-propoxy) -phenyl] -methanone,
2,3-difluoro-4-{4-[5-methanesulfonyl-2-(2,2,3,3-tetrafluoro-propoxy)-benzoyl]- piperazin- 1 -yl} -benzonitrile,
3,5-Difluoro-4-{4-[5-methanesulfonyl-2-(2,2,3,3-tetrafluoro-propoxy)-benzoyl]- piperazin- 1 -yl} -benzonitrile,
[4-(3,4-dicr_loro-phenyl)-piperazin-l-yl]-[5-methanesulfonyl-2-(2,2,2-trifluoro-ethoxy)- phenyl] -methanone, rac-5-chloro-2-{4-[5-methanesulfonyl-2-(2,2,2-trifluoro-l-methyl-ethoxy)-benzoyl]- piperazin-l-yl}-benzonitrile, , rac-3,5-difluoro-4-{4-[5-methanesulfonyl-2-(2,2,2-trifluoro-l-methyl-ethoxy)-benzoyl]- piperazin-l-yl}-benzonitrile, rac-2,5-difluoro-4-{4-[5-methanesulfonyl-2-(2,2,2-trifluoro-l-methyl-ethoxy)-benzoyl]- piperazin-l-yl}-benzonitrile, rac-2,6-difluoro-4-{4-[5-methanesulfonyl-2-(2,2,2-trifluoro-l-methyl-ethoxy)-benzoyl]- piperazin- 1 -yl } -benzonitrile, rac-4-{4-[5-methanesulfonyl-2-(2,2,2-trifluoro-l-methyl-ethoxy)-benzoyl]-piperazin-l- yl} -benzonitrile, rac-3-fluoro-4-{4-[5-methanesulfonyl-2-(2,2,2-trifluoro-l-methyl-ethoxy)-benzoyl]- piperazin- 1 -yl}-benzonitrile, rac-2-fluoro-4-{4-[5-methanesulfonyl-2-(2,2,2-trifluoro-l-methyl-ethoxy)-benzoyl]- piperazin-l-yl}-benzonitrile, rac-5-methanesulfonyl-2-(2,2,2-trifluoro-l-methyl-ethoxy)-phenyl]-[4-(4- trifluoromethyl-phenyl)-piperazin- 1 -yl] -methanone, rac-[4-(2-fluoro-4-trifluoromethyl-phenyl)-piperazin-l-yl]-[5-methanesulfonyl-2- (2,2,2-trifluoro-l-methyl-ethoxy)-phenyl]-methanone, rac- [4-(3-fluoro-4-trifluoromethyl-phenyl)-piperazin- 1-yl] - [5-methanesulfonyl-2-
(2,2,2-trifluoro-l-methyl-ethoxy)-phenyl] -methanone,
[4-(2-fluoro-4-trifluoromethyl-phenyl)-piperazin-l-yl]-[5-methanesulfonyl-2-((S or R)-
2,2,2-trifluoro-l-methyl-ethoxy)-phenyl]-methanone, [5-methanesulfonyl-2-((S or R)-2,2,2-trifluoro-l-methyl-ethoxy)-phenyl]-[4-(4- trifluoromethyl-phenyl) -piperazin- 1-yl] -methanone and
[5-methanesulfonyl-2-((R or S)-2,2,2-trifluoro-l-methyl-ethoxy)-phenyl]-[4-(4- trifluoromethyl-phenyl)-piperazin- 1 -yl] -methanone.
9. Compounds of formula I according to claim 1, wherein Ar is substituted phenyl, R2 is (C.-C6)-alkyl, (C C6)-alkyl substituted by halogen, CH2)n-(C3-C7)-cycloalkyl, bicycle[2.2J]heptyl, (CH2)n-O-(Cι-C6)-alkyl or CH2)n-heterocycloa_kyl and R5 is NO2.
10. Compounds of formula I according to claim 9, wherein the compounds are
l-(3-fluoro-4-{4-[2-(2-me_hoxy-ethoxy)-5-nitro-benzoyl]-piperazin-l-yl}-phenyl)- ethanone, (2-isopropoxy-5-nitro-phenyl)-[4-(4-trifluoromethyl-phenyl)-piperazin-l-yl]- methanone,
(2-cyclopropylmethoxy-5-nitro-phenyl)- [4- (4-trifluoromethyl-phenyl) -piperazin- 1-yl] - methanone,
(2-cyclobutylmethoxy-5-nitro-phenyl)-[4-(4-trifluoromethyl-phenyl)-piperazin-l-yl]- methanone,
(2-butoxy-5-nitro-phenyl)-[4-(4-trifluoromethyl-phenyl)-piperazin-l-yl]-methanone,
[2-(2,2-dimethyl-propoxy)-5-nitro-phenyl] - [4-(4-trifluoromethyl-phenyl)-piperazin- 1- yl] -methanone,
(2-isobutoxy-5-nitro-phenyl)-[4-(4-trifluoromethyl-phenyl)-piperazin-l-yl]- methanone, (2-cyclopentyloxy-5-nitro-phenyl)-[4-(4-trifluoromethyl-phenyl)-piperazin-l-yl]- methanone,
(5-nitro-2-propoxy-phenyl)-[4-(4-trifluoromethyl-phenyl)-piperazin-l-yl]-methanone,
(2-cyclobutoxy-5-nitro-phenyl)-[4-(4-trifluoromethyl-phenyl)-piperazin-l-yl]- methanone,
Rac-(2-sec-butoxy-5-nitro-phenyl)-[4-(4-trifluoromethyl-phenyl)-piperazin-l-yl]- methanone,
[5-nitro-2-(2,2,3,3-tetrafluoro-propoxy)-phenyl]-[4-(4-trifluoromethyl-phenyl)- piperazin- 1 -yl] -methanone, [5-nitro-2-(2,2,2-trifluoro-ethoxy)-phenyl]-[4-(4-trifluoromethyl-phenyl)-piperazin-l- yl] -methanone,
[2-(bicyclo[2.2J]hept-2-yloxy)-5-nitro-phenyl]-[4-(4-trifluoromethyl-phenyl)- piperazin- 1 -yl] -methanone,
[2-(2-chloro-ethoxy)-5-nitro-phenyl]-[4-(4-trifluoromethyl-phenyl)-piperazin-l-yl]- methanone and
[5-nitro-2-(2,2,3,3,3-pentafluoro-propoxy)-phenyl]-[4-(4-trifluoromethyl-phenyl)- piperazin- 1 -yl] -methanone.
11. Compounds of formula I according to claim 1, wherein Ar is substituted phenyl, R2 is (C.-C6)-alkyl, (C1-C6)-alkyl substituted by halogen or (CH2)„-(C.-C7)-cycloalkyl and R5 is S(O)2NHCH3.
12. Compounds of formula I according to claim 11, which compounds are
3-[4-(4-Cyano-3-fluoro-phenyl)-piperazine-l-carbonyl]-N-methyl-4-trifluoromethoxy- benzenesulfonamide,
3-[4-(4-cyano-3-fluoro-phenyl)-piperazine-l-carbonyl]-4-isobutoxy-N-methyl- benzenesulfonamide,
3-[4-(4-cyano-3-fluoro-phenyl)-piperazine-l-carbonyl]-4-cyclopentyloxy-N-methyl- benzenesulfonamide,
3- [4-(4-cyano-3-fluoro-phenyl)-piperazine- 1-carbonyl] -4-cyclobutoxy-N-methyl- benzenesulfonamide, 3- [4-(4-cyano-3-fluoro-phenyl)-piperazine- 1-carbonyl] -4-cyclobutylmethoxy-N- methyl-benzenesulfonamide,
3- [4-(4-cyano-phenyl)-piperazine- 1-carbonyl] -4-isobutoxy-N-methyl- benzenesulfonamide,
3-[4-(4-cyano-phenyl)-piperazine-l-carbonyl]-4-cyclopentyloxy-N-methyl- benzenesulfonamide, 3- [4-(4-cyano-phenyl)-piperazine- 1 -carbonyl] -4-cyclobutylmethoxy-N-methyl- benzenesulfonamide,
3-[4-(4-cyano-2-fluoro-phenyl)-piperazine-l-carbonyl -4-isobutoxy-N-methyl- benzenesulfonamide, 3-[4-(4-cyano-2-fluoro-phenyl)-piperazine-l-carbonyl -4-(2,2-dimethyl-propoxy)-N- methyl-benzenesulfonamide,
3-[4-(4-cyano-2-fluoro-phenyl)-piperazine-l-carbonyl -4-isopropoxy-N-methyl- benzenesulfonamide,
3-[4-(4-cyano-2-fluoro-phenyl)-piperazine-l-carbonyl -4-cyclopentyloxy-N-methyl- benzenesulfonamide,
3-[4-(4-cyano-2-fluoro-phenyl)-piperazine-l-carbonyl -4-cyclobutoxy-N-methyl- benzenesulfonamide,
3- [4-(4-cyano-2-fluoro-phenyl)-piperazine- 1-carbonyl -4-cyclopropylmethoxy-N- methyl-benzenesulfonamide, 3-[4-(4-cyano-2-fluoro-phenyl)-piperazine-l-carbonyl -4-cydobutylmethoxy-N- methyl-benzenesulfonamide,
3- [4- (4-acetyl-2-fluoro-phenyl)-piperazine- 1-carbonyl -4-isobutoxy-N-methyl- benzenesulfonamide,
3-[4-(4-acetyl-2-fluoro-phenyl)-piperazine-l-carbonyl -4- (2,2-dimethyl-propoxy) -N- methyl-benzenesulfonamide,
3-[4-(4-acetyl-2-fluoro-phenyl)-piperazine-l-carbonyl -4-cyclopentyloxy-N-methyl- benzenesulfonamide,
3- [4-(4-acetyl-2-fluoro-phenyl)-piperazine- 1-carbonyl -4- cyclobutoxy-N-methyl- benzenesulfonamide, 3-[4-(4-acetyl-2-fluoro-phenyl)-piperazine-l-carbonyl -4-cyclopropylmethoxy-N- methyl-benzenesulfonamide,
4-isobutoxy-N-methyl-3-[4-(4-trifluoromethyl-phenyl -piperazine- 1-carbonyl]- benzenesulfonamide,
4-(2,2-dimethyl-propoxy)-N-methyl-3-[4-(4-trifluoromethyl-phenyl)-piperazine-l- carbonyl] -benzenesulfonamide,
4-isopropoxy-N-methyl-3- [4-(4-trifluoromethyl-phenyl)-piperazine- 1-carbonyl] - benzenesulfonamide,
4-cyclopentyloxy-N-methyl-3-[4-(4-trifluoromethyl-phenyl)-piperazine-l-carbonyl] benzenesulfonamide, 4-cyclobutoxy-N-methyl-3-[4-(4-trifluoromethyl-phenyl)-piperazine-l-carbonyl]- benzenesulfonamide, 4-cyclopropylmethoxy-N-methyl-3-[4-(4-trifluoromethyl-phenyl)-piperazine-l- carbonyl] -benzenesulfonamide,
4-cyclobutylmethoxy-N-methyl-3- [4-(4-trifluoromethyl-phenyl)-piperazine- 1 - carbonyl] -benzenesulfonamide, N-methyl-3-[4-(4-trifluoromethyl-phenyl)-piperazine- 1-carbonyl] -4-(3,3,3-trifluoro- propoxy)-benzenesulfonamide,
3-[4-(4-cyano-2-fluoro-phenyl)-piperazine-l-carbonyl]-N-methyl-4-(2,2,2-trifluoro- ethoxy)-benzenesulfonamide,
N-methyl-4-(2,2,2-trifluoro-ethoxy)-3-[4-(4-trifluoromethyl-phenyl)-piperazine-l- carbonyl] -benzenesulfonamide, rac-N-methyl-4-(2,2,2-trifluoro-l-methyl-efhoxy)-3-[4-(4-trifluoromethyl-phenyl)- piperazine- 1-carbonyl] -benzenesulfonamide, rac-3-[4-(4-cyano-2,5-difluoro-phenyl)-piperazine-l-carbonyl]-N-methyl-4-(2,2,2- trifluoro- 1 -methyl-ethoxy) -benzenesulfonamide and rac-3-[4-(4-cyano-2,3-difluoro-phenyl)-piperazine-l-carbonyl]-N-methyl-4-(2,2,2- trifluoro- 1 -methyl-ethoxy) -benzenesulfonamide.
13. Compounds of formula I according to claim I, wherein Ar is a substituted 6-membered heteroaryl group, containing one, two or three nitrogen atoms, R is (Cι-C6)-alkyl or CH2)n-(C3-C7)-cycloalkyl, and R5 is SO2CH3.
14. Compounds of formula I according to claim 13, which compounds are
[4-(3-chloro-5-trifluoromethyl-pyridin-2-yl)-piperazin-l-yl]-(2-cyclopropylmethoxy-5- methanesulfonyl-phenyl)-methanone,
6-[4-(2-cyclopentyloxy-5-methanesulfonyl-benzoyl)-piperazin-l-yl] -nicotinonitrile,
(2-cyclopentyloxy-5-methanesulfonyl-phenyl)-[4-(5-trifluoromethyl-pyridin-2-yl)- piperazin- 1-yl] -methanone,
[4-(3-chloro-5-trifluoromethyl-pyridin-2-yl)-piperazin-l-yl]-(2-cyclopentyloxy-5- methanesulfonyl-phenyl)-methanone,
(2-cyclopentyloxy-5-methanesulfonyl-phenyl)-[4-(6-trifluoromethyl-pyridin-3-yl)- piperazin- 1-yl] -methanone, [4-(3-fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-l-yl]-(2-isopropoxy-5- methanesulfonyl-phenyl)-methanone and
(2-cyclopentyloxy-5-methanesulfonyl-phenyl)-[4-(3-fluoro-5-trifluoromefhyl-pyridin-2- yl)-piperazin- 1-yl] -methanone.
15. Compounds of formula I according to claim 1, wherein, wherein Ar is a substituted 6-membered heteroaryl group, containing one, two or three nitrogen atoms, R2 is (C1-C6)-alkyl substituted by halogen and R5 is SO2CH3.
16. Compounds of formula I according to claim 15, which compounds are
rac- [4-(3-chloro-5-trifluoromethyl-pyridin-2-yl)-piperazin- 1-yl] - [5-methanesulfonyl-2-
(2,2,2-trifluoro-l-methyl-ethoxy)-phenyl]-methanone, rac-[5-methanesulfonyl-2-(2,2,2-trifluoro-l-methyl-ethoxy)-phenyl]-[4-(5- trifluoromethyl-pyridin-2-yl)-piperazin- 1 -yl] -methanone, rac-[4-(5-bromo-pyridin-2-yl)-piperazin-l-yl]-[5-methanesulfonyl-2-(2,2,2-trifluoro-l- methyl-ethoxy)-phenyl] -methanone, rac- [4-(3-fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin- 1-yl] - [5-methanesulfonyl-2-
(2,2,2-trifluoro-l-methyl-ethoxy)-phenyl]-methanone, rac-[5-methanesulfonyl-2-(2,2,2-trifluoro-l-methyl-ethoxy)-phenyl]-[4-(6- trifluoromethyl-pyridin-2-yl)-piperazin-l-yl] -methanone,
[5-methanesulfonyl-2-((S or R)-2,2,2-trifluoro-l-methyl-ethoxy)-phenyl]-[4-(5- trifluoromethyl-pyridin-2-yl)-piperazin-l-yl] -methanone,
[5-methanesulfonyl-2-((R or S)-2,2,2-trifluoro-l-methyl-ethoxy)-phenyl]-[4-(5- trifluoromethyl-pyridin-2-yl)-piperazin-l-yl] -methanone, [4-(3-fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-l-yl]-[5-methanesulfonyl-2-((S)-
2,2,2-trifluoro- l-methyl-ethoxy)-phenyl] -methanone and
[4-(3-fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-l-yl]-[5-methanesulfonyl-2-
(2,2,2-trifluoro-lJ-dimethyl-ethoxy)-phenyl]-methanone.
17. A process for preparing a compound of formula I as defined in claim 1, which process comprises a) reacting a compound of formula
Figure imgf000232_0001
with a compound of formula
Figure imgf000233_0001
in the presence of an activating agent such as TBTU (2-(lH-benzotriazole-l-yl)-lJ,3,3- tetramethyluroniumtetrafluoroborate) to a compound of formula
Figure imgf000233_0002
wherein the substituents are as defined above, or b) reacting a compound of formula
Figure imgf000233_0003
with a compound of formula R2OH optionally in the presence of a catalyst, such as Cu(I)I and a base like potassium carbonate, cesium carbonate or sodium, to a compound of formula
Figure imgf000233_0004
wherein X is halogen and the other substituents are as defined above, or c) reacting a compound of formula
Figure imgf000234_0001
with a compound of formula R2X in the presence of a base and optionally in the presence of microwaves to a compound of formula
Figure imgf000234_0002
wherein X is halogen, mesylate or triflate and the other substituents are as defined above, or d) reacting a compound of formula
Figure imgf000234_0003
with a compound of formula R2OH under Mitsunobu conditions in the present of a phosphine to a compound of formula
Figure imgf000234_0004
wherein the substituents are as defined above, or e) reacting a compound of formula
Figure imgf000235_0001
with a compound of formula ArX to a compound of formula
Figure imgf000235_0002
wherein X is halogen and the other substituents are as defined above, or f) reacting a compound of formula
Figure imgf000235_0003
with a corresponding amine or alcohol in the presence of an activating agent to a compound of formula
Figure imgf000235_0004
wherein R9 is (CrC6)-alkyl, (C3-C6)-cycloalkyl, ( -C6)-alkoxy or NR7R8; and the other substituents are as defined above, or g) reacting a compound of formula
Figure imgf000235_0005
with a compound of formula RONH2 to a compound of formula
Figure imgf000236_0001
wherein R is H or alkyl and the other substituents are as defined above, or h) reacting a compound of formula
Figure imgf000236_0002
with a reducing agent like sodium borohydride (when R is H) or an alkylating agent like alkyllithium (when R is alkyl) to a compound of formula
Figure imgf000236_0003
wherein R is H or alkyl and the other substituents are as defined above, and if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts.
18. A compound according to claim 1, whenever prepared by a process as claimed in claim 17 or by an equivalent method.
19. A medicament containing one or more compounds as claimed in claim 1 or containing l-[5-(aminosulfonyl)-2-methoxybenzoyl]-4-(3-chlorophenyl)-piperazine, l-[5-(aminosulfonyl)-2-methoxybenzoyl]-4-(4-fluoroρhenyl)-piperazine, l-[5-(aminosulfonyl)-2-methoxybenzoyl]-4-[3-(trifluoromethyl)phenyl] -piperazine, 4-(3-amino-4-nitrophenyl)-l-[4-(dimethylamino)-2-methoxy-5-nitrobenzoyl]-2- methyl-piperazine, 1 - [4-(dimethylamino)-2-methoxy-5-nitrobenzoyl] -2-methyl-4-(4-nitrophenyl)- piperazine,
4-[4-(dimethylamino)-2-methoxy-5-nitrobenzoyl]-2-methyl-l-(4-nitrophenyl)- piperazine, l-(2-chloro-4-nitrophenyl)-4-[4-(dimethylamino)-2-methoxy-5-nitrobenzoyl]- piperazine, l-[4-(dimethylamino)-2-methoxy-5-nitrobenzoyl]-4-(2,4-dinitrophenyl)-2-methyl- piperazine, l-(4-chloro-2-nitrophenyl)-4- [4-(dimethylamino)-2-methoxy-5-nitrobenzoyl] - piperazine and 4-[4-(dimethylamino)-2-methoxy-5-nitrobenzoyl]-l-(2,4-dinitrophenyl)-2-methyl- piperazine. and pharmaceutically acceptable excipients.
20. A medicament according to claim 19 for the treatment of illnesses based on the glycine uptake inhibitor.
21. A medicament according to claim 20, wherein the illnesses are psychoses, pain, disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.
22. The use of a compound as claimed in claim 1 or of l-[5-(aminosulfonyl)-2-methoxybenzoyl]-4-(3-chlorophenyl)-piperazine, l-[5-(aminosulfonyl)-2-methoxybenzoyl]-4-(4-fluorophenyl)-piρerazine, l-[5-(aminosulfonyl)-2-mefhoxybenzoyl]-4-[3-(trifluoromethyl)phenyl]-piperazine, 4-(3-amino-4-nitrophenyl)-l-[4-(dimethylamino)-2-methoxy-5-nitrobenzoyl]-2- methyl-piperazine, l-[4-(dimethylamino)-2-methoxy-5-nitrobenzoyl]-2-methyl-4-(4-nitrophenyl)- piperazine, 4-[4-(dimethylamino)-2-methoxy-5-nitrobenzoyl]-2-methyl-l-(4-nitrophenyl)- piperazine, l-(2-chloro-4-nitrophenyl)-4-[4-(dimethylamino)-2-methoxy-5-nitrobenzoyl]- piperazine, l-[4-(dimethylamino)-2-methoxy-5-nitrobenzoyl]-4-(2,4-dinitrophenyl)-2-methyl- piperazine, l-(4-chloro-2-nitrophenyl)-4-[4-(dimethylamino)-2-methoxy-5-nitrobenzoyl]- piperazine and 4-[4-(dimethylamino)-2-methoxy-5-nitrobenzoyl]-l-(2,4-dinitrophenyl)-2-methyl- piperazine. for the manufacture of medicaments for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.
23. The invention as herein before described. ***
PCT/EP2004/008633 2003-08-11 2004-08-02 Piperazine with or-substituted phenyl group and their use as glyt1 inhibitors WO2005014563A1 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
DE602004011076T DE602004011076T2 (en) 2003-08-11 2004-08-02 PIPERAZINE WITH OR-SUBSTITUTED PHENYL GROUP AND ITS USE AS GLYT1 INHIBITORS
YUP-2006/0076A RS20060076A (en) 2003-08-11 2004-08-02 Piperazine with or-substituted phenyl group and their use as glyt1 inhibitors
PL04763703T PL1656361T3 (en) 2003-08-11 2004-08-02 Piperazine with or-substituted phenyl group and their use as glyt1 inhibitors
DK04763703T DK1656361T3 (en) 2003-08-11 2004-08-02 Piperazine with OR-substituted phenyl group and its use as GLYT1 inhibitors
NZ544820A NZ544820A (en) 2003-08-11 2004-08-02 Piperazine with or-substituted phenyl group and their use as GlyT1 inhibitors
MEP-2008-277A ME00116B (en) 2003-08-11 2004-08-02 Piperazine with or-substituted phenyl group and their use as glyt1 inhibitors
CA2534675A CA2534675C (en) 2003-08-11 2004-08-02 Piperazine with or-substituted phenyl group and their use as glyt1 inhibitors
RS20060076A RS53252B (en) 2003-08-11 2004-08-02 Piperazine with or-substituted phenyl group and their use as glyt1 inhibitors
SI200430616T SI1656361T1 (en) 2003-08-11 2004-08-02 Piperazine with or-substituted phenyl group and their use as glyt1 inhibitors
EP04763703A EP1656361B1 (en) 2003-08-11 2004-08-02 Piperazine with or-substituted phenyl group and their use as glyt1 inhibitors
MXPA06001665A MXPA06001665A (en) 2003-08-11 2004-08-02 Piperazine with or-substituted phenyl group and their use as glyt1 inhibitors.
CN2004800297559A CN1867554B (en) 2003-08-11 2004-08-02 Piperazine with or-substituted phenyl group and their use as GLYT1 inhibitors
BRPI0413497A BRPI0413497B8 (en) 2003-08-11 2004-08-02 piperazine with or substituting phenyl group, and its use and preparation process, as well as medicine
JP2006522944A JP4252598B2 (en) 2003-08-11 2004-08-02 Piperazine having an OR-substituted phenyl group and their use as a GLYT1 inhibitor
EA200600336A EA009986B1 (en) 2003-08-11 2004-08-02 Piperazine with or-substituted phenyl group and their use as glyt1 inhibitors
AU2004263306A AU2004263306B2 (en) 2003-08-11 2004-08-02 Piperazine with or-substituted phenyl group and their use as GLYT1 inhibitors
IL173274A IL173274A (en) 2003-08-11 2006-01-19 Piperazines with or-substituted phenyl group, process for their preparation and their use for preparation of medicaments for use as glyt1 inhibitors
NO20060541A NO332263B1 (en) 2003-08-11 2006-02-02 Piperazine with OR-substituted phenyl group, process for the preparation thereof, medicaments containing such and compounds for the treatment of disease
TNP2006000042A TNSN06042A1 (en) 2003-08-11 2006-02-03 Piperazine with or-substituted phenyl group and their use as glyt 1 inhibitors
EGPCTNA2006000136A EG26404A (en) 2003-08-11 2006-02-09 Piperazine with or-substituted phenyl group and their use as GLYT1 inhibitors
HK07104591.8A HK1098147A1 (en) 2003-08-11 2007-04-30 Piperazine with or-substituted phenyl group and their use as glyt1 inhibitors
HR20080137T HRP20080137T3 (en) 2003-08-11 2008-03-26 Piperazine with or-substituted phenyl group and their use as glyt1 inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03017614 2003-08-11
EP03017614.3 2003-08-11

Publications (1)

Publication Number Publication Date
WO2005014563A1 true WO2005014563A1 (en) 2005-02-17

Family

ID=34130061

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/008633 WO2005014563A1 (en) 2003-08-11 2004-08-02 Piperazine with or-substituted phenyl group and their use as glyt1 inhibitors

Country Status (37)

Country Link
US (2) US7319099B2 (en)
EP (1) EP1656361B1 (en)
JP (1) JP4252598B2 (en)
KR (1) KR100774622B1 (en)
CN (1) CN1867554B (en)
AR (1) AR045360A1 (en)
AT (1) ATE382611T1 (en)
AU (1) AU2004263306B2 (en)
BR (1) BRPI0413497B8 (en)
CA (1) CA2534675C (en)
CO (1) CO5650253A2 (en)
CR (1) CR8193A (en)
CY (1) CY1108616T1 (en)
DE (1) DE602004011076T2 (en)
DK (1) DK1656361T3 (en)
EA (1) EA009986B1 (en)
EC (1) ECSP066358A (en)
EG (1) EG26404A (en)
ES (1) ES2297458T3 (en)
HK (1) HK1098147A1 (en)
HR (1) HRP20080137T3 (en)
IL (1) IL173274A (en)
MA (1) MA27995A1 (en)
ME (1) ME00116B (en)
MX (1) MXPA06001665A (en)
MY (1) MY145356A (en)
NO (1) NO332263B1 (en)
NZ (1) NZ544820A (en)
PL (1) PL1656361T3 (en)
PT (1) PT1656361E (en)
RS (2) RS53252B (en)
SI (1) SI1656361T1 (en)
TN (1) TNSN06042A1 (en)
TW (1) TWI289556B (en)
UA (1) UA85194C2 (en)
WO (1) WO2005014563A1 (en)
ZA (1) ZA200601146B (en)

Cited By (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006072436A1 (en) * 2005-01-07 2006-07-13 F. Hoffmann-La Roche Ag [4-(heteroaryl) piperazin-1-yl]-(2,5-substituted -phenyl)methanone derivatives as glycine transporter 1 (glyt-1) inhibitors for the treatment of neurological and neuropsychiatric disorders
WO2006072435A1 (en) * 2005-01-06 2006-07-13 F.Hoffmann-La Roche Ag Sulfanyl substituted phenyl methanones as glycine transporter 1 (glyt-1) inhibitors for the treatment of neurological and neuropsychiatric disorders
WO2006094842A1 (en) * 2005-03-11 2006-09-14 Glaxo Group Limited Acylated piperidihes as glycine transporter inhibitors
WO2006094840A1 (en) * 2005-03-11 2006-09-14 Glaxo Group Limited Compounds
WO2006094843A1 (en) * 2005-03-11 2006-09-14 Glaxo Group Limited Piperazine derivatives as glyt1 inhibitors
WO2007006650A2 (en) * 2005-07-08 2007-01-18 F. Hoffmann-La Roche Ag Asymmetric reduction of 1,1,1-trifluoroacetone
WO2007078335A2 (en) * 2005-12-21 2007-07-12 Decode Genetics, Ehf. Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation
WO2007134457A1 (en) * 2006-05-22 2007-11-29 Merck Frosst Canada Ltd. Cyclic amine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
WO2007147770A2 (en) 2006-06-22 2007-12-27 F. Hoffmann-La Roche Ag Substituted phenyl methanone derivatives
WO2008012240A1 (en) 2006-07-27 2008-01-31 F. Hoffmann-La Roche Ag Asymmetric hydrogenation of 1,1,1-trifluoroacetone
WO2008080821A1 (en) * 2006-12-28 2008-07-10 F. Hoffmann-La Roche Ag Crystalline forms glyt1
WO2008107334A2 (en) 2007-03-05 2008-09-12 F. Hoffmann-La Roche Ag Process for the synthesis of glyt-1 inhibitors
US7462617B2 (en) * 2003-09-09 2008-12-09 Hoffmann-La Roche Inc. Substituted acylpiperazine derivatives
US7605163B2 (en) 2003-08-11 2009-10-20 Hoffmann-La Roche Inc. Benzoyl-piperazine derivatives
WO2010025375A1 (en) * 2008-08-29 2010-03-04 Treventis Corporation Compositions and methods of treating amyloid disease
US20100168437A1 (en) * 2006-11-30 2010-07-01 Dow Agrosciences Llc Process for the preparation of 2-substituted-5-(1-alkylthio)alkylpyridines
US7767677B2 (en) 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US7777036B2 (en) 2004-09-20 2010-08-17 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
US7829712B2 (en) 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
WO2011002067A1 (en) * 2009-07-02 2011-01-06 武田薬品工業株式会社 Heterocyclic compound and use thereof
US7919496B2 (en) 2004-09-20 2011-04-05 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
US8026360B2 (en) 2004-09-20 2011-09-27 Xenon Pharmaceuticals Inc. Substituted pyridazines as stearoyl-CoA desaturase inhibitors
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
WO2012019970A1 (en) 2010-08-09 2012-02-16 F. Hoffmann-La Roche Ag Combination of glyt1 compound with antipsychotics
US8153679B2 (en) 2008-11-04 2012-04-10 Hoffmann-La Roche Inc. Radiolabelled inhibitors of the glycine 1 transporter
US8420670B2 (en) 2007-08-22 2013-04-16 Abbott Laboratories 4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy
US8541457B2 (en) 2005-06-03 2013-09-24 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors
US8563617B2 (en) 2009-02-16 2013-10-22 AbbVie Deutschland GmbH & Co. KG Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy
US8609672B2 (en) 2010-08-27 2013-12-17 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
US8642587B2 (en) 2009-02-16 2014-02-04 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
US8653100B2 (en) 2008-04-01 2014-02-18 Abbvie Inc. Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
US8735383B2 (en) 2006-06-28 2014-05-27 Amgen Inc. Glycine transporter-1 inhibitors
US8846741B2 (en) 2011-11-18 2014-09-30 Abbvie Inc. N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8853196B2 (en) 2011-08-05 2014-10-07 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2014192865A1 (en) * 2013-05-30 2014-12-04 大日本住友製薬株式会社 Phenylpiperazine derivative
WO2014209033A1 (en) * 2013-06-27 2014-12-31 Korea Institute Of Science And Technology Pharmaceutical composition for preventing or treating cognitive impairment-related disease comprising morpholine or piperazine based compounds, and donepezil
CN104628679A (en) * 2013-11-08 2015-05-20 江苏恩华药业股份有限公司 New synthesis method and intermediate of Bitopertin
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2015082367A1 (en) * 2013-12-03 2015-06-11 F. Hoffmann-La Roche Ag Pharmaceutical composition
CN105017098A (en) * 2015-07-17 2015-11-04 大连奇凯医药科技有限公司 Preparation technology of alkyloxybenzsulfamide and its derivatives
WO2015165842A1 (en) * 2014-04-30 2015-11-05 F. Hoffmann-La Roche Ag Glyt1 inhibitors for use in the treatment of hematological disorders
RU2577039C2 (en) * 2014-02-28 2016-03-10 Закрытое Акционерное Общество "Вертекс" Substance having combined antiaggregant, anticoagulant and vasodilator activity, and method of producing n, n '-substituted piperazines
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
US9586945B2 (en) 2013-10-17 2017-03-07 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9586942B2 (en) 2013-10-17 2017-03-07 AbbVie Deutschland GmbH & Co. KG Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US10562884B2 (en) 2018-06-05 2020-02-18 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
US11568956B2 (en) 2008-08-29 2023-01-31 Treventis Corporation Methods for identifying inhibitors of amyloid protein aggregation

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050119251A1 (en) * 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
CA2537292C (en) * 2003-09-09 2013-04-02 F. Hoffmann-La Roche Ag 1- (2-amino-benzol) -piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
CA2580781A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coa-desaturase (scd)
WO2006034446A2 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridine derivatives for inhibiting human stearoyl-coa-desaturase
KR100880093B1 (en) * 2004-12-09 2009-01-23 에프. 호프만-라 로슈 아게 Phenyl-piperazin methanone derivatives
JP4709849B2 (en) * 2004-12-15 2011-06-29 エフ．ホフマン−ラ ロシュ アーゲー Bicyclic and tricyclic substituted phenylmethanones as glycine transporter I (GLYT-1) inhibitors for the treatment of Alzheimer's disease
US7485637B2 (en) * 2005-01-04 2009-02-03 Hoffmann-La Roche Inc. Benzoyl-tetrahydropiperidine derivatives
AU2006207650B2 (en) * 2005-01-18 2011-01-27 F. Hoffmann-La Roche Ag 2, 5-disubstituted phenyl methanone derivatives as glycine transporter 1 (GlyT-I) inhibitors for the treatment of neurological and neuropsychiatry disorders
EP1844045B1 (en) * 2005-01-26 2009-11-04 F.Hoffmann-La Roche Ag Phenyl methanone derivatives and their use as glycine transporter 1 inhibitors
MX2007009342A (en) * 2005-02-07 2007-09-21 Hoffmann La Roche Heterocyclic substituted phenyl methanones as inhibitors of the glycine transporter 1.
GB0523853D0 (en) * 2005-11-24 2006-01-04 3M Innovative Properties Co Fluorinated surfactants for use in making a fluoropolymer
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine/Piperazine derivatives
US8835437B2 (en) 2007-06-08 2014-09-16 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
CL2008001671A1 (en) * 2007-06-08 2009-07-17 Janssen Pharmaceutica Nv Dgat1 inhibitor piperidine / piperazine derivative compounds, pharmaceutical composition comprising them; and its use in the treatment of metabolic diseases especially diabetes.
CA2687918C (en) * 2007-06-08 2016-11-08 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
EP2296659B1 (en) 2008-06-05 2016-12-21 Janssen Pharmaceutica, N.V. Drug combinations comprising a DGAT inhibitor and a PPAR-agonist
CN101759665B (en) * 2008-12-23 2012-03-28 江苏恩华药业股份有限公司 Substituent phenylpiperazine aryl alkanol derivant and application thereof in preparing analgesics
JP6428604B2 (en) * 2013-04-04 2018-11-28 味の素株式会社 Deprotection method
WO2015164520A1 (en) 2014-04-24 2015-10-29 Dart Neuroscience, Llc Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c] pyrazole and 4,5,6,7-tetrahydro-2h-pyrazolo [4,3-c] pyridine compounds as glyt1 inhibitors
EP3215500A1 (en) 2014-11-05 2017-09-13 Dart NeuroScience (Cayman) Ltd. Substituted azetidinyl compounds as glyt1 inhibitors
CN105712952B (en) * 2014-12-22 2021-03-26 上海翰森生物医药科技有限公司 2-substituted oxy-5-methylsulfonyl phenyl piperazine amide analogue and preparation method and application thereof
CN106397312B (en) * 2015-07-31 2020-03-24 广东东阳光药业有限公司 Method for preparing GLYT-1 inhibitor
CN116212025A (en) 2020-01-09 2023-06-06 迪斯克医药公司 Method for treating erythropoiesis protoporphyria, X-linked protoporphyria or congenital erythropoiesis protoporphyria

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0171636A1 (en) * 1984-08-14 1986-02-19 RAVIZZA S.p.A. Pharmacologically active piperazino derivatives and the process for their preparation
WO1999045011A1 (en) * 1998-03-06 1999-09-10 Janssen Pharmaceutica N.V. Glycine transport inhibitors
WO2002022612A1 (en) * 2000-08-31 2002-03-21 Oxford Glycosciences (Uk) Limited Thiazolidine derivatives and its use as antifungal agent

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5018112A (en) * 1982-10-18 1991-05-21 Conoco Inc. Method for hydrocarbon reservoir identification
JPH0651625B2 (en) 1986-12-29 1994-07-06 株式会社大塚製薬工場 Antihyperlipidemic agent
DE10112040A1 (en) 2001-03-14 2002-10-02 Aventis Pharma Gmbh Improved process for the preparation of sulfonylcarboxamide derivatives
WO2003053366A2 (en) * 2001-12-20 2003-07-03 Osi Pharmaceuticals, Inc. Pyrimidine a2b selective antagonist compounds, their synthesis and use
SI1656361T1 (en) 2003-08-11 2008-04-30 Hoffmann La Roche Piperazine with or-substituted phenyl group and their use as glyt1 inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0171636A1 (en) * 1984-08-14 1986-02-19 RAVIZZA S.p.A. Pharmacologically active piperazino derivatives and the process for their preparation
WO1999045011A1 (en) * 1998-03-06 1999-09-10 Janssen Pharmaceutica N.V. Glycine transport inhibitors
WO2002022612A1 (en) * 2000-08-31 2002-03-21 Oxford Glycosciences (Uk) Limited Thiazolidine derivatives and its use as antifungal agent

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"ambinter stock screening collection", 1 January 2004, AMBINTER , 46 QUAI LOUIS BLERIOT,PARIS,F-75016, FRANCE *
"LABOTEST STOCK", 26 April 2004, LABOTEST, FALKENBERGER STR 4, NIEDERSCHONA, 09600 GERMANY *
CAULFIELD W L ET AL: "The first potent and selective Inhibitors of the Glycine Transporter Type 2", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 44, no. 17, 16 August 2001 (2001-08-16), pages 2679 - 2682, XP002183670, ISSN: 0022-2623 *
DATABASE CHEMCATS CHEMICAL ABSTRACTS SERVICE COLUMBUS, OHIO, US; 2004, XP002299149 *
DATABASE CHEMCATS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2004, XP002299148 *

Cited By (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7605163B2 (en) 2003-08-11 2009-10-20 Hoffmann-La Roche Inc. Benzoyl-piperazine derivatives
US7462617B2 (en) * 2003-09-09 2008-12-09 Hoffmann-La Roche Inc. Substituted acylpiperazine derivatives
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
US8026360B2 (en) 2004-09-20 2011-09-27 Xenon Pharmaceuticals Inc. Substituted pyridazines as stearoyl-CoA desaturase inhibitors
US7919496B2 (en) 2004-09-20 2011-04-05 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
US7767677B2 (en) 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US7777036B2 (en) 2004-09-20 2010-08-17 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
US7829712B2 (en) 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
WO2006072435A1 (en) * 2005-01-06 2006-07-13 F.Hoffmann-La Roche Ag Sulfanyl substituted phenyl methanones as glycine transporter 1 (glyt-1) inhibitors for the treatment of neurological and neuropsychiatric disorders
US7220744B2 (en) 2005-01-07 2007-05-22 Hoffman-La Roche Inc. Monocyclic substituted phenyl methanones
WO2006072436A1 (en) * 2005-01-07 2006-07-13 F. Hoffmann-La Roche Ag [4-(heteroaryl) piperazin-1-yl]-(2,5-substituted -phenyl)methanone derivatives as glycine transporter 1 (glyt-1) inhibitors for the treatment of neurological and neuropsychiatric disorders
WO2006094843A1 (en) * 2005-03-11 2006-09-14 Glaxo Group Limited Piperazine derivatives as glyt1 inhibitors
WO2006094840A1 (en) * 2005-03-11 2006-09-14 Glaxo Group Limited Compounds
WO2006094842A1 (en) * 2005-03-11 2006-09-14 Glaxo Group Limited Acylated piperidihes as glycine transporter inhibitors
US8541457B2 (en) 2005-06-03 2013-09-24 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors
WO2007006650A2 (en) * 2005-07-08 2007-01-18 F. Hoffmann-La Roche Ag Asymmetric reduction of 1,1,1-trifluoroacetone
AU2006268765B2 (en) * 2005-07-08 2010-12-23 F. Hoffmann-La Roche Ag Asymmetric reduction of 1,1,1-trifluoroacetone
WO2007006650A3 (en) * 2005-07-08 2007-04-12 Hoffmann La Roche Asymmetric reduction of 1,1,1-trifluoroacetone
WO2007078335A3 (en) * 2005-12-21 2007-11-29 Decode Genetics Inc Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation
WO2007078335A2 (en) * 2005-12-21 2007-07-12 Decode Genetics, Ehf. Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation
US7750012B2 (en) 2005-12-21 2010-07-06 Decode Genetics Ehf Biaryl nitrogen-heterocycle inhibitors of LTA4H for treating inflammation
WO2007134457A1 (en) * 2006-05-22 2007-11-29 Merck Frosst Canada Ltd. Cyclic amine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
US7951836B2 (en) 2006-06-22 2011-05-31 Hoffmann-La Roche Inc. Substituted phenyl methanone derivatives
WO2007147770A3 (en) * 2006-06-22 2008-05-22 Hoffmann La Roche Substituted phenyl methanone derivatives
WO2007147770A2 (en) 2006-06-22 2007-12-27 F. Hoffmann-La Roche Ag Substituted phenyl methanone derivatives
AU2007263083B2 (en) * 2006-06-22 2012-10-04 F. Hoffmann-La Roche Ag Substituted phenyl methanone derivatives
KR101072796B1 (en) 2006-06-22 2011-10-14 에프. 호프만-라 로슈 아게 Substituted phenyl methanone derivatives
JP2009541251A (en) * 2006-06-22 2009-11-26 エフ．ホフマン−ラ ロシュ アーゲー Substituted phenylmethanone derivatives
CN101472886B (en) * 2006-06-22 2011-07-13 弗·哈夫曼-拉罗切有限公司 Substituted phenyl methanone derivatives
US8735383B2 (en) 2006-06-28 2014-05-27 Amgen Inc. Glycine transporter-1 inhibitors
US9663476B2 (en) 2006-06-28 2017-05-30 Amgen Inc. Glycine transporter-1 inhibitors
WO2008012240A1 (en) 2006-07-27 2008-01-31 F. Hoffmann-La Roche Ag Asymmetric hydrogenation of 1,1,1-trifluoroacetone
US7504544B2 (en) 2006-07-27 2009-03-17 Hoffmann-La Roche Inc. Asymmetric hydrogenation of 1,1,1-trifluoroacetone
US20100168437A1 (en) * 2006-11-30 2010-07-01 Dow Agrosciences Llc Process for the preparation of 2-substituted-5-(1-alkylthio)alkylpyridines
NO342150B1 (en) * 2006-12-28 2018-04-03 Hoffmann La Roche Crystalline Form A of [4- (3-fluoro-5-trifluoromethylpyridin-2-yl) -piperazin-1-yl] - [5-methanesulfonyl-2 - ((S) -2,2,2-trifluoro-1- methyl ethoxy-phenyl] -methanone, method of preparation thereof, pharmaceutical composition comprising it and its use in the treatment of disease
WO2008080821A1 (en) * 2006-12-28 2008-07-10 F. Hoffmann-La Roche Ag Crystalline forms glyt1
JP2010514725A (en) * 2006-12-28 2010-05-06 エフ．ホフマン−ラ ロシュ アーゲー GLYT1 in crystalline form
US8039473B2 (en) * 2006-12-28 2011-10-18 Hoffmann-La Roche Inc. Solid forms of [4-(3-fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl-[5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone
JP4799666B2 (en) * 2006-12-28 2011-10-26 エフ．ホフマン−ラ ロシュ アーゲー GLYT1 in crystalline form
AU2007341356B2 (en) * 2006-12-28 2013-08-29 F. Hoffmann-La Roche Ag Crystalline forms Glyt1
KR101130146B1 (en) * 2006-12-28 2012-03-28 에프. 호프만-라 로슈 아게 Crystalline forms glyt1
US7812161B2 (en) 2007-03-05 2010-10-12 Hoffman-La Roche Inc. Synthesis of GlyT-1 inhibitors
KR101143073B1 (en) * 2007-03-05 2012-05-08 에프. 호프만-라 로슈 아게 Process for the synthesis of glyt-1 inhibitors
WO2008107334A3 (en) * 2007-03-05 2008-10-23 Hoffmann La Roche Process for the synthesis of glyt-1 inhibitors
WO2008107334A2 (en) 2007-03-05 2008-09-12 F. Hoffmann-La Roche Ag Process for the synthesis of glyt-1 inhibitors
AU2008223915B2 (en) * 2007-03-05 2013-05-02 F. Hoffmann-La Roche Ag Process for the synthesis of GLYT-1 inhibitors
US8420670B2 (en) 2007-08-22 2013-04-16 Abbott Laboratories 4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy
US8653100B2 (en) 2008-04-01 2014-02-18 Abbvie Inc. Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
US8957089B2 (en) 2008-04-01 2015-02-17 AbbVie Deutschland GmbH & Co. KG Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
US8420640B2 (en) 2008-08-29 2013-04-16 Treventis Corporation Methods of treating amyloid disease using analogs of 1-(4-nitrophenyl) piperazine
WO2010025375A1 (en) * 2008-08-29 2010-03-04 Treventis Corporation Compositions and methods of treating amyloid disease
US11568956B2 (en) 2008-08-29 2023-01-31 Treventis Corporation Methods for identifying inhibitors of amyloid protein aggregation
US8153679B2 (en) 2008-11-04 2012-04-10 Hoffmann-La Roche Inc. Radiolabelled inhibitors of the glycine 1 transporter
US8642587B2 (en) 2009-02-16 2014-02-04 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
US8563617B2 (en) 2009-02-16 2013-10-22 AbbVie Deutschland GmbH & Co. KG Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9096619B2 (en) 2009-02-16 2015-08-04 AbbVie Deutschland GmbH & Co. KG Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9067871B2 (en) 2009-02-16 2015-06-30 AbbVie Deutschland GmbH & Co. KG Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2011002067A1 (en) * 2009-07-02 2011-01-06 武田薬品工業株式会社 Heterocyclic compound and use thereof
WO2012019970A1 (en) 2010-08-09 2012-02-16 F. Hoffmann-La Roche Ag Combination of glyt1 compound with antipsychotics
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9227930B2 (en) 2010-08-13 2016-01-05 Abbvie Inc. Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9238619B2 (en) 2010-08-13 2016-01-19 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8609672B2 (en) 2010-08-27 2013-12-17 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8853196B2 (en) 2011-08-05 2014-10-07 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846741B2 (en) 2011-11-18 2014-09-30 Abbvie Inc. N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2014192865A1 (en) * 2013-05-30 2014-12-04 大日本住友製薬株式会社 Phenylpiperazine derivative
WO2014209033A1 (en) * 2013-06-27 2014-12-31 Korea Institute Of Science And Technology Pharmaceutical composition for preventing or treating cognitive impairment-related disease comprising morpholine or piperazine based compounds, and donepezil
US9527824B2 (en) 2013-06-27 2016-12-27 Korea Institute Of Science And Technology Pharmaceutical composition for preventing or treating cognitive impairment-related disease comprising morpholine or piperazine based compounds, and donepezil
US9586945B2 (en) 2013-10-17 2017-03-07 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9586942B2 (en) 2013-10-17 2017-03-07 AbbVie Deutschland GmbH & Co. KG Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
CN104628679A (en) * 2013-11-08 2015-05-20 江苏恩华药业股份有限公司 New synthesis method and intermediate of Bitopertin
WO2015082367A1 (en) * 2013-12-03 2015-06-11 F. Hoffmann-La Roche Ag Pharmaceutical composition
CN105636581A (en) * 2013-12-03 2016-06-01 豪夫迈·罗氏有限公司 Pharmaceutical composition
RU2577039C2 (en) * 2014-02-28 2016-03-10 Закрытое Акционерное Общество "Вертекс" Substance having combined antiaggregant, anticoagulant and vasodilator activity, and method of producing n, n '-substituted piperazines
US9877963B2 (en) 2014-04-30 2018-01-30 Hoffmann-La Roche Inc. GlyT1 inhibitors for use in the treatment of hematological disorders
WO2015165842A1 (en) * 2014-04-30 2015-11-05 F. Hoffmann-La Roche Ag Glyt1 inhibitors for use in the treatment of hematological disorders
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
CN105017098A (en) * 2015-07-17 2015-11-04 大连奇凯医药科技有限公司 Preparation technology of alkyloxybenzsulfamide and its derivatives
US10562884B2 (en) 2018-06-05 2020-02-18 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
US10604507B2 (en) 2018-06-05 2020-03-31 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
US10766877B2 (en) 2018-06-05 2020-09-08 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
US10981894B2 (en) 2018-06-05 2021-04-20 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
US11566015B2 (en) 2018-06-05 2023-01-31 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof

Also Published As

Publication number Publication date
CA2534675A1 (en) 2005-02-17
DE602004011076D1 (en) 2008-02-14
TNSN06042A1 (en) 2007-10-03
ATE382611T1 (en) 2008-01-15
EG26404A (en) 2013-10-21
AU2004263306A1 (en) 2005-02-17
ECSP066358A (en) 2006-08-30
AU2004263306B2 (en) 2010-04-22
AR045360A1 (en) 2005-10-26
TWI289556B (en) 2007-11-11
PL1656361T3 (en) 2008-06-30
RS20060076A (en) 2008-08-07
DE602004011076T2 (en) 2009-01-02
PT1656361E (en) 2008-03-05
US20080119486A1 (en) 2008-05-22
NZ544820A (en) 2009-02-28
BRPI0413497B1 (en) 2017-12-19
JP4252598B2 (en) 2009-04-08
RS53252B (en) 2014-08-29
BRPI0413497A (en) 2006-10-17
US20050209241A1 (en) 2005-09-22
ZA200601146B (en) 2007-05-30
IL173274A0 (en) 2006-06-11
EA200600336A1 (en) 2006-08-25
ME00116B (en) 2010-10-10
CN1867554B (en) 2011-07-06
NO332263B1 (en) 2012-08-13
BRPI0413497B8 (en) 2021-05-25
AU2004263306A2 (en) 2005-02-17
DK1656361T3 (en) 2008-05-05
TW200524883A (en) 2005-08-01
MA27995A1 (en) 2006-07-03
ES2297458T3 (en) 2008-05-01
KR100774622B1 (en) 2007-11-08
JP2007501820A (en) 2007-02-01
CR8193A (en) 2006-10-06
EP1656361A1 (en) 2006-05-17
HK1098147A1 (en) 2007-07-13
CA2534675C (en) 2013-07-23
IL173274A (en) 2012-06-28
SI1656361T1 (en) 2008-04-30
NO20060541L (en) 2006-03-08
US7319099B2 (en) 2008-01-15
HRP20080137T3 (en) 2008-06-30
CO5650253A2 (en) 2006-06-30
US7605163B2 (en) 2009-10-20
EP1656361B1 (en) 2008-01-02
KR20060037434A (en) 2006-05-03
MY145356A (en) 2012-01-31
CY1108616T1 (en) 2014-04-09
UA85194C2 (en) 2009-01-12
MEP27708A (en) 2010-06-10
EA009986B1 (en) 2008-04-28
CN1867554A (en) 2006-11-22
MXPA06001665A (en) 2006-04-28

Similar Documents

Publication Publication Date Title
EP1656361A1 (en) Piperazine with or-substituted phenyl group and their use as glyt1 inhibitors
US7427612B2 (en) Benzoyl-piperazine derivatives
EP1703909B1 (en) 1-benzoyl-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
WO2006072435A1 (en) Sulfanyl substituted phenyl methanones as glycine transporter 1 (glyt-1) inhibitors for the treatment of neurological and neuropsychiatric disorders

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480029755.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004763703

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: CR2006-008193

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 544820

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2004263306

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: P-2006/0076

Country of ref document: YU

ENP Entry into the national phase

Ref document number: 2534675

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 200601146

Country of ref document: ZA

Ref document number: 06012502

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 1020067002786

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 12006500309

Country of ref document: PH

Ref document number: PA/a/2006/001665

Country of ref document: MX

Ref document number: 506/CHENP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006522944

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2004263306

Country of ref document: AU

Date of ref document: 20040802

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004263306

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200600336

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 1200600369

Country of ref document: VN

WWP Wipo information: published in national office

Ref document number: 1020067002786

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004763703

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0413497

Country of ref document: BR

WWG Wipo information: grant in national office

Ref document number: 2004763703

Country of ref document: EP